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ABSTRACT 
DAKOTA J SUCHYTA: Synthesis and Anticancer Action of Nitric Oxide-Releasing Liposomes 
(Under the direction of Mark H. Schoenfisch) 
The implementation of nitric oxide (NO)-based therapeutics has been met with 
formidable challenges relating to NO’s gaseous, reactive nature and difficulties associated with 
controlled delivery. Although macromolecular vehicles have been developed for applications in 
NO release, a common limitation associated with these systems is exposure of the NO donor to 
the surrounding medium, resulting in unintended NO release. To overcome this issue, liposomes 
were investigated as new vehicles for NO delivery whereby the NO donor is encapsulated within 
the aqueous core, protected from the external solution by a lipid membrane. 
Liposomes with encapsulated N-diazeniumdiolate NO donors were first synthesized 
using a reverse-phase evaporation protocol. Encapsulation efficiencies for several molecular NO 
donors were in the range of 33–41%. Relative to the unencapsulated (free) NO donor, NO-
release half-lives at pH 7.4 were up to 7-times greater upon encapsulation, yet the NO-releasing 
liposomes still exhibited their unique pH-sensitive release properties. The liposomes retained 
~80% of the encapsulated NO concentrations after 3 months of storage at 4°C, indicating 
excellent stability. In order to determine if the liposomes held merit as therapeutic agents, 
cytotoxicity against human pancreatic cancer cells were performed that demonstrated the 
liposomal NO donors required less NO to kill versus the free NO donor (183 µM and 2.4 mM, 
respectively). 
 iv 
The ability to tune NO-release kinetics of these liposomes was further studied. It was 
possible to vary the NO-release kinetics by altering the encapsulated NO donor molecule or the 
phospholipid composing the bilayer (independently or in combination). Phospholipid headgroup 
surface area was determined to be a main factor in controlling NO-release half-lives. As the 
surface area of the lipid headgroup was decreased from 0.660 nm2 to 0.420 nm2, a concomitant 
increase in NO-release half-life was also observed. The composition of the lipid bilayer is known 
to affect in vivo properties, so NO-release kinetics were also measured in serum and whole 
blood. Half-lives in serum were equivalent to those measured in buffer, while those measured in 
blood were ~60% faster. 
An investigation into the cytotoxicity of slow (t1/2 > 72 h) versus fast (t1/2 ~ 2.5 h) NO-
releasing liposomes demonstrated how the biological consequences were dependent on the NO-
release rate. Fast NO-releasing liposomes yielded consistently higher LD50 values (>230 µM 
NO), relative their slow-releasing counterparts (<230 µM NO), across 9 different cancer cell 
lines encompassing 3 different types of cancer (breast, colorectal, and pancreatic). The fast-
release system was able to eradicate 50% of the cells much quicker (~36 h vs. 72 h for slow-
release system). Flow cytometry studies suggest that this faster killing is due to a more rapid 
intracellular build-up of NO, which was observed for both the free and encapsulated NO donors. 
Western blotting revealed that both the slow and fast NO-release systems could induce apoptosis, 
albeit to different degrees. 
 
 
 
 
 v 
 
 
 
 
To my amazing parents, Richard and Shannan,  
who have always supported and encouraged me to follow my passion. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 vi 
 
 
 
 
ACKNOWLEDGEMENTS 
I am deeply grateful for the many people who I have encountered in my life and who 
have given me support, advice, criticism, and friendship. The teachers who have inspired and 
motivated me deserve my endless gratitude. For my 8th grade teacher, Karla Morgan, who 
initially fueled my imagination and curiosity for science, and ultimately chemistry. Through my 
high school years, Sandy Schafer taught me the wonders of chemistry and pushed me to pursue 
my studies. Professor David Baker and Professor Ronald Sharp were my first college professors 
who showed me the difficulties, nuances, failures, and successes that the field of chemistry had 
to offer. My true introduction to research laboratory chemistry began with Professor Mark 
Meyerhoff who accepted me into his lab as a first-year undergraduate. He taught me how to 
think critically about experiments, encouraged me to pursue my own interests, and supported me 
throughout my first attempts at publishing scientific data. My scientific interests eventually led 
me to Professor Mark Schoenfisch, who I can wholeheartedly say formed me into the chemist I 
am today. He provided me with an opportunity to research my own desires and gave me an 
independence I could only hope for in graduate school. He taught me that it is not just about 
finishing the project, but overachieving every single part of it. 
 There are many colleagues that deserve my appreciation as well. Dr. Bo Peng, who 
mentored me as an undergraduate. Dr. Gary Jensen, Dr. Alexander Wolf, and Dr. Andrea Bell-
Vlasov were some of the best colleagues and friends I could have asked for when entering the 
field of chemistry. They provided me with in-depth conversations about science and life that 
helped shape me into a better scientist. Without Dr. Chris Backlund and Dr. Rebecca Hunter I 
 vii 
would not have assimilated very easily into graduate school. Their entertainment, 
encouragement, and criticism will never be forgotten. One of my biggest friends and mentors in 
all of graduate school would be Dr. Robert Soto. His meticulous work ethic, tremendous writing 
abilities, and amiable personality inspires me to work harder and be more critical of myself every 
single day, both as a person and a scientist. My fellow classmates, including Nathan Whitman, 
Matthew Boyce, Micah Brown, and Matthew Campbell provided me with support, advice, and 
amusement throughout my graduate studies. Finally, the Schoenfisch lab members deserve my 
thanks, including Evan Feura, Mona Ahonen, James Taylor, Maggie Malone-Povolny, Lei Yang, 
Jackson Hall, Kaitlyn Rouillard, Haibao Jin, Sara Maloney, and Pedro De Jesus Cruz for all their 
continuous support. I wish you all the best of luck and I am confident that you will be successful 
in whatever career you choose.  
 I must show my appreciation to friends and family who supported me during my time 
here in graduate school. Richie Sabias, Jake Hash, and Marc Roedel were a few of the key 
contributors of my personal solace throughout both life and graduate school. I cherish their 
friendships everyday. One of my closest friends, Mark Bokhart, has been by my side through all 
of my college chemistry days. Whether it came to graduate school, my scientific career, or my 
personal life, he always provided a listening ear, a good laugh, and sound advice. The hardest 
parts of graduate school were significantly less stressful because I had a remarkable woman by 
my side. Christelle Siohan has continuously given me hope, love, and support. She is an 
inspiration for me to not only be a better person, but a better father each day to our beautiful 
daughter, Luna Suchyta. My brother, Nicholas Suchyta, will always be a source of fuel to my 
work ethic and humor. I can’t imagine getting through graduate school without him. And finally, 
my wonderful parents, Richard and Shannan Suchyta, have always supported me in each and 
 viii 
every one of my endeavors. I cannot write enough sentences that express my undying love and 
gratitude for everything that you both have sacrificed for me. Let this dissertation be a testament 
to how well you raised me.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 ix 
 
 
 
 
TABLE OF CONTENTS 
LIST OF TABLES .................................................................................................................xiv 
LIST OF FIGURES................................................................................................................. xv 
LIST OF ABBREVIATIONS AND SYMBOLS...................................................................xix 
CHAPTER 1. THERAPEUTIC ACTIVITY OF NITRIC OXIDE 
AND METHODS OF DELIVERY FOR CANCER TREATMENT........................................ 1 
1.1.   Nitric oxide therapy ........................................................................................... 1 
       1.1.1.   Antibacterial activity of nitric oxide ........................................................ 1 
       1.1.2.   Anticancer activity of nitric oxide ........................................................... 3 
1.2.   N-diazeniumdiolate NO donors ......................................................................... 5 
       1.2.1.   Synthesis of N-diazeniumdiolates ............................................................ 6 
       1.2.2.   Therapeutic utility of N-diazeniumdiolates.............................................. 9 
1.3.   Macromolecular NO-releasing systems ........................................................... 10 
       1.3.1.   Nitric oxide-releasing silica nanoparticles ............................................. 10 
       1.3.2.   Nitric oxide-releasing dendrimers.......................................................... 12 
1.4.   Liposomes as drug delivery vehicles ............................................................... 13 
       1.4.1.   Synthesis and characterization of liposomes ......................................... 15 
       1.4.2.   Pre-clinical liposome systems ................................................................ 17 
       1.4.3.   Commercial liposome systems............................................................... 19 
       1.4.4.   Intracellular uptake of liposomes ........................................................... 21 
       1.4.5.   Ligand-bearing liposomes...................................................................... 22 
1.5.   Nitric oxide-releasing liposomes ..................................................................... 23 
       1.5.1.   NO gas-encapsulated liposomes ............................................................ 23 
       1.5.2.   Metal nitrosyl complex-encapsulated liposomes ................................... 24 
 x 
       1.5.3.   Organic nitrate-encapsulated liposomes ................................................ 25 
       1.5.4.   N-diazeniumdiolate-encapsulated liposomes ......................................... 25 
1.6.   Summary of dissertation research .................................................................... 27 
         References ........................................................................................................ 29 
CHAPTER 2. ENCAPSULATION OF N-DIAZENIUMDIOLATES 
WITHIN LIPOSOMES FOR ENHANCED NITRIC OXIDE 
DONOR STABILITY AND DELIVERY .............................................................................. 41 
2.1.   Introduction ...................................................................................................... 41 
2.2.   Experimental section........................................................................................ 43 
       2.2.1.   Materials................................................................................................. 43 
       2.2.2.   Synthesis of N-diazeniumdiolates .......................................................... 44 
       2.2.3.   Preparation of liposomes........................................................................ 44 
       2.2.4.   Characterization of liposome size .......................................................... 45 
       2.2.5.   Phospholipid content assay .................................................................... 45 
       2.2.6.   Nitric oxide release from liposomes ...................................................... 45 
       2.2.7.   Cytotoxicity assay .................................................................................. 47 
2.3.   Results and Discussion..................................................................................... 47 
       2.3.1.   Synthesis of NO-releasing liposomes .................................................... 47 
       2.3.2.   Liposomal NO-release measurements ................................................... 48 
       2.3.3.   Stability of NO-releasing liposomes over time...................................... 55 
       2.3.4.   Cytotoxicity of DPTA/NO-encapsulated liposomes.............................. 55 
2.4.   Conclusions ...................................................................................................... 59 
         References ........................................................................................................ 60 
CHAPTER 3. CONTROLLED RELEASE OF NITRIC OXIDE 
FROM LIPOSOMES .............................................................................................................. 63 
3.1.   Introduction ...................................................................................................... 63 
3.2.   Experimental section........................................................................................ 65 
       3.2.1.   Materials................................................................................................. 65 
 xi 
       3.2.2    Synthesis of N-diazeniumdiolates .......................................................... 66 
       3.2.3.   Preparation of liposomes........................................................................ 66 
       3.2.4.   Characterization of liposomes size ........................................................ 67 
       3.2.5.   Nitric oxide release from liposomes ...................................................... 67 
       3.2.6.   Turbidity assay ....................................................................................... 68 
       3.2.7.   Serum protein adsorption onto liposomes.............................................. 68 
       3.2.8.   Nitric oxide release from liposomes in blood and serum....................... 68 
3.3.   Results and Discussion..................................................................................... 69 
       3.3.1.   Nitric oxide donor structure ................................................................... 69 
       3.3.2.   Nitric oxide-release measurements ........................................................ 72 
       3.3.3.   Effects of lipid bilayer hydrophobicity and charge................................ 73 
       3.3.4.   Bilayer properties and NO release ......................................................... 76 
       3.3.5.   Nitric oxide-release kinetics in biological media................................... 80 
3.4.   Conclusions ...................................................................................................... 85 
         References ........................................................................................................ 86 
CHAPTER 4. ANTICANCER POTENCY OF NITRIC OXIDE-
RELEASING LIPOSOMES.................................................................................................... 91 
4.1.   Introduction ...................................................................................................... 91 
4.2.   Experimental section........................................................................................ 93 
       4.2.1.   Materials................................................................................................. 93 
       4.2.2.   Synthesis of N-diazeniumdiolate NO donors......................................... 94 
       4.2.3.   Liposome synthesis ................................................................................ 94 
       4.2.4.   Characterization of liposomes................................................................ 95 
       4.2.5.   Nitric oxide release ................................................................................ 95 
       4.2.6.   Cytotoxicity assays ................................................................................ 96 
       4.2.7.   Confocal fluorescence microscopy ........................................................ 97 
       4.2.8.   Flow cytometry ...................................................................................... 97 
 xii 
 
       4.2.9.   Western blot analysis ............................................................................. 98 
4.3.   Results and Discussion..................................................................................... 99 
       4.3.1.   Cytotoxicity of the liposomes .............................................................. 100 
       4.3.2.   Intracellular liposome uptake and NO delivery ................................... 106 
       4.3.3.   Kinetics of intracellular NO accumulation .......................................... 109 
       4.3.4.   Effect of liposomes on intracellular signaling ..................................... 111 
4.4.   Conclusions .................................................................................................... 113 
         References ...................................................................................................... 114 
CHAPTER 5. SUMMARY AND FUTURE DIRECTIONS ................................................ 119 
5.1.   Summary of dissertation research .................................................................. 119 
5.2.   Future directions ............................................................................................ 121 
       5.2.1.   Conjugation of targeting ligands to liposome surface ......................... 121 
       5.2.2.   Dual-encapsulation to enhance anticancer action ................................ 124 
       5.2.3.   Antibacterial properties of NO-releasing liposomes............................ 125 
5.3.   Conclusions .................................................................................................... 127 
5.4.   References ...................................................................................................... 129 
APPENDIX A. SUPPLEMENTAL MATERIAL OF CHAPTER 2 .................................... 133 
APPENDIX B. SUPPLEMENTAL MATERIAL OF CHAPTER 3 .................................... 136 
APPENDIX C. SUPPLEMENTAL MATERIAL OF CHAPTER 4 .................................... 156 
APPENDIX D. SELECTIVE MONOPHOSPHORYLATION OF 
CHITOSAN VIA PHOSPHORUS OXYCHLORIDE .......................................................... 160 
D.1.   Introduction ................................................................................................... 160 
D.2.   Experimental section ..................................................................................... 162 
       D.2.1.   Materials.............................................................................................. 162 
       D.2.2.   Synthesis of phosphorylated chitosan ................................................. 163 
       D.2.3.   Nuclear magnetic resonance (NMR) spectroscopy............................. 163 
       D.2.4.   X-ray photoelectron spectroscopy (XPS)............................................ 163 
 xiii 
       D.2.5.   Molecular weight determination ......................................................... 164 
       D.2.6.   Calcium chelation................................................................................ 164 
D.3.   Results and Discussion.................................................................................. 165 
       D.3.1.   Controlling phosphorylation efficiency .............................................. 170 
       D.3.2.   Molecular weight ................................................................................ 180 
       D.3.3.   Calcium chelation efficiency............................................................... 180 
D.4.   Conclusions ................................................................................................... 182 
          References ..................................................................................................... 184 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 xiv 
LIST OF TABLES 
 
Table 2.1.  Encapsulation efficiencies (EE) of various NO donor 
compositions.................................................................................................... 49 
Table 2.2.  Nitric oxide-release properties of liposomes in PBS (pH = 7.4) 
at 37 °C............................................................................................................ 52 
Table 2.3.  Nitric oxide-release properties of liposomes in acetate buffer 
(pH = 7.4) at 37 °C .......................................................................................... 57 
Table 3.1.  Physicochemical properties of DPPC liposomes encapsulating 
various NO donors........................................................................................... 70 
Table 3.2.  Nitric oxide-release properties of DPPC liposomes as a 
function of NO donor in PBS (pH 7.4) at 37 °C ............................................. 71 
Table 3.3.  Physicochemical properties of PAPA/NO liposomes as a 
function of bilayer composition ...................................................................... 74 
Table 3.4.  Nitric oxide-release properties of PAPA/NO liposomes as a 
function of bilayer hydrophobicity and charge in PBS (pH 7.4) 
at 37 °C............................................................................................................ 77 
Table 4.1.  Properties of NO-releasing liposomes........................................................... 101 
Table 5.1.  Ligands used for active targeting .................................................................. 122 
Table B.1.  Nitric oxide-release properties of DPPC liposomes as a 
function of encapsulated N-diazeniumdiolate NO donor in 
MES (pH = 5.4) at 37 °C............................................................................... 144 
Table B.2.  Fluorophore encapsulation efficiency for DPPC and DPPG 
liposome ........................................................................................................ 147 
Table B.3.  Nitric oxide-release properties of PAPA/NO liposomes as a 
function of bilayer hydrophobicity and charge in MES (pH = 
5.4) at 37 °C................................................................................................... 149 
Table D.1.  Chitosan concentration effect on phosphorylation P/N atomic 
ratio................................................................................................................ 178 
Table D.2.  Molecular weight and dispersity (Đ) of P-chitosan as a function 
of POCl3 reaction time................................................................................... 181 
Table D.3.  Calcium chelation amount of P-chitosan as a function of 
phosphorylation degree ................................................................................. 183 
 
 xv 
LIST OF FIGURES 
 
Figure 1.1.  Antibacterial mechanisms of action of nitric oxide and other 
nitrosative and oxidative agents ........................................................................ 2 
Figure 1.2.  The downstream effects on cancer cells after treatment with 
nitric oxide......................................................................................................... 4 
Figure 1.3.  Mechanism of N-diazeniumdiolate formation via sequential 
NO addition and proton-initiated NO release.................................................... 7 
Figure 1.4.  Structures of common N-diazeniumdiolates with their reported 
half-lives in 10 mM PBS (pH 7.4, 37 °C) ......................................................... 8 
Figure 1.5.  Representation of a liposome and its ability to encapsulate both 
lipophilic and hydrophilic drugs...................................................................... 14 
Figure 1.6.  Nitric oxide-releasing liposome and mechanism of NO release ..................... 26 
Figure 2.1.  Structures of the NO donors SPER/NO and DPTA/NO ................................. 46 
Figure 2.2.  Nitric oxide release profiles of various encapsulated NO donors 
and free NO donor ........................................................................................... 50 
Figure 2.3.  Fluorescence emission of pyranine-loaded liposomes in various 
conditions ........................................................................................................ 54 
Figure 2.4.  Comparison of NO remaining from SPER/NO-loaded 
liposomes after storage under various conditions ........................................... 56 
Figure 2.5.  In vitro efficacy of liposomal and free DPTA/NO on human 
PANC-1 cells after 24 h incubation ................................................................ 58 
Figure 3.1.  Fluorescence emission of pyranine-encapsulated liposomes 
prepared from DMPC, DPPC, and DSPC diluted in 10 mM 
PBS (pH 7.4, 37 °C) ........................................................................................ 79 
Figure 3.2.  Relationship between the liposomal NO-release half-life and 
phospholipid headgroup surface area using PAPA/NO-
encapsulated liposomes ................................................................................... 81 
Figure 3.3.  Nitric oxide release in biological fluids from various 
PAPA/NO liposomes....................................................................................... 83 
Figure 3.4.  Neutral DPPC PAPA/NO liposome NO-release kinetics in 
various media .................................................................................................. 84 
Figure 4.1.  Nitric oxide-release profiles from liposomal DETA/NO and 
PAPA/NO liposomes in10 mM PBS (pH 7.4, 37 °C) ................................... 102 
 xvi 
Figure 4.2.  PA14c cytotoxicity of liposomal DETA/NO and PAPA/NO 
and calculated LD50 values ............................................................................ 103 
Figure 4.3.  Time-course cytotoxicity study of liposomal DETA/NO and 
PAPA/NO at their respective LD50 values against human MCF-
7 breast cancer cells....................................................................................... 105 
Figure 4.4.  Confocal fluorescence micrographs and densitometric analysis 
of MCF-7 cells incubated with DETA/NO and PAPA/NO 
liposomes....................................................................................................... 107 
Figure 4.5.  Orthogonal view of MCF-7 cells after treatment with 
PAPA/NO liposomes..................................................................................... 108 
Figure 4.6.  Change in median fluorescence intensity over time indicating 
intracellular NO accumulation, as determined by flow 
cytometry, after treating MCF-7 cells with both free form and 
liposomal form of DETA/NO and PAPA/NO............................................... 110 
Figure 4.7.  Western blot and densitometric analysis of MCF-7 cells after 
various treatments.......................................................................................... 112 
Figure A.1.  Nitric oxide release profile of free DPTA/NO versus liposomal 
DPTA/NO in 10 mM PBS (pH 7.4, 37 °C) ................................................... 133 
Figure A.2.  Transmission electron micrograph of DPTA/NO loaded 
liposomes....................................................................................................... 134 
Figure A.3.  Cytotoxicity on human PANC-1 cells after a 24 h incubation 
using varying concentrations of free DPTA/NO........................................... 135 
Figure B.1.  Proton-initiated decomposition mechanism of N-
diazeniumdiolates to liberate NO .................................................................. 136 
Figure B.2.  UV-vis spectra of PROLI/NO, DEA/NO, PAPA/NO, and 
SPER/NO in 50 mM NaOH .......................................................................... 137 
Figure B.3.  FTIR spectra of PROLI/NO, DEA/NO, PAPA/NO, and 
SPER/NO....................................................................................................... 138 
Figure B.4.  UV-vis spectra of PROLI/NO, DEA/NO, PAPA/NO, and 
SPER/NO in 10 mM PBS (pH 7.4) ............................................................... 140 
Figure B.5.  UV-vis spectra of sodium nitrate and sodium nitrite in 10 mM 
PBS (pH 7.4) ................................................................................................. 141 
Figure B.6.  UV-vis spectra of PROLI/NO, DEA/NO, PAPA/NO, and 
SPER/NO in 10 mM MES (pH 5.4) .............................................................. 142 
 xvii 
Figure B.7.  N-diazeniumdiolate NO donors with their reported NO-release 
half-lives in 10 mM PBS (pH 7.4, 37 °C). .................................................... 143 
Figure B.8.  Structures of lipids used to make liposomes ................................................. 145 
Figure B.9.  Transmission electron micrographs of DMPC-, DPPC-, and 
DSPC-based PAPA/NO liposomes. .............................................................. 146 
Figure B.10.  Transmission electron micrographs of DPPG- and DPTAP-
based PAPA/NO liposomes........................................................................... 148 
Figure B.11.  Hydrodynamic diameter and polydispersity index of various 
liposome compositions over time.................................................................. 150 
Figure B.12.  Turbidity and protein adsorption measurements of various 
liposome compositions .................................................................................. 151 
Figure B.13.  Nitric oxide release from neutral DPPC PAPA/NO  liposomes 
suspended in 10 mM PBS (pH 7.4, 37 °C) containing 157 
mg/mL hemoglobin. ...................................................................................... 152 
Figure B.14.  Hemolytic activity of various PAPA/NO-encapsulated 
liposome systems........................................................................................... 153 
Figure C.1.  Molecular structures of PAPA/NO and DETA/NO ...................................... 156 
Figure C.2.  Transmission electron micrographs of PAPA/NO and 
DETA/NO liposomes .................................................................................... 157 
Figure C.3.  Cytotoxicity plot of PAPA/NO and DETA/NO liposomes as a 
function of NO concentration against human HPNE epithelial 
pancreatic cells .............................................................................................. 158 
Figure C.4.  Change in median fluorescence intensity over time, as 
determined by flow cytometry, after treating MCF-7 cells with 
various concentrations of free and liposomal PAPA/NO.............................. 159 
Figure D.1.  1H NMR spectrum of phosphorylated chitosan............................................. 166 
Figure D.2.  1H NMR spectrum in D2O of P-chitosan after washing with 2 
M HCl............................................................................................................ 167 
Figure D.3.  31P NMR spectra of phosphorylated chitosan prepared in 
neutral and basic D2O.................................................................................... 168 
Figure D.4.  31P NMR spectrum of D-glucosamine 6-phosphate and D-
glucosamine 1-phosphate .............................................................................. 171 
Figure D.5.  31P NMR spectrum of D-glucosamine 6-phosphate prepared in 
acidic and basic D2O...................................................................................... 172 
 xviii 
Figure D.6.  31P NMR spectrum of phosphorylated alginate. ............................................ 173 
Figure D.7.  31P NMR spectrum of phosphorylated cellulose............................................ 174 
Figure D.8.  31P NMR spectrum of phosphorylated D-glucosamine .................................. 175 
Figure D.9.  31P NMR spectrum of phosphorylated N-acetylglucosamine ........................ 176 
Figure D.10.  31P NMR spectra of phosphorylated chitosan synthesized by the 
POCl3 and P2O5 methods ............................................................................... 177 
Figure D.11.  Atomic P/N ratio as a function of reaction time for reactions 
with 20 mg/mL chitosan (10 molar ratio of POCl3) ...................................... 179 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 xix 
LIST OF ABBREVIATION AND SYMBOLS 
~   approximately 
°  degree(s) 
°C  degree(s) Celsius 
=  equals 
>  greater than 
≥  greater than or equal to 
<  less than 
≤  less than or equal to 
%   percentage(s) 
× g  times the force of gravity 
a.u.   arbitrary units 
Ar  argon gas 
As2O3  arsenic trioxide 
Ca2+  calcium ion 
CaCl2  calcium chloride 
cGMP  cyclic guanosine monophosphate 
Chol  cholesterol 
cm  centimeter(s) 
cm-1  wavenumber 
CO2   carbon dioxide gas 
d  day(s) 
Đ  dispersity 
 xx 
DAF-FM 4-amino-5-methylamino-2’,7’-difluorofluorescein diacetate 
dL  deciliter(s) 
D2O  deuterium oxide 
DEA  diethylamine 
DEA/NO N-diazeniumdiolate-modified diethylamine 
DETA/NO N-diazeniumdiolate-modified diethylenetriamine 
DLS  dynamic light scattering 
DMEM Dulbecco’s modified Eagle’s medium 
DMPCS dimyristoylphosphatidylcholine 
DMSO  dimethyl sulfoxide 
DNA  deoxyribonucleic acid 
DOTMA N-[1-(2,3-dioleyloxy)propyl]-N,N,N-trimethyl ammonium chloride 
DPBS  Dulbecco’s phosphate-buffered saline 
DPPC  dipalmitoylphosphatidylcholine 
DPPE  dipalmitoylphosphatidylethanolamine 
DPPG  dipalmitoylphosphatidylglycerol 
DPTAP dipalmitoyltrimethylammoniumpropane 
DPTA/NO N-diazeniumdiolate-modified dipropylenetriamine 
DSPC  distearoylphosphatidylcholine 
DSPE  distearoylphosphatidylethanolamine 
EDTA  ethylenediaminetetraacetic acid 
EE  encapsulation efficiency 
e.g.  exempli gratia (for example) 
 xxi 
et al.  et alia (and others) 
EtOH  ethanol 
eV   electronvolt 
FBS  fetal bovine serum 
FTIR  Fourier transform infrared spectroscopy 
g  gram(s) 
GPC  gel permeation chromatography 
GTP  guanosine triphosphate 
h  hour(s) 
H2O2  hydrogen peroxide 
HCl  hydrochloric acid 
HNO3  nitric acid 
H3PO4  orthophosphoric acid 
H2SO4  sulfuric acid 
i.e.  id est (that is) 
IC50  inhibitory concentration that reduces biological function by 50% 
ICP-OES inductively coupled plasma-optical emission spectrometry 
kDa   kilodalton(s) 
kV  kilovolt(s) 
LD50  lethal dose that kills 50% of test sample 
m  meter(s) 
M  molar 
MΩ  Megaohm(s) 
 xxii 
MSA  methanesulfonic acid 
MES  2-(N-morpholino)ethanesulfonic acid 
mg  milligram(s) 
MIC  minimum inhibitory concentration 
min   minute(s) 
mL  milliliter(s) 
mm  millimeter(s) 
mM  millimolar 
mmol  millimole(s) 
MTS 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxy 
phenyl)-2-(4-sulfophen-yl)-2H-tetrazolium 
mo  month(s) 
mol  mole(s) 
N2  nitrogen gas 
NaOH  sodium hydroxide 
NIR  near infrared 
nm  nanometer(s) 
nM   nanomolar 
NMR  nuclear magnetic resonance spectroscopy 
nmol  nanomole(s) 
NO  nitric oxide 
[NO]max maximum NO flux 
[NO]total total amount of NO released 
NO2  nitrogen dioxide 
 xxiii 
NO3-  nitrate 
N2O3  nitrogen trioxide 
N2O4  nitrogen tetroxide 
NOS  nitric oxide synthase 
O2   oxygen 
O2-  superoxide 
ONOO- peroxynitrite 
P2O5  phosphorus pentoxide 
PAMAM poly(amidoamine) 
PAPA   N-propyl-1,3-propanediamine 
PAPA/NO N-diazeniumdiolate-modified N-propyl-1,3-propanediamine 
PARP  poly adenosine diphosphate ribose polymerase 
PBS   phosphate-buffered saline 
PDI  polydispersity index 
PEG  polyethylene glycol 
pH  -log of proton concentration 
pKa  -log of acid dissociation constant 
PMS  phenazine methosulfate 
POCl3  phosphorus oxychloride 
PPI  poly(propyleneimine) 
ppb  part(s) per billion 
ppm  part(s) per million 
psi  pounds per square inch 
 xxiv 
PROLI  L-proline 
PROLI/NO N-diazeniumdiolate-modified L-proline 
RBC  red blood cell 
Rh-PE 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine 
rhoadmine B sulfonyl) ammonium 
RhoA  Ras homolog gene family member A 
RNS  reaction nitrogen species 
RPMI  Roswell Park Memorial Institute 
RSNO  S-nitrosothiol 
s  second(s) 
SDS  sodium dodecyl sulfate 
siRNA  small interfering ribonucleic acid 
SPER  spermine 
SPER/NO N-diazeniumdiolate-modified spermine 
t1/2  half-life 
Tc  transition temperature 
td  total duration of NO release 
TAP  trimethylammoniumpropane 
TBST  tris-buffered saline with Tween 20 
TEM  transmission electron microscopy 
THF  tetrahydrofuran 
µg  microgram(s) 
µL  microliter(s) 
 xxv 
µm  micrometer(s) 
µM  micromolar 
µmol   micromole(s) 
UV  ultraviolet 
UV-vis ultraviolet-visible spectroscopy 
v/v  volume/volume 
vol%   percent by volume 
vs  versus 
w/v  weight/volume 
XPS  X-ray photoelectron spectroscopy 
 
 
 
 
 
 
 
 
 1 
 
 
 
 
 
CHAPTER 1: THERAPEUTIC ACTIVITY OF NITRIC OXIDE AND METHODS OF 
DELIVERY FOR CANCER TREATMENT 
 
1.1 Nitric oxide therapy 
          Nitric oxide (NO) is an endogenously produced gasotransmitter formed by the reaction of 
the enzyme nitric oxide synthase (NOS) and the amino acid arginine.1 NO is considered a potent 
vasodilator and cardioprotectant.2 Sodium nitroprusside, a common NO donor, has been utilized 
in medical settings for almost 100 years due to its effective blood pressure regulation action and 
inexpensive production costs. In addition to cardiovascular health, NO is recognized as a vital 
regulator of the immune response.3 Research has heavily focused on the development of 
therapeutics for the treatment of NO-impaired disorders with the hope that exogenous NO will 
reverse the severity of certain diseases. 
1.1.1. Antibacterial activity of nitric oxide 
Upon bacterial invasion, the immune response is initiated and macrophages are recruited 
to eradicate the invaders.4-5 Upon stimulation by proinflammatory cytokines such as interleukins 
and lipopolysaccharides, macrophages release NO to inhibit bacterial reproduction and induce 
cell death (Figure 1.1).6 Nitric oxide directly impedes bacterial respiration as well as 
ribonucleotide reductase, thus impacting DNA synthesis and repair.7 Replication is further 
prevented by altering zinc translocation among crucial metalloproteins.7 While NO can directly 
influence the reproduction of bacteria, its indirect effects are far more common. Known NO-
reactive species include hydrogen peroxide (H2O2), oxygen (O2), superoxide (O2-), and certain  
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Figure 1.1. Antibacterial mechanisms of action of nitric oxide and other nitrosative and 
oxidative agents. Reprinted with permission from ACS Nano, 2008, 2, Hetrick, E.M.; Shin, J.H.; 
Stasko, N.A.; Johnson, C.B.; Wespe, D.A.; Holmuhamedov, E.; Schoenfisch, M.H. “Bactericidal 
efficacy of nitric oxide-releasing silica nanoparticles” pages 235–246, Copyright 2008 American 
Chemical Society. 
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biomolecules (e.g., amino acids and peptides).7-8 Common byproducts from the reactions of NO 
with these molecules, notably dinitrogen trioxide (N2O3), dinitrogen tetroxide (N2O4), nitrogen 
dioxide (NO2), and peroxynitrite (ONOO-), are capable of inducing severe cellular damage. 
Peroxynitrite is a key factor for the formation of potent nitrosative agents such as N2O3 and NO2 
radicals. Both N2O3 and N2O4 nitrosate membrane proteins, leading to membrane fractures and 
holes, while NO2 radicals are causative agents for lipid peroxidation.8-10 Additionally, NO with 
H2O2 exacerbates oxidative injury by promoting flavin reduction and Fenton chemistry (i.e., 
production of hydroxyl radicals from iron).7 This multi-mechanistic antibacterial approach 
hinders the ability of bacteria to foster resistance to NO. 
1.1.2. Anticancer activity of nitric oxide 
 Cancer is known for its increased rate of replication, genomic instability, inhibited DNA 
repair mechanisms, and ultimately metastasis.11 When used as a therapeutic, NO is able to target 
many of the chief promoters that accelerate metastasis (Figure 1.2). Directly damaging cancer 
cell DNA is a common strategy to prevent growth and metastasis. Reactive nitrogen and oxygen 
species, byproducts of NO scavenging, deaminate DNA bases (e.g., cytosine to uracil), nitrosate 
nucleophilic sites, and cause single-strand breaks.12-13 These alkylations and deaminations are 
not easily fixed in cancer cells due to the impaired DNA repair process, thus attenuating overall 
replication.  
 Aside from damaging DNA, NO is capable of interacting with major proteins involved in 
the cell cycle. Phosphorylation of two common proteins, p53 and c-Jun, leads to tumor cell 
apoptosis due to altering their native binding states. When exposed to concentrations of NO in 
the range of 400–800 nM, both p53 and c-Jun become phosphorylated (i.e., activated).12-13 p53 is  
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Figure 1.2. The downstream effects on cancer cells after treatment with nitric oxide. Reprinted 
with permission from Medicinal Research Reviews, 2007, 27, Mocellin, S.; Bronte, V.; Nitti, D. 
“Nitric oxide, a double edged sword in cancer biology: Searching for therapeutic opportunities” 
pages 317–352, Copyright 2006 John Wiley and Sons. 
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mutated in 50% of human malignancies, which impairs its ability to initiate programmed cell 
death. When wild-type p53 is phosphorylated, however, these typically closed apoptotic channels 
are reinitiated. For example, exposure of neuroblastoma cells to NO leads to apoptosis.13-14 In a 
pancreatic cancer model, NO was able to arrest all cell lines at the G1 phase, and ultimately 
induce apoptosis, likely from p53 activation.15 Nitrosation of DNA repair proteins (e.g., 8-
oxoguanine glycosylase-1 and DNA alkyl-transferase) by RNS would inevitably reduce the 
ability of cancer cells to replicate, thus leading to epigenetic damage.13,16  
 Chemosensitization, the enhancement of a chemotherapeutic with an alternative 
medicine, is another technique benefited by NO. Due to the vasodilatory effects of NO, patients 
pretreated with NO-releasing drugs (e.g., sodium nitroprusside) generally exhibit less constricted 
blood vessels at tumor sites.17 The increased tumor blood flow allows for greater accumulation 
of the chemotherapeutic at the malignant site or an increased anticancer action due to the higher 
oxygen levels. When NO was co-administered with doxorubicin, hypoxia-induced doxorubicin 
resistance was reversed in multiple human and murine prostate cancer cell models.17-19 Similar to 
chemotherapy, radiotherapy also has been shown to benefit from NO pre-treatments. The higher 
ensuing tumor oxygen levels were reported to enhance radical formation and oxidative damage.17  
1.2 N-diazeniumdiolate NO donors 
          In normal physiological conditions, the half-life of NO ranges from 0.1 to 1 s.20-22 The 
final decomposition product of NO is the innocuous nitrate (NO3-) anion that is formed after a 
series of physiological reactions (e.g., NO auto-oxidation followed by nitrite oxidation). NO’s 
lifetime is dependent on both the concentration of NO, and the concentration (and type) of the 
NO scavengers present. Some of the most common scavengers in the bloodstream are oxygen, 
hemoglobin, thiol-rich proteins, and superoxide. To better utilize NO as a therapeutic, the 
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development of NO donors, which are molecules capable of storing and releasing NO, have been 
an active area of research.9-10 Arguably the most investigated class of NO donors is N-
diazeniumdiolates, discussed below. 
1.2.1. Synthesis of N-diazeniumdiolates 
 The general synthesis of N-diazeniumdiolates involves the reaction of secondary amines 
with high pressures of NO gas under dilute basic conditions.23-24 Secondary amines, as opposed 
to primary or tertiary amines, afford the greatest N-diazeniumdiolate stability post-synthesis, thus 
making them the most heavily studied NO storage/release system. Larry K. Keefer pioneered the 
synthesis, identification, characterization, and NO-release properties of N-diazeniumdiolates.25-31 
It is speculated that the N-diazeniumdiolate formation process occurs via the addition of one NO 
molecule onto the secondary amine, followed by the attachment of an additional molecule of NO 
to form the N-diazeniumdiolate (Figure 1.3a).32-33 However, others have speculated that 2 
molecules of NO combine together (i.e., dimerize), with the dimer attaching to the parent 
secondary amine.34-35 In reality, a combination of these two processes is most likely. 
 Release of NO from N-diazeniumdiolates is highly dependent on the pH and temperature 
of the aqueous solution. At high pH values (>12), few protons exist to cleave the N-
diazeniumdiolate bond, thereby making basic solutions of N-diazeniumdiolates very stable (i.e., 
weeks). However, at low pH values, the NO donor coordinating amine protonates, resulting in 
degradation of the N-diazeniumdiolate and concomitant NO release (Figure 1.3b). In addition to 
pH, N-diazeniumdiolate stability is also dependent on the molecular structure of the parent 
amine.25 Nitric oxide-release half-lives of common N-diazeniumdiolates at pH 7.4 range from 2 s 
to 20 h (Figure 1.4).25,31 At elevated temperatures the NO release is accelerated even more due to 
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Figure 1.3. Mechanism of N-diazeniumdiolate (a) formation via sequential NO addition (b) and 
proton-initiated NO release. 
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Figure 1.4. Structures of common N-diazeniumdiolates with their reported half-lives in 10 mM 
PBS (pH 7.4, 37 °C). 
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thermal energy promoting breakdown of N-diazeniumdiolate bond. This disparity in stability is 
linked to the anionic character of the diazeniumdiolate moiety. Substituents that can reduce the 
anionic character (i.e., ionically stabilize) often lead to greater stability of the N-
diazeniumdiolate, with longer NO-release half-lives. For example, the stable N-diazeniumdiolate 
diethylenetriamine/NO (DETA/NO) has a reported half-life at pH 7.4 of ~20 h, the result of N-
diazeniumdiolate stabilization by its two protonated primary amines.25 Cationic charges capable 
of stabilizing the NO donating group are exploited to increase the NO-release half-life under 
physiological conditions. 
1.2.2. Therapeutic utility of N-diazeniumdiolates 
 N-diazeniumdiolates are commonly used to study NO’s roles in various biological 
applications.36-38 Studies using DETA/NO have demonstrated that MDA-MB-231 breast cancer 
cells are less apt to develop resistance to doxorubicin when first exposed to NO.39 It was 
hypothesized that the chemosensitization of DETA/NO was linked to the NO donor reducing the 
local hypoxic environment. Spermine/NO (SPER/NO) has also been shown to aid in the 
eradication of MCF-7 breast cancer cells via the induction of apoptosis. At ~100 µM SPER/NO, 
phosphorylation of p53 at the Ser15 site led to a signaling cascade to reopen previously closed 
cell cycle pathways and allow for apoptosis to occur.40 Apoptosis may also be initiated in bone 
cancer F10 cells upon incubation with >20 µM DEA/NO (LD50=30 µM).41 Further, the number 
of metastatic (i.e., invasive) cells was reduced by 50%, supporting the role of NO in reducing 
metastasis.  
Promising in vivo studies with N-diazeniumdiolates have shown that in vitro data is 
replicated in animal models. Administration of a piperazine-derived N-diazeniumdiolate (JS-K) 
into rats infected with renal cell carcinoma resulted in an increase in expression of 
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phosphorylated p53 (Ser15), as well as a reduction in tumor volume due to apoptosis.42 
Moreover, rats treated with the NO donor had 75% fewer lung metastases relative to the control 
rats, perhaps not surprising as NO was shown to increase expression of E-cadherin, a critical 
transmembrane protein that is involved in cell-cell adhesion.43 
1.3 Macromolecular NO-releasing systems 
          Although low molecular weight NO donors have shown great promise as potential 
therapeutics, off-target cytotoxicity of small molecules is a major obstacle as a result of their 
size, high reactivity, and poor localization to the site of interest.44-46 As a remedy, 
macromolecular NO-delivery systems (e.g., gold or silica nanoparticles) have been developed to 
possibly promote passive localization and attenuate off-target cytotoxicity.47-54 Silica 
nanoparticles and dendrimers have received significant attention due to their ability to store large 
quantities of NO. 
1.3.1. Nitric oxide-releasing silica nanoparticles 
 With silica being relatively non-toxic, inexpensive, and chemically modifiable, 
investigations into its therapeutic utility were promising. Indeed, the density of surface silanol 
groups affords straightforward functionalization with silanes bearing secondary amines.55-58 
Upon reacting these particles with high pressures of NO gas, N-diazeniumdiolates are readily 
formed on the particle exterior. Total NO storage was shown to span 0.05 to 3.77 µmol NO per 
mg of particles depending on the secondary amine attached to the particle surface.55 When the 
antibacterial action of the NO-releasing particles was compared to a low molecular weight NO 
donor (i.e., PROLI/NO), the true benefit of macromolecular chemistry is demonstrated, with 8-
times less NO required to eradicate planktonic Pseudomonas aeruginosa (P. aeruginosa).57 The 
localized NO release from the silica particles afforded lower NO concentrations for bacteria 
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eradication. At these concentrations, L929 mouse fibroblasts retained high  (>80%) cellular 
viability. Particle size also played a pivotal role in biocidal action, with smaller 50 nm particles 
requiring half the amount of NO-releasing material to kill (0.8 mg/mL) relative to the larger 200 
nm particles (1.5 mg/mL), which was attributed to the greater association and uptake of the 
smaller particles with the bacterial cell membrane.59  
Nitric oxide-releasing silica particles have also had success in killing large biofilm 
colonies. Biofilms are formed when planktonic bacteria form a community and collectively 
excrete a polysaccharide matrix. Due to the high viscosity and poor permeability of this matrix, 
many antibacterial agents require much larger concentrations to kill. When both Pseudomonas 
aeruginosa and Escherichia coli were treated with fast NO-releasing silica nanoparticles, a 5-log 
reduction in biofilm viability was observed.60 As expected, a 10-times higher concentration of 
material was required for killing (8 mg/mL) relative to the planktonic-killing concentration (0.8 
mg/mL). Unfortunately, at these larger anti-biofilm concentrations, the NO-releasing systems 
were also toxic to healthy mouse fibroblasts (~70% killing), demonstrating the concentration 
dependence on cytotoxicity for NO-releasing silica nanoparticles. Smaller system size (50 nm) 
continued to enhance Pseudomonas aeruginosa biofilm killing, requiring only 6 mg/mL versus 
10 mg/mL for the 150 nm particles.61 
In addition to killing bacteria, NO-releasing silica nanoparticles have shown to be potent 
anticancer agents. For 90 nm fast NO-releasing silica particles, the inhibitory concentrations 
(IC50) against 11 different cell lines were in the range of 60 to 100 µg/mL.62 Protein expression 
studies revealed that apoptosis was one of the major pathways leading to cell death, as evidenced 
by cleaved poly adenosine diphosphate ribose polymerase (PARP) and cleaved Caspase 3 
signals.62 Interestingly, larger (350 nm) particles showed preferential killing to Ras-transformed 
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ovarian cancer cells over their nontransformed counterparts (61 and 220 µg/mL, respectively). It 
was hypothesized that this difference in killing could be employed in vivo as a means to exploit 
the enhanced permeation and retention effect, and thus reduce off-target cytotoxicity. 
1.3.2. Nitric oxide-releasing dendrimers 
Dendrimers are hyperbranched nanostructures that possess a symmetrical and well-
defined polymeric structure. As the generation or size of the dendrimer increases, so does the 
number of exterior functional groups. Dendrimers formed from poly(propyleneimine) (PPI) and 
poly(amidoamine) (PAMAM) were shown to possess a high density of secondary amine groups 
for functionalization with N-diazeniumdiolate NO donors.63 In fact, dendrimers were shown to 
yield the largest NO totals per mass out of all macromolecular systems (0.91–3.80 µmol/mg).64 
Significant antibacterial action was induced upon exposing Gram-negative (Pseudomonas 
aeruginosa) and Gram-positive (Staphylococcus aureus) planktonic bacteria to NO-releasing PPI 
dendrimers.65  
Further studies on the anti-biofilm action of dendrimers revealed that killing was not only 
dependent on concentration, but also on generation and functional group modification.66-67 An 
increase in dendrimer size led to an increase in the number of secondary amines, thus increasing 
the amount of NO per molecule. Greater biofilm killing was therefore observed for the larger 
generations versus the lower generations (i.e., generation 3 vs. 1) against Staphylococcus aureus 
and Pseudomonas aeruginosa biofilms (concentration to kill reduced by half).66 Additionally, as 
the terminal units (exterior functional groups) were altered from propyl to dodecyl groups, a 
significant reduction in the NO dose to kill was observed.67 For example, NO-releasing PAMAM 
dendrimers bearing propyl groups required 52.5 mM NO to kill Streptococcus mutans, while 
dendrimers bearing dodecyl groups required only 1.8 mM. This disparity in concentration was 
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most likely the result of the long alkyl chains (i.e., dodecyl) intercalating into the bacterial cell 
membrane leading to cell death, which reduced the amount of NO needed for eradication. 
However, more NO was required to kill for the shorter alkyl chains (i.e., propyl) as they cannot 
effectively damage the bacterial membrane. 
1.4 Liposomes as drug delivery vehicles 
          The ideal NO-releasing macromolecular delivery system would protect the NO donor until 
the site of interest is reached. Current NO-release systems fall short in this regard as the NO 
donor is exposed to the aqueous environment (e.g., bloodstream) leading to N-diazeniumdiolate 
degradation and NO release. Premature NO release decreases the amount of NO available for 
therapeutic action, and may increase off-target cytotoxicity. Bloodstream delivery systems that 
confer protection to the NO donor would overcome the issue of premature NO donor 
degradation. 
 Similar to the structure of a cell, liposomes are vesicles that contain an inner aqueous 
core surrounded by a phospholipid bilayer (Figure 1.5). The composition of both the aqueous 
compartment (e.g., ionic strength) and the bilayer may be modified to achieve different vesicle 
properties (e.g., size and charge). Additionally, cationic lipids may be incorporated into the 
bilayer to produce a charged liposome surface that will ultimately affect encapsulation 
efficiency, liposome size, and cellular uptake. As the liposome structure is composed of only 
phospholipids, the delivery vehicle is non-toxic and degradable in vivo, unlike other particle 
systems (e.g., silica and gold).68 Further, the similarity in surface between cells and liposomes 
suggests potential for cellular uptake through bilayer fusion, a process that cannot occur for other 
drug delivery vehicles. 68-69 
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Figure 1.5. Representation of a liposome and its ability to encapsulate both lipophilic and 
hydrophilic drugs. 
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1.4.1. Synthesis and characterization of liposomes 
 Choosing a suitable liposome preparation method depends on the required liposome size, 
equipment available, and identity of the encapsulated molecule. The two most widely used 
protocols are thin-film hydration and the reverse phase evaporation techniques.68 Thin-film 
hydration method requires the evaporation of a phospholipid solution (usually dissolved in 
chloroform) under a nitrogen stream or other low pressure environment.70-72 Afterwards, a “thin 
film” is formed on the bottom of the flask, which is then subjected to rehydration in an aqueous 
phase. The molecule of interest to be encapsulated may either be added to the phospholipid 
solution or the aqueous phase, depending on its solubility. Sonication of the liquid causes 
phospholipid bilayers to form and desorb from the flask to produce liposomes. This method 
tends to form large, multilamellar liposomes (i.e., concentric bilayers encapsulating one another). 
The reproducibility of the number of lamellar phases is poor, and thus extrusion through 
polycarbonate membranes is ultimately required to obtain narrow distributions of liposome sizes 
and lamellarities.73 Unfortunately, the extrusion process leads to low encapsulation efficiencies 
(<15%). Additionally, the thin-film hydration method is not easily scaled up like other 
techniques (e.g., reverse phase evaporation), further limiting its use in industrial liposome 
production.74 
 Another popular method for synthesizing liposomes is through a reverse phase 
evaporation technique developed by Szoka and Papahadjopoulos.75-77 An organic phase 
containing the lipids and an aqueous phase are sonicated at a temperature slightly higher (~5 °C) 
than that of the transition temperature (where the phospholipid tails convert from an ordered, 
solid phase into a more fluid phase) to form an opalescent emulsion of phospholipids. 
Afterwards, the organic phase is evaporated at elevated temperatures, causing the hydrophobic 
 16 
lipid tails to collapse onto one another in the aqueous phase and form bilayers.76 A benefit of this 
technique is that liposomes are typically small (<300 nm) and have encapsulation efficiencies up 
to 60%. Purification by extrusion is not generally required for the reverse phase evaporation 
process as the resulting liposomes are unilamellar in nature and have a narrow size distribution. 
However, heat-sensitive molecules, such as proteins, may be degraded due to the required 
heating during sonication and rotoevaporation steps. To avoid this, phospholipids with low 
transition temperatures are preferred. 
 Common ex vivo liposome characterization techniques examine size, shape, 
polydispersity, drug encapsulation efficiency, drug retention, and aggregation over time. 
Dynamic light scattering (DLS) may be used to measure both the hydrodynamic radius of the 
liposomes and size distribution.78-79 Size and shape may also be examined using transmission 
electron microscopy (TEM).80 TEM potentially allows for observation of the liposome interior, 
as well as its deformability. Freeze-fracture TEM is a specialized form of TEM where the 
liposome sample is fixed using liquid nitrogen, fractured, and sputtered coated with a metal.81-82 
Through fracturing the liposome vesicle, the interior becomes visible and properties such as 
number of lamellae are observed. The efficiency of drug encapsulation is measured to determine 
how well the molecule of interest is encapsulated. Of note, such characterization measurements 
are highly dependent on the molecule encapsulated. Other tools for characterization include 
absorbance, fluorescence, or flow cytometry to compare the concentration of the stock solution 
to that of the ruptured liposomes (equal concentrations would indicate a 100% encapsulation 
efficiency).83 Drug retention and vesicle aggregation are measured concurrently over time using 
a combination of DLS, TEM, and fluorescence (or whichever technique was used to identify the 
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encapsulant). Aggregation is minimized by lyophilizing the liposomes or by storing them at 4 
°C.84 
1.4.2. Pre-clinical liposome systems 
 Many liposomal systems are being researched in the hopes of entering clinical trials for 
medical applications (e.g., anticancer, diagnostic) with encapsulants ranging from small 
molecules to large macromolecular structures. Delivery of macromolecules is a prevalent method 
for eradicating diseases and building immunity to foreign invaders.85-87 For example, siRNA and 
DNA have been encapsulated within positively charged liposomes.88-91 Positive lipids such as N-
[1-(2,3-dioleyloxy)propyl]-N,N,N-trimethyl ammonium chloride (DOTMA) electrostatically bind 
to the negatively charged DNA molecules, causing the formation of a vesicular complex.92 These 
ionic amalgams have greater encapsulation efficiencies over liposomes bearing neutral charge. 
Intracellular delivery of these macromolecules is also more effective (relative to their free form) 
since the liposome bilayer may fuse with cell membranes.69 
 Quantum dots have also been encapsulated within liposomes in order to enhance their 
solubility in aqueous solutions.93-96 The hydrophobic ligands that are usually appended to the 
surface of quantum dots destabilizes the particles in aqueous solutions, thereby precluding their 
use from efficient in vivo imaging. However, through the use of liposomes, the quantum dots are 
able to dissolve in the lipid bilayer for bloodstream delivery. After intravenous delivery of the 
liposomes in rats, near infrared (NIR) images show accumulation of quantum dots throughout the 
body, the liver and spleen in particular.96 In addition to therapeutics, quantum dot-loaded 
liposomes have been used as fluorescent labels in immunoassays.95 Sensitivities and limits of 
detection of assays using these liposomes were five times greater than that of assays using 
unencapsulated quantum dots. 
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 Small molecule liposomal systems are by far the most utilized for research and medical 
applications. Chen et al. synthesized arsenic trioxide (As2O3)-loaded liposomes for use as an 
anticancer agent since free As2O3 has led to acute poisoning in patients.97 Encapsulated As2O3 
within a liposome prevents rapid damage to the cell membrane and promotes an extended release 
profile. The longer release durations mitigate undesirable off-target cytotoxicity to healthy cells. 
Cell viability studies verified that higher concentrations of liposomal As2O3 were required to kill 
human cells relative to unencapsulated As2O3 (>200 and 10 µM, respectively).  
While in some cases liposomes may be used to mitigate toxicity, they are more generally 
employed to enhance cytotoxic action. Gemcitabine is the gold standard chemotherapeutic for 
treating advanced stage pancreatic cancer.98 Gemcitabine’s short plasma half-life (8–17 min) 
requires high doses to be administered, which can lead to adverse side effects in patients.99 
Liposomal gemcitabine was synthesized by Fresta and coworkers to increase drug 
pharmacokinetics.99 Cytotoxicity studies comparing free gemcitabine to liposomal gemcitabine 
confirmed enhanced killing (2–3 fold decrease in IC50 value). Similarly, ibuprofen-loaded 
liposomes have been used as a treatment of lung cancer. Daily administration of ibuprofen has 
been shown to reduce the risk of lung cancer, but continuous exposure to ibuprofen causes 
gastrointestinal bleeding and renal toxicity.100 Cheng et al. have demonstrated greater cell death 
against multiple lung cancer cells lines when using liposomal ibuprofen instead of free ibuprofen 
(<400 vs. >1,500 µM, respectively). Further in vivo xenograft studies verified that liposomal 
ibuprofen may induce oxidative stress against the cancer cells, as indicated by elevated stress 
marker levels in urine.  
Another common drug that has benefited from liposomal encapsulation is docetaxel, a 
highly-utilized chemotherapeutic used to treat prostate, neck, and breast cancer.101 The poor 
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water-solubility of docetaxel requires the use of surfactants (e.g., Tween 80) and organic solvents 
to aid in dissolution and delivery. Unfortunately, Tween 80 elicits hypersensitivity effects in 
vivo. Formulating docetaxel-loaded liposomes has increased both its solubility and blood 
circulation time. Biodistribution measurements revealed that liposomal docetaxel had a 5-times 
longer circulation half-life than the free form (260 vs. 52 min, respectively). 
The treatment of glaucoma requires continuous drug exposure to reduce intraocular 
pressure. As such, glaucoma patients must enroll in a daily eye drop regimen rather than a 
monthly dose. Latanoprost, the leading treatment of glaucoma, has been encapsulated into 
liposomes in an attempt to increase the release duration and eliminate the need for a daily eye 
drop schedule. Natarajan et al. were able to synthesize a liposomal system capable of continuous 
latanoprost release for >30 days (60% is released within 30 days).102 Evaluation of the system on 
a nonhuman primate model revealed that intraocular pressure was consistently lower compared 
to untreated and eye drop treated controls. Moreover, a single injection of the liposomes led to 
intraocular pressure reduction for 120 d. The authors attributed the sustained release profile to 
the protection of the encapsulated latanoprost conferred by the phospholipid bilayer. 
1.4.3. Commercial liposome systems 
 A number of liposome formulations have commercially emerged for the treatment of 
multiple diseases.85 One of the most well-known formulations is that of liposomal doxorubicin 
(Doxil), the first FDA-approved nanocarrier to be used in hospitals as a treatment for ovarian 
cancer and Kaposi sarcoma.103 A unique transmembrane ammonium sulfate gradient is used to 
load doxorubicin at high concentrations within the liposomes.104 A greater anticancer action was 
observed for Doxil relative to free doxorubicin. 105 The in vivo utility of the liposomes is in part 
due to the introduction of phospholipids bearing polyethylene glycol (PEG) headgroups into the 
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bilayer.106 The PEGylated lipids increased the hydration of the exterior surface, helping prevent 
aggregation during storage (i.e., long shelf-life) and mitigating any immune response upon 
administration.107-108 When compared to free doxorubicin in vivo, Doxil had a 300-times longer 
clearance lifetime as a result of the liposomal encapsulation and PEGylation of the liposome 
surface.103  
 In addition to Doxil, other liposomal drugs now include Ambisome, Marqibo, and 
DaunoXome. Ambisome (liposomal amphotericin B) is a therapy that utilizes the lipid bilayer to 
dissolve amphotericin B in order to treat fungal infections.109-111 Marqibo is a liposomal 
formulation of vincristine sulfate to treat acute lymphoblastic leukemia.112 DaunoXome utilizes 
liposomally encapsulated daunorubicin to treat acute myeloid leukemia and non-Hodgkin 
lymphoma.113-114 Along these lines, liposomes loaded with morphine sulfate (DepoDur) have 
been used as an enhanced version of an epidural to last longer and provide extended pain relief to 
mothers.115-116  Depocyt (liposomal cytarabine) has been administered to patients who suffer 
from lymphomatous meningitis and has proven to be more effective than the free cytarabine.117-
118 Drugs for photodynamic therapy have been encapsulated within liposomes to better treat 
individuals suffering from neovascularization ailments.119-120 Liposomal formulations have been 
used to enhance the immunogenicity of vaccines.121 For example, the liposomal influenza virus 
vaccine (Inflexal V), first introduced onto the Swiss market in 1997, has been used over 41 
million times.121-123 Additionally, the liposomal hepatitis A vaccine (Epaxal) has been shown to 
be well tolerated and immunogenic in patients.124-125  
 While there isn’t an approved liposomal cisplatin system yet, it is worth mentioning the 
current success of Lipoplatin, which is the liposomal form of cisplatin that is currently in clinical 
trials for treatment of multiple cancers (e.g., breast, ovarian, lung).126-129 Systemic administration 
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of cisplatin often leads to severe adverse effects such as renal tubular damage. To mitigate such 
issues, Lipoplatin was introduced as the liposomal formulation.127 Preclinical trials have shown 
that Lipoplatin exhibits lower off-target toxicity than cisplatin, but is still able to induce 
apoptosis in malignant cells.129 Further Phase I trials determined that the maximum tolerated 
dose was as high as 350 mg/m2, over double that of the free cisplatin dose (100 mg/m2). 
However, hematological and gastrointestinal toxicity has been noted, albeit it to a much lower 
degree than free cisplatin. Many Phase II trials have been carried out and demonstrated that the 
combination of Lipoplatin and another chemotherapeutic (e.g., gemcitabine) is more effective 
than dual-administration of cisplatin and gemcitabine. Phase III clinical trials are currently 
underway to evaluate the potential effectiveness of Lipoplatin and gemcitabine.129 
1.4.4. Intracellular uptake of liposomes 
 The therapeutic efficacy of liposomes is highly dependent on its ability to be uptaken 
rapidly into the cell. The translocation of liposomes to the interior of a cell is a complicated 
process that depends on a number of factors such as liposome size and charge, type of cell, and 
rate of metabolic processes.130 Clathrin-mediated endocytosis is a common pathway whereby 
liposomes exceeding 100 nm are able to enter cells. A less common, but still relevant pathway is 
that of macropinocytosis, which is reserved for vesicles larger than 1 µm.131 In this process, 
when external macromolecular structures are in close proximity to the cell, invagination of the 
cell membrane occurs along with coating the cytoplasmic face of this vesicle with the triskelion 
protein clathrin.132 After complete invagination, heat shock protein hsc70 aids in removing the 
external clathrin coat. The formed endosome then travels according to the pathway its on (e.g., 
endolysosomal pathway) and the internal contents (i.e., drug) of the liposome may either be 
released during this entire process or once the lysosome is reached. 
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 Other clathrin-independent pathways exist to internalize liposomes.132-133 For example, 
caveolins are scaffolding proteins that can replace clathrin to aid in liposome uptake. The exact 
initiation of this pathway has yet be fully understood, as even the same molecule (e.g., albumin) 
interacting with the same cell may not utilize caveolin pathways consistently.133 Another method 
of entry is mediated by dynamin, a guanosine triphosphate (GTP) hydrolase enzyme that assists 
in the fusion of liposomes with the cell membrane. This process is actually regulated by a 
GTPase called Ras homolog gene family member A (RhoA).133 Examples of molecules that 
regularly enter mammalian cells via this mechanism include receptors for interleukin-2, common 
γ chain cytokines, and immunoglobulin E.  
1.4.5. Ligand-bearing liposomes 
 In order to increase in vivo blood circulation times or the binding affinity of liposomes to 
a particular cell, ligands are commonly attached to the vehicle’s exterior surface.134 Doxil 
employs PEG groups to make the liposome surface appear more endogenous and prevent an 
immune response that clears liposomes from the bloodstream. By increasing the water density 
near the liposome surface, it becomes difficult for opsonins to adhere and “mark” the 
liposome.108 Without the opsonins on the liposomes surface, white blood cells aren’t able to 
locate the vehicles and remove them from the bloodstream. These PEG chains may be replaced 
by other structures that are capable of increasing surface hydrophilicity (e.g., sugars). 
 Cell targeting to prevent off-target cytotoxicity is achieved by exploiting the unique 
receptors present (or overexpressed) on the cell of interest and attaching the receptor compliment 
to the liposome. Folate groups at the outer surface of the liposome via covalent attachment or 
intercalation into the lipid bilayer represent one example. Many human tumors overexpress 
folate receptors on their surface because folic acid is a key vitamin required for the rapid 
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deoxyribonucleic acid (DNA) synthesis exhibited by malignant cells.135 HeLa and KB cells 
exposed to folate-appended arsenic trioxide liposomes were shown to be 9- and 28-times, 
respectively, more toxic than the same liposomes without the folate groups.136 Other non-
antibody ligands (and their respective diseases) include transferrin (multiple cancers), 
galactosamine (hepatoma), and granulocyte macrophage colony-stimulating factor (leukemic 
blasts).134 Antibodies conjugated to liposomes are continuously being discovered and produced, 
including anti-tenascin (breast cancer), anti-CD33 (acute myeloid leukemia), and anti-CD20 
(non-Hodgkin lymphoma).134 Difficulties associated with synthesizing liposomes bearing various 
markers are high cost, degradation or denaturing of the marker during liposome synthesis (e.g., 
organic solvents, high ionic strengths, high temperatures), and low purity (inability to remove 
liposomes without marker from those that have it). 
1.5 Nitric oxide-releasing liposomes 
          Unlike current macromolecular systems (e.g., dendrimers and silica nanoparticles) where 
the NO donor is appended to the exterior, liposomes are able to encapsulate the NO donor behind 
a lipid bilayer that confers protection until subsequent localization or delivery (Figure 1.5). To 
date, little research has been performed on developing NO-releasing liposomes that exploit this 
unique characteristic of the vehicle. 
1.5.1. NO gas-encapsulated liposomes 
 Liposomes incorporating NO gas within the aqueous core have been prepared by 
exposing liposomes directly to gaseous NO.137-139 These systems yield NO payloads of ~10 µL 
NO per mg of lipid. The kinetics of NO release are rapid upon exposure to aqueous solutions 
(t1/2=10 min). The rates of NO release may be slightly varied by encapsulating a mixture of 
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NO and argon. A 1:9 volumetric ratio of NO to argon was shown to yield the best system with 
NO totals of 0.045 µmol NO/mg lipid. Exposure of smooth muscle cells to the NO-releasing 
liposomes resulted in 20 and 80% cell viability at 5 µM NO and 2 µM NO, respectively, 
revealing a concentration dependence on cytotoxicity. The 1:9 ratio liposomes were then injected 
into rabbits that had injured carotid arteries to assess the effects of NO on the vasculature healing 
process. After 14 days post-injection, histological studies revealed that NO induced inhibition of 
arterial closure by 40% relative to the untreated controls, supporting that NO release can promote 
healing and widening of injured arteries. 
1.5.2. Metal nitrosyl complex-encapsulated liposomes 
 Metal complexes bearing nitrosyl groups, light-sensitive NO donors, have also been 
encapsulated within liposomes.140 Ostrowksi et al. loaded egg phosphatidylcholine-based 
liposomes with the NO donor trans-Cr(cyclam)(ONO)2+. The liposomes were ~125 nm in 
diameter and retained their structure and NO for at least 2 weeks. After irradiation with 350 nm 
light, the liposomes produced up to 8 nM NO, with no detectable NO concentrations in the 
absence of light. The amount of NO released from the free metal complex proved dependent on 
the oxygen levels of the solution. The total amount of NO released in solutions purged with 
helium was 1.56 nmol, compared to 0.02 nmol for an air-saturated solution. The disparity in 
measured NO concentrations was attributed to scavenging of the liberated NO gas. However, the 
liposomal metal complex did not show scavenging, most likely due to differential partitioning of 
the NO into the bilayer or the bilayer reacting with any photoproducts.140 The liposome system 
exhibited on/off control of NO release, as well as NO payloads ranging from 1 to 10 nM 
depending on the duration of irradiation (10–30 s). While this system demonstrates the utility of 
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liposomes for controlling NO-release kinetics, the reliance on an external light source for NO 
release and the low NO payloads limits their use for therapeutic applications. 
1.5.3. Organic nitrate-encapsulated liposomes 
 Organic nitrates, the most common NO donor utilized in medical settings (e.g., glyceryl 
trinitrate and isosorbide dinitrate) have also been encapsulated within liposomes. Pedrini et al. 
reported on a doxorubicin derivative with a pendant organic nitrate group capable of releasing 
NO (NitDox) and dual-action therapy.141 To further enhance cytotoxicity towards cancer cells, 
NitDox was loaded into ~200 nm PEGylated liposomes. Comparing the degradation half-life of 
free NitDox (16 h) and liposomal NitDox (19–25 h) in human serum, it was revealed that the 
liposomes protected the organic nitrate from hydrolytic and enzymatic degradation. The 
cytotoxicity of the liposomes towards breast and ovarian cancer were then compared to free 
doxorubicin, free NitDox, and a liposomal form of doxorubicin. All liposome formulations 
resulted in greater cytotoxicity towards the cell lines relative to free drugs, which was attributed 
to more efficient cellular uptake. However, the NitDox-loaded liposomes proved to be more 
cytotoxic than the doxorubicin-loaded liposomes, indicating that dual-action release (both NO 
and doxorubicin) enhanced overall toxicity. 
1.5.4. N-diazeniumdiolate-encapsulated liposomes 
 As mentioned above, N-diazeniumdiolates undergo a proton-initiated decomposition 
mechanism to release NO. With NO release highly dependent on pH, N-diazeniumdiolates 
represent a unique class of NO donors that can undergo spontaneous decomposition in vivo to 
liberate their stored NO, unlike the previously mentioned NO donors that rely on enzymes 
(organic nitrates) or light (nitrosyl metal complexes) to initiate NO release. With respect to 
cancer, the low pH of malignant sites could act as a trigger to increase the rate of NO liberation,  
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Figure 1.6. Nitric oxide-releasing liposome and mechanism of NO release. 
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thus leading to high, local concentrations of NO at the tumor site. A single, prior study 
demonstrated the feasibility of encapsulating N-diazeniumdiolates within liposomes, although 
the liposomes were not extensively characterized (e.g., encapsulation efficiency and NO totals) 
or studied further (e.g., stability or cytotoxicity).142 Nevertheless, an important conclusion of this 
one report was that the NO release at pH 7.4 could be prolonged (up to a half-life of 449 min) 
through the use of thermally stable lipids. The researchers hypothesized that the enhanced 
rigidity of the bilayer provided better protection of the NO donor from the external solution 
(Figure 1.6). Collectively, the data suggested further N-diazeniumdiolate protection in vivo, 
while still maintaining their unique pH-sensitive NO release capabilities. 
1.6 Summary of dissertation research 
           The focus of my dissertation research was to synthesize a macromolecular liposome 
system capable of delivering NO to eradicate cancer cells. Initially, I studied the encapsulation of 
N-diazeniumdiolate NO donors within liposomes and their ensuing stability. Preliminary 
cytotoxicity assays were carried out to examine if the NO-releasing liposomes exerted any 
anticancer action against pancreatic cancer cells. Upon proving that a stable liposomal 
formulation could be synthesized, the liposomal formulation was optimized in order to better 
understand the release mechanism. Lastly, the kinetic-dependent killing of the NO-releasing 
liposomes against 9 human cancer lines, encompassing three different cancers was investigated. 
To summarize, my research aims were to:  
(1) synthesize N-diazeniumdiolate-encapsulated liposomes and determine their 
stability and cytotoxicity towards human cancer cells; 
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(2) tune both NO-release properties (e.g., NO totals and half-life) and liposomal 
properties (e.g., surface charge) while understanding how these affect NO release 
in biological media; and, 
(3) evaluate the role of liposomal NO-release kinetics with respect to cytotoxicity 
against human breast, pancreatic, and colorectal cancer cells. 
The goal of this introductory chapter was to set the stage for using NO as a  
chemotherapeutic, review current NO-release materials, and demonstrate that liposomes provide 
advantages over other NO delivery systems. In Chapter 2, the formulation of NO-releasing 
liposomes is discussed with evaluation of size, NO totals, stability, and cytotoxicity. Chapter 3 
describes the effects of the encapsulated NO donor and composition of the lipid bilayer on NO-
release properties, and role of media on stability and NO release. The cytotoxicity of two 
liposome systems with distinct NO-release profiles (e.g., slow and fast) is described in Chapter 4 
to better understand the effect of killing and intracellular NO delivery with respect to liposomal 
NO-release kinetics. Finally, Chapter 5 provides a summary of my work with suggested future 
studies involving NO-releasing liposomes. 
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CHAPTER 2: ENCAPSULATION OF N-DIAZENIUMDIOLATES WITHIN 
LIPOSOMES FOR ENHANCED NITRIC OXIDE DONOR STABILITY AND 
DELIVERY1 
 
2.1 Introduction 
 Nitric oxide (NO) is often proposed as a potential therapeutic due to the many roles it plays in 
human physiology.1-4 For example, NO functions as an antiplatelet agent because it helps 
regulate the production of cyclic guanosine monophosphate (cGMP) and concentration of 
calcium ions (Ca2+) within platelets required for platelet activation.5 In addition to its 
antithrombotic properties, NO exhibits broad-spectrum antibacterial activity and is central to the 
innate immune response.6 Nitric oxide exerts antibacterial action through the reaction with other 
oxidants and production of cytotoxic byproducts (e.g., dinitrogentrioxide, peroxynitrite) that 
subsequently induce DNA deamination and cell membrane damage.7-8 Nitric oxide has been 
shown to kill cancer cells through similar nitrosative and oxidative stresses.9 Another potential 
mechanism of NO’s anticancer action is through the regulation of intracellular protein 
expression. For example, Hofseth et. al. reported the effects of NO on the reactivation of the p53 
tumor suppressor protein.10  In this manner, cell death may be reinitiated to control cellular 
proliferation since p53 controls cell cycle entry/exit and apoptosis.11 A major advantage of 
                                                
1 This chapter was adapted from an article that previously appeared in Molecular Pharmaceutics. 
The original citation is as follows: Suchyta, D.J.; Schoenfisch, M.H. “Encapsulation of N-
diazeniumdiolates within liposomes for enhanced nitric oxide donor stability and delivery” 
Molecular Pharmaceutics 2015, 12, 3569-3574. 
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exogenous NO over current chemotherapeutics would be the limited off-target cytotoxicity as 
NO has a relatively short lifetime in physiological milieu.1  
 The reactivity and short half-life of NO in biological media necessitates the use of NO 
donors as sources of NO. N-diazeniumdiolate NO donors have received considerable attention 
due to their ability to spontaneously (i.e., non-enzymatically) produce NO under physiological 
conditions, as a result of donor breakdown by water (protons).12 This NO release mechanism 
gives rise to controllable NO-release kinetics that are dependent on both NO donor and pH.13-14 
Unfortunately, the use of free NO donors often results in insufficient control over targeting the 
delivery and insufficient NO payloads for therapeutic applications.15 Macromolecular NO-
release scaffolds (e.g., dendrimers, nanoparticles) consisting of multiple NO donors have been 
developed to achieve greater NO payloads and delivery.16 Nanoparticle-based delivery vehicles 
have shown a broad range of NO-release kinetics that are highly dependent on the NO donor 
utilized (e.g., S-nitrosothiol, N-diazeniumdiolate).17  The therapeutic action of these NO-release 
systems has been demonstrated against both bacteria and cancer cells with directed cell 
membrane and DNA damage.18 While the NO payloads of these scaffolds are substantial (>1 
µmol NO/mg), the majority of the NO can be released too rapidly depending on their 
structure.8,18-19 Ideally, next generation NO-release scaffolds would be stable or only minimally 
breakdown at pH 7.4 and 37 °C until certain physiology (e.g., a change in pH) would trigger a 
burst of NO release. Such pH-triggered NO delivery might prove useful in the development of 
new anticancer agents, exploiting the acidic (pH 5.4−7.6) microenvironments inside tumors.20-21 
In this respect, the majority of NO would be released at the tumor site avoiding potential off-
target cytotoxicity. 
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 Liposomes are nanostructures composed of an inner aqueous core surrounded by a 
bilayer of phospholipids that have been used to enhance drug delivery against many diseases 
(e.g., cancer).22 Encapsulation of a NO-releasing chromium complex within liposomes proved 
that the lipid bilayer can confer protection to the NO donor.23 Tai et al. previously reported the 
encapsulation of spermine/NO within a phosphatidylcholine-based liposome utilizing a thin-film 
hydration method to achieve NO release.24 Unfortunately, their resulting liposomes yielded low 
NO totals and their stability was unknown. Herein, we describe an alternative approach for 
preparing NO-releasing liposomes containing N-diazeniumdiolate NO donors with attention to 
vehicle formation, stability, and pH-triggered delivery. In contrast to other macromolecular NO-
release systems (e.g., nanoparticles), the N-diazeniumdiolate NO donor is encapsulated within an 
aqueous core whereby a high interior pH limits undesirable NO donor decomposition. 
2.2 Experimental section 
2.2.1. Materials 
Dipalmitoylphosphatidylcholine (DPPC) was purchased from Avanti Polar Lipids 
(Alabaster, AL). Cholesterol (Chol), iron (III) chloride hexahydrate, ammonium thiocyanate, 
bis(3-aminopropyl)amine, fetal bovine serum (FBS), penicillin streptomycin, Dulbecco’s 
modified Eagle’s medium (DMEM), phosphate-buffered saline (PBS) for cell culture, and 
dipropylenetriamine were obtained from Sigma (St. Louis, MO). Phenazine methosulfate (PMS), 
chloroform, anhydrous acetonitrile, sulfuric acid, and isopropyl ether were purchased from 
Fisher Scientific (Fair Lawn, NJ). 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-
(4-sulfophen-yl)-2H-tetrazolium inner salt (MTS) was from Promega (Madison, WI). Sephadex 
G-25 was from GE Healthcare (Pittsburgh, PA). Spermine was purchased from Alfa Aesar 
(Ward Hill, MA). Pure nitric oxide (NO) gas (99.5%) was obtained from Praxair (Sanford, NC). 
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Argon, nitrogen (N2), nitric oxide (NO) calibration gas (26.80 ppm, balance N2), and carbon 
dioxide (CO2) gas cylinders were from Airgas National Welders (Durham, NC). A Millipore 
Milli-Q UV Gradient A10 System (Bedford, MA) was used to purify distilled water to a 
resistivity of 10.2 MΩ·cm and a total organic content ≤6 ppb. PANC-1 cells (ATCC number 
CRL 1469) were a gift from Dr. Channing Der of the Department of Pharmacology at the 
University of North Carolina (Chapel Hill, NC). 
2.2.2. Synthesis of N-diazeniumdiolates 
Previously reported methods were employed to synthesize the NO donors (Figure 2.1).12-
13 Briefly, the precursor molecule was dissolved in anhydrous acetonitrile (typically 33.3 
mg/mL). The solution was subsequently purged with argon at 100 psi inside a stainless steel Parr 
bomb. Six sequential purges removed any residual oxygen in the solution. The solution was then 
charged with 10 bar NO for 3 d. After 3 d, the solution was purged six times with argon to 100 
psi to remove any residual NO. The final solutions, containing the precipitated product, were 
poured over a Hirsch funnel, washed twice with diethyl ether, and dried under vacuum overnight. 
The final product was stored at -20 °C until use. 
2.2.3. Preparation of liposomes 
 Liposomes were made using a 1:1 molar ratio of DPPC to Chol (typically 33 µmol DPPC 
to 33 µmol Chol) using the method of Szoka and Papahadjopoulos.25 Lipids were dissolved in a 
1:1 volumetric ratio of chloroform to isopropyl ether and added to a round-bottom flask with a 
septum under a nitrogen atmosphere. Subsequently, the N-diazeniumdiolate was dissolved in 50 
mM NaOH to make a 14 mM stock NO donor solution and injected into the flask, which was 
sonicated for 4 min at 45 °C. The organic phase was removed using rotoevaporation, and the 
resulting liposomes were allowed to sit at 45 °C for 30 min. The unencapsulated material was 
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removed using four Sephadex G-25 spin columns packed in 10-mL syringes to minimize dilution 
of the liposomes. The final liposome solution was stored at 4 °C protected from light. 
2.2.4. Characterization of liposome size 
For dynamic light scattering measurements, the liposomes were diluted with water and 
analyzed with a Zetasizer Nano (Malvern Instruments, UK). Transmission electron microscopy 
(TEM) images were taken using liposomes diluted 1:1 with Milli-Q water. The liposomes were 
cast Formvar coated, square mesh copper TEM grids (Electron Microscopy Sciences, Hatfield, 
PA). After 45 minutes to allow evaporation of the solvent, a negative-stain was performed using 
2% uranyl acetate. A drop of the stain was left on the grid for 1 min and subsequently removed 
using filter paper, followed by a 15 min dry time. The liposomes were imaged using a JEOL 
100CX II transmission electron microscope at an accelerating voltage of 100 kV. 
2.2.5. Phospholipid content assay 
Total phospholipid content of the final liposome solution was determined using the 
Stewart assay.26 Briefly, a 0.1 M ammonium ferrothiocyanate solution was made by dissolving 
27.03 g iron (III) chloride hexahydrate and 30.4 g of ammonium thiocyanate in 1 liter of Milli-Q 
water. One microliter of the liposomes was mixed with 1.999 mL of the ammonium 
ferrothiocyanate solution. Subsequently, 2 mL of chloroform was added and the solution was 
vortexed for 15 s. Centrifugation ensued at 116 × g for 5 min and the lower layer was analyzed at 
485 nm using a UV-Vis Lambda 40 Spectrophotometer (Perkin Elmer, Waltham, MA). 
2.2.6. Nitric oxide release from liposomes 
Analysis of liposomal NO totals and release kinetics were evaluated using a Sievers 
(Boulder, CO) chemiluminescence nitric oxide analyzer (NOA).27-28 The instrument was 
calibrated using a NO zero filter (0 ppm NO) and a 26.80 ppm NO standard (balance N2). Before 
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Figure 2.1. Structures of the NO donors synthesized (a) SPER/NO, (b) and DPTA/NO 
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NO analysis, the liposomes were passed through a Sephadex G-25 spin column to remove any 
material that may have permeated the liposomal bilayer during storage. After passage through 
the column, an aliquot of the liposomes was injected into a 2:1 volumetric ratio of ethanol to 
0.183 M sulfuric acid (30 mL total volume) at 37 °C for encapsulation efficiency determination. 
Kinetic studies were performed in 10 mM acetate buffer (pH 5.4) and 10 mM PBS (pH 7.4) at 37 
°C. 
2.2.7. Cytotoxicity assay 
PANC-1 cells were cultured in DMEM supplemented with 10 vol% FBS and 1 wt% 
penicillin/streptomycin. Cells were maintained at 37 °C in a humidified incubator with 5% CO2. 
For cell viability evaluations, the MTS assay was used as previously described.29 Briefly, cells 
(2×104 cells/mL) were treated with various volumes of drug and plated in triplicate (200 µL total 
volume per well). Following a 24 h incubation period at 37 °C, the supernatant of each well was 
removed, rinsed with PBS (100 µL) to remove any liposomes, and DMEM was added (100 µL). 
The cells were further incubated with 20 µL of MTS reagent (20:1 v/v MTS to PMS) at 37 °C for 
90 minutes. Subsequently, the supernatant was removed and added to a new 96-well plate. The 
absorbance of the resulting solutions was measured at 490 nm using a Thermoscientific 
Multiskan EX plate reader (Waltham, MA). The ratio of absorbance values between the samples 
and the controls multiplied by 100 was determined to be the percent cell viability.  
2.3 Results and discussion 
2.3.1. Synthesis of NO-releasing liposomes 
Nitric oxide-releasing liposomes were synthesized by dissolving the N-diazeniumdiolate 
NO donor (spermine/NO [SPER/NO] and/or dipropylenetriamine/NO [DPTA/NO]) in 50 mM 
NaOH. This solution was added to a dipalmitoylphosphatidylcholine (DPPC)/cholesterol organic 
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mixture and briefly sonicated to form an emulsion. Subsequent removal of the organic phase by 
rotoevaporation resulted in the formation of 275 ± 21 nm liposomes (diameter; dynamic light 
scattering). Transmission electron microscopy further confirmed the formation of liposomes 
(Appendix A). Unencapsulated solute was removed by passing the liposomal solution through a 
Sephadex G-25 centrifuge column.30 Liposomes were stored at 4 °C to ensure vesicle stability 
and minimize NO donor decomposition. 
2.3.2. Liposomal NO-release measurements 
Real-time NO release was measured from the NO donor-containing liposomes using a 
Sievers chemiluminescence nitric oxide analyzer (Boulder, CO).27-28 Prior to NO analysis, the 
liposomal solution was passed through a Sephadex G-25 mini centrifuge column to remove 
solute that may have permeated the bilayer during storage. Total NO release was determined by 
adding the liposomes to a 1:2 sulfuric acid/ethanol solution, which in turn compromised the 
stability of the liposomes and decomposed the N-diazeniumdiolates to NO. The same procedure 
was used to breakdown the free NO donor. The encapsulation efficiency (EE) for the NO-
releasing liposomes was calculated based on total NO release for both the free and encapsulated 
NO donor (Table 2.1). Of note, the EE increased with increasing DPTA/NO to SPER/NO molar 
ratios. This phenomenon is attributed to the lower molecular weight of DPTA/NO. 
Nitric oxide release from the liposomes was monitored under physiological conditions 
(pH 7.4, 37 °C) to understand how NO donor encapsulation influenced breakdown of the N-
diazeniumdiolates. As shown in Figure 2.2, the initial burst associated with NO donor 
decomposition for free SPER/NO was more rapid than for liposome encapsulated SPER/NO 
(t1/2=35 vs. 162 min, respectively). Additionally, the initial rate of release was slowed further  
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Table 2.1. Encapsulation efficiencies (EE) of various NO donor compositions.a 
NO donor EE (%)b 
SPER/NO 33.7 ± 1.5 
DPTA/NO:SPER/NO (50:50) 36.8 ± 2.1 
DPTA/NO 41.3 ± 3.5 
aFrom n≥3 separate preparations. bRatio of µmol of NO inside liposomes to µmol used for 
synthesis multiplied by 100. 
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Figure 2.2. Nitric oxide release profiles of various encapsulated NO donors and free NO donor. 
Release profile from liposomal (a) DPTA/NO, (b) DPTA/NO:SPER/NO (50:50 molar ratio), (c) 
SPER/NO,  (d) and free SPER/NO for the first 3 hours in 10 mM PBS (pH 7.4, 37 °C). Same 
amount of lipid was injected (0.70 mg) for profiles a-c. NO release was measured in real-time. 
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(Table 2.2) by employing a more stable NO-releasing molecule (i.e., DPTA/NO; t1/2=3 h). For 
the encapsulated DPTA/NO, the duration of NO release is dramatically extended versus the free 
NO donor (Appendix A). In this manner, tunable NO release was achieved under physiological 
conditions by altering the low molecular weight NO donor selected for encapsulation. We 
hypothesize the NO release can also be attributed to slower decomposition of the donor within 
the liposomes rather than slow diffusion of the NO donor out of the liposome. Since the 
liposomes are below their 42 °C transition temperature (Tc), the liposome bilayer remains rigid 
and impermeable to molecules, especially charged molecules (i.e., our NO donors). Relative to 
free NO donors, SPER/NO and DPTA/NO-containing liposomes exhibited increased NO-release 
half-lives (~4 and 7 times greater, respectively). Moreover, increasing the molar ratio of 
DPTA/NO to SPER/NO inside the vesicles (i.e., 0, 50, 100 mol% DPTA/NO) enhanced both the 
half-life and duration of NO release. In fact, DPTA/NO-based liposomes released NO 
continuously for ~3 d. The ability to tune the NO-release kinetics by simply varying the ratio 
and/or type of encapsulated NO donor represents a unique property of liposomes over previously 
reported macromolecular scaffolds. 
Liposomal NO release was also monitored under acidic conditions (pH 5.4) to ascertain 
NO production relevant to the microenvironment of tumors.21-22 While the lipid bilayer provides 
both NO donor protection and tunable release kinetics at pH 7.4, the NO release in acidic 
solution was rapid, regardless of the N-diazeniumdiolate NO donor utilized (Table 2.3). The NO-
release kinetics of the liposomal systems were essentially equivalent to the free NO donors under 
the same conditions (i.e., DPTA/NO: t1/2=5.3±0.2 min; SPER/NO t1/2=3.4±0.8 min) as a result of 
the rapid NO donor decomposition by protons. Indeed, the duration of NO release for 
DPTA/NO-containing liposomes was only slightly longer than those with SPER/NO. 
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Table 2.2. Nitric oxide-release properties of liposomes in PBS (pH = 7.4) at 37 °C.a 
NO donor t1/2b                  
(h) 
[NO]maxc 
(ppb/mg) 
tdd                              
(h) 
[NO]totale 
(µmol/mg) 
SPER/NO 2.7 ± 0.7 217 ± 98 18.4 ± 0.5 0.19 ± 0.02 
DPTA/NO:SPER/NOf 16.6 ± 2.1 114 ± 17 51.2 ± 2.1 0.29 ± 0.03 
DPTA/NO 20.4 ± 2.7 29 ± 8 65.9 ± 1.8 0.26 ± 0.05 
aError bars indicate standard deviation from n≥3 separate preparations. bHalf-life of NO release. 
cThe highest instantaneous amount of NO generated. dDuration of NO release until the measured 
NO reached 10 ppb per 300 µL of liposomes (three-times the detection limit of the instrument). 
eLipid concentration was 23.3 ± 5.4 mg phospholipid per mL of aqueous phase. fMolar ratio of 
50:50. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 53 
Further studies were performed to determine the cause of the faster NO-release kinetics 
under pH 5.4 conditions. We rationalized that the rapid NO release stemmed from either 
compromised lipid structure, which would result in leaching of the NO donor into the acidic 
media, or increased proton influx through the liposome bilayer. The first explanation was 
dismissed as dynamic light scattering analysis of the liposomes in pH 5.4 acetate buffer indicated 
that liposome size/shape was preserved, suggesting the faster NO-release kinetics must be the 
result of a greater influx of protons. To verify this hypothesis, the interior pH of the liposomes 
was monitored using the bilayer-impermeable pH-sensitive dye pyranine.31 Under basic 
conditions pyranine fluoresces strongly, whereas protonation of the 8-hydroxyl group (pKa=7.2) 
yields a decrease in fluorescence, thus allowing for suitable analysis of the intraliposomal pH. 
After formation of pyranine-loaded liposomes, the fluorescence emission was analyzed after 
being diluted 100-fold (same as the NOA experiments) in NaOH, PBS, and acetate buffer 
(Figure 2.3). A small change in fluorescence intensity between the NaOH-diluted (2.3a) and 
PBS-diluted (2.3c) liposomes indicates that the intraliposomal pH remains relatively basic, 
supporting the observed extended NO-release kinetics in PBS. Upon bursting of the liposomes 
with a surfactant, the 512 nm emission peak almost completely disappears (2.3d). The large drop 
in fluorescence after liposome destruction confirms that the lipid bilayer confers protection to the 
NO donor by maintaining a basic interior (i.e., hindering proton permeation). However, upon 
exposure of the liposomes to acetate buffer (2.3e), the fluorescence decreases dramatically, and 
was similar to free pyranine in acetate buffer, indicating a drop in intraliposomal pH (2.3f). In 
fact, this behavior was expected as the number of ion channels in lipid bilayers have been 
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Figure 2.3. Fluorescence emission of pyranine-loaded liposomes (0.47 mg) made in 50 mM 
NaOH diluted 100-fold in (a) 50 mM NaOH, (c) 10 mM PBS (pH 7.4), (e) and 10 mM acetate 
buffer (pH 5.4). Free pyranine fluorescence after bursting of liposomes suspended in (b) 50 mM 
NaOH, (d) 10 mM PBS, (f) and 10 mM acetate buffer using 5 µL of Triton X-100. Spectra were 
measured at 37 °C using a 450 nm excitation wavelength. 
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reported to increase under acidic conditions.32 Such channels are obviously well suited to 
accommodate bilayer translocation of motile hydrogen ions. Thus, the faster NO release can be 
attributed to increased donor degradation and not a compromised bilayer. 
2.3.3. Stability of NO-releasing liposomes over time 
The stability of the NO-releasing liposomes was evaluated in a series of solutions as a 
function of pH. For these studies, the NO remaining within liposomes prepared in PBS (pH 7.4), 
borate buffer (pH 9.0) or NaOH (pH >12) was monitored over time. As expected, liposomes 
synthesized and stored in NaOH were characterized as having larger NO payloads (0.23 µmol 
NO/mg) relative to those made (and stored) in PBS or borate buffer (Figure 2.4). Substantial NO 
loss occurred for systems synthesized in PBS/borate solutions due to poor N-diazeniumdiolate 
stability in the non-alkaline media. After 3 months of storage at 4 °C, the liposomes in PBS and 
borate buffer lost 99 and 65% of their total stored NO. Clearly, the stability of the NO donor is 
maximized under basic conditions. 
2.3.4. Cytotoxicity of DPTA/NO-encapsulated liposomes 
Cytotoxicity was assessed against human PANC-1 pancreatic cancer cells over 24 h to 
investigate the anticancer action of both free DPTA/NO and liposomal DPTA/NO (Figure 2.5). 
We hypothesized that cancer cell killing would be greater for liposomes containing larger 
payloads of NO. DPTA/NO-based liposomes were thus chosen for the cytotoxicity study over 
the SPER/NO system. The encapsulated NO donor reduced cell viability by 50% (the LD50) at 
only 183 µM NO, whereas free DPTA/NO elicited cytotoxic effects (Appendix A) at much 
higher NO concentrations (2.4 mM). The increased cytotoxic effect elicited by liposomal 
DPTA/NO is greater because of the larger payload of NO that can be delivered, since less of the 
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Figure 2.4. Comparison of NO remaining from SPER/NO-loaded liposomes. Liposomes made in 
(■) 50 mM PBS, (●) 50 mM borate buffer, (▼) and 50 mM NaOH. The amount of NO remaining 
within the liposomes was determined by injecting the liposomes into an acidic solution at 
discrete timepoints. 
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Table 2.3. Nitric oxide-release properties of liposomes in acetate buffer (pH = 5.4) at 37 °C.a 
NO donor t1/2b                  
(min) 
[NO]maxc 
(ppb/mg) 
tdd                              
(h) 
[NO]totale 
(µmol/mg) 
SPER/NO 3.9 ± 0.5 8154 ± 859 1.0 ± 0.1 0.29 ± 0.03 
DPTA/NO:SPER/NOf 4.9 ± 0.7 5857 ± 990 1.3 ± 0.1 0.34 ± 0.08 
DPTA/NO 5.4 ± 0.3 6389 ± 1360 1.3 ± 0.1 0.39 ± 0.09 
aError bars indicate standard deviation from n≥3 separate preparations. bHalf-life of NO release. 
cThe highest instantaneous amount of NO generated. dDuration of NO release. eLipid 
concentration was 23.3 ± 5.4 mg phospholipid per mL of aqueous phase. fMolar ratio of 50:50. 
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Figure 2.5. In vitro efficacy of liposomal and free DPTA/NO on human PANC-1 cells after 24 h 
incubation. Liposomal DPTA/NO (■), liposomal DPTA (▼), and free DPTA/NO donor (●). Error 
bars indicate standard deviation from n≥3 separate experiments. Asterisk denotes p <0.05 
between DPTA/NO liposomes and both the free donor and DPTA-containing liposomes. 
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total NO is released prior to reaching the cell. Furthermore, an increase in intracellular uptake of 
the NO donor afforded by the liposomes, relative to the unencapsulated donor, would potentially 
allow for a more efficacious delivery of NO into the cell. Such trends have been reported 
previously for other liposomally encapsulated chemotherapeutic drugs (e.g., gemcitabine).33 
Liposomes loaded with only DPTA (i.e., no NO release capabilities) were mildly cytotoxic at 
larger concentrations (>300 µM) due to the anticancer properties of DPTA alone.34 However, 
these systems still exhibited significantly lower anticancer action compared to their NO-releasing 
counterpart. The reduced dose of liposomally-derived NO required (0.23 mg liposomes) to 
induce cytotoxic effects to pancreatic cancer cells demonstrates their promising therapetuic 
potential over free NO donor systems that require mM concentrations.35 
2.4 Conclusions 
The preparation of NO-releasing liposomes utilizing an alkaline interior aqueous phase 
enables the encapsulation of varying concetrations of NO with long shelf-lives (>3 mo). A 
preliminary investigation into the utility of these liposomal NO donors as anticancer agents 
demonstrates their therapeutic potential over small molecule NO donors. As the understanding of 
NO and its biological effects continues to expand, so does the need for diverse NO-releasing 
platforms that are robust, facilitate targeting, and possess tunable biological action. Nitric oxide-
releasing liposomes represent a unique strategy for cancer treatment in particular due to their pH-
triggered release. Varying the lipid bilayer content (e.g., phospholipid composition, charge) 
should further enhance the stability of this NO-delivery system and influence NO-release 
payloads. Future studies utilizing a more thermally stable lipid (e.g., 1,2-distearoyl-sn-glycero-3-
phosphocholine), could potentially prolong the NO-release duration even further due to greater 
bilayer rigidity. Such experiments are currently underway in our laboratory. 
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CHAPTER 3: CONTROLLED RELEASE OF NITRIC OXIDE FROM LIPOSOMES2 
 
3.1 Introduction          
 The drug delivery field has demonstrated that the encapsulation of therapeutics (e.g., 
antifungals, biocides, chemotherapeutics, and virucides) within liposomes is an effective strategy 
for controlled delivery to select targets of interest.1-4 Using liposomes as drug delivery vehicles 
affords many benefits, including reduced immune response, increased cellular uptake, and 
protection of drug payload from premature action or breakdown.5 Although liposomes passively 
localize themselves at the site of interest,5 post-delivery accumulation of the encapsulated 
therapeutic (e.g., cisplatin and doxorubicin) has been shown to negatively impact surrounding 
healthy tissue. 6-7 The need to develop therapeutics with limited off-target cytotoxicity remains 
highly desirable.                      
 Nitric oxide (NO) is an endogenously produced free radical involved in multiple 
physiological processes, including blood pressure regulation, the immune response to pathogens, 
neurotransmission, and cellular proliferation.8-11 Unlike current chemotherapeutics, NO is rapidly 
converted to a harmless metabolite (i.e., nitrite) and cleared in biological media, mitigating the 
toxic accumulation common to most drugs. Based on NO’s promise as a potential therapeutic, a 
significant body of research has focused on strategies to exogenously deliver NO using synthetic 
                                                
2 This chapter was adapted from an article that previously appeared in ACS Biomaterials Science 
& Engineering. The original citation is as follows: Suchyta, D.J.; Schoenfisch, M.H. “Controlled 
release of nitric oxide from liposomes” ACS Biomaterials Science & Engineering 2017, 3, 2136-
2143. 
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NO donors, such as metal-NO complexes, S-nitrosothiols (RSNOs), and N-diazeniumdiolates.12-
16 N-Diazeniumdiolates are a particularly attractive vehicle for NO storage and delivery because 
they undergo pH-dependent decomposition (faster release as the pH is lowered) to liberate NO 
(Appendix B). Furthermore, the breakdown and release of NO is a direct function of the 
molecular structure of the donor, enabling exquisite control over the rate of release.16 Structures 
bearing cationic primary amines can electrostatically stabilize their anionic diazeniumdiolate 
group, thus yielding longer NO-release half-lives. For example, spermine/NO (SPER/NO) 
exhibits a much longer half-life than proline/NO (PROLI/NO) at pH 7.4 (t1/2 = 37 min and 2 s, 
respectively).17 This breakdown of N-diazeniumdiolates to NO can be used therapeutically by 
exploiting the microenvironment of certain disease sites (e.g., cancer, dental caries, and 
ulcerative colitis) that exhibit a lowered pH due to altered cellular metabolisms. In contrast to 
healthy tissue, where pH homeostasis is maintained near pH 7.4, these diseased tissues should 
promote more rapid NO release at the site of interest, thereby mitigating off-target 
cytotoxicity.18-20           
 Others have previously demonstrated that liposomes can encapsulate NO donors in order 
to enhance delivery and prolong NO release.21-24 In contrast to these studies that used gaseous 
NO and NO photodonors, our lab has utilized encapsulated N-diazeniumdiolates to deliver NO. 
The liposomes exhibited enhanced NO donor stability (>3 mo shelf-life) along with greater in 
vitro cytotoxicity toward pancreatic cancer cells compared to the free, unencapsulated NO 
donor.25 However, the kinetic tunability of this system was rather limited (i.e., controlled only by 
pH) with the relationship between liposomal characteristics (e.g., composition and size) and NO-
release properties remaining unclear. As such, the focus of this research is developing strategies 
for altering the properties of NO release (e.g., half-life and total storage) by modifying the N-
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diazeniumdiolate and phospholipid structures. The utility of these changes on protein surface 
adsorption in serum (important for determining scaffold clearance in the bloodstream) is also 
investigated, with attention to NO-release properties as a function of solution media.26-27 
3.2 Experimental section 
3.2.1. Materials 
Dimyristoylphosphatidylcholine (DMPC), dipalmitoylphosphatidylcholine (DPPC), 
distearoylphosphatidylcholine (DSPC), dipalmitoylphosphatidylglycerol (DPPG), 
dipalmitoyltrimethylammoniumpropane chloride salt (DPTAP), 
dipalmitoylphosphatidylethanolamine-N-[methoxy(polyethyleneglycol)-2000] (DPPE-
PEG2000), dipalmitoylphosphatidylethanolamine (DPPE), and 
distearoylphosphatidylethanolamine (DSPE) were purchased from Avanti Polar Lipids 
(Alabaster, AL). Cholesterol (Chol), N-propyl-1,3-propanediamine (PAPA), L-proline (PROLI), 
diethylamine (DEA), spermine (SPER), pyranine, coumarin, 5(6)-carboxyfluorscein, Dowex 
1X2 chloride (200-400 mesh) anion exchange resin, hemoglobin from bovine, and fetal bovine 
serum (FBS) were obtained from Sigma (St. Louis, MO). Chloroform, anhydrous acetonitrile, 
sulfuric acid, diethyl ether, sodium hydroxide, and the Bradford assay kit were purchased from 
Fisher Scientific (Fair Lawn, NJ). The source of Sephadex G-25 was GE Healthcare (Pittsburgh, 
PA). Pure nitric oxide (NO) gas (99.5%) was obtained from Praxair (Sanford, NC). Nitrogen 
(N2), argon (Ar), and nitric oxide (NO) calibration gas cylinders (26.80 ppm, balance N2) were 
obtained from Airgas National Welders (Durham, NC). A Millipore Milli-Q UV Gradient A10 
System (Bedford, MA) was used to purify distilled water to a resistivity of 18.2 MΩ·cm and a 
total organic content of ≤6 ppb. Canine blood was freshly collected into EDTA-coated 
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vacutainers by the Francis Owen Blood Lab (Carrboro, NC). Serum was isolated from the blood 
samples within 15 min of initial collection. 
3.2.2. Synthesis of N-diazeniumdiolates 
A previously reported method was used to synthesize the NO donors.17 Briefly, the 
precursor amine (i.e., PROLI, DEA, PAPA, or SPER) was dissolved in anhydrous acetonitrile at 
a concentration of 33.3 mg/mL. The solution was then purged with argon to 100 psi inside a 
stainless steel Parr bomb. Six sequential purges (three quick purges of 10 s each, followed by 
three slow purges of 10 min each) was used to remove residual oxygen. The solution was 
subsequently charged with 145 psi NO for 3 d. After 3 d, the solution was purged six times with 
argon to 100 psi to remove residual NO. The precipitated product was poured over a Hirsch 
funnel, washed twice with diethyl ether, and dried under vacuum overnight. The final NO-
releasing product (i.e., PROLI/NO, DEA/NO, PAPA/NO, or SPER/NO) was stored at -20 °C 
until further use. Spectroscopic characterization was performed on the NO donors, including 
their decomposition products at pH 5.4 and 7.4 (Appendix B). 
3.2.3. Preparation of liposomes 
 Liposomes were synthesized using a 1:1 molar ratio of lipid to Chol (49.5 µmol 
lipid:49.5 µmol Chol) following the report by Szoka and Papahadjopoulos.28 Chloroform and 
diethyl ether (5 mL each) were used to dissolve the lipids in a round-bottomed flask under a N2 
atmosphere. The N-diazeniumdiolate donor (i.e., PROLI/NO, DEA/NO, PAPA/NO, or 
SPER/NO) was dissolved in 50 mM NaOH to make a 14 mM stock NO donor solution and 
subsequently injected (1.5 mL) into the flask, which was sonicated for 4 min at a temperature 5 
°C higher than the transition temperature of the phospholipid. The organic phase was removed 
by rotoevaporation and the resulting liposomes incubated above their respective transition 
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temperature for 30 min. The unencapsulated donor was removed using four Sephadex G-25 spin 
columns packed in 10-mL syringes. The final volume of purified liposomes collected from the 
column was stored at 4 °C. Fluorophore-encapsulated liposomes were prepared in the same 
manner as NO-releasing liposomes. 
3.2.4. Characterization of liposome size 
Dynamic light scattering (DLS) measurements were performed to determine liposome 
size and polydispersity. The liposomes were diluted with water and their size characterized using 
a Zetasizer Nano (Malvern Instruments, UK). Transmission electron micrographs (TEM) were 
also collected to confirm liposome formation. Liposome samples for TEM analysis were 
prepared by diluting the stock solution with Milli-Q water (1:1 volumetric ratio) and casting the 
suspension onto Formvar-coated, square mesh copper TEM grids (Electron Microscopy 
Sciences, Hatfield, PA). The solvent was allowed to evaporate for 45 min prior to applying a 
negative-stain using 2% (w/v) uranyl acetate. A drop of the stain was left on the grid for 30 s 
after which the droplet was removed using filter paper. The sample was then allowed to dry for 5 
min. The liposomes were imaged using a JEOL 100CX II transmission electron microscope at an 
accelerating voltage of 100 kV. 
3.2.5. Nitric oxide release from liposomes 
Nitric oxide totals and the overall release kinetics were evaluated using a Sievers 
chemiluminescence Nitric Oxide Analyzer (NOA; Boulder, CO).29-30 The instrument was 
calibrated using a NO zero filter (0 ppm NO) and a 26.80 ppm NO standard (balance N2). An 
aliquot of the liposomes was injected into a 2:1 volumetric ratio of ethanol to 0.183 M sulfuric 
acid (30 mL total volume) at 37 °C to determine the NO donor encapsulation efficiency. The 
encapsulation efficiency, or the extent to which the NO donor is entrapped within the liposomal 
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aqueous core, was calculated by comparing the liposome NO payload to the amount of NO in the 
free donor solution used during preparation of the liposomes. Studies to evaluate NO-release 
kinetics were performed in 10 mM MES buffer (pH 5.4) and 10 mM PBS (pH 7.4) at 37 °C. The 
presented data and error are from at least 3 separate liposome preparations. Nitric oxide release 
was terminated when the NO concentration dropped below 10 ppb per 300 µL liposomes. 
3.2.6. Turbidity assay 
Liposomes (30 µL) were mixed with 600 µL FBS and incubated at 37 °C with slight 
agitation. After 1 h, 100 µL was removed, placed into a 96-well plate, and then the absorbance at 
450 nm measured using a Thermoscientific Multiskan EX plate reader (Waltham, MA). The 
relative turbidity increase was compared against that of a control solution (30 µL of 50 mM 
NaOH mixed with 600 µL FBS). Of note, no further changes in turbidity were observed after 1 h 
incubation with FBS. 
3.2.7. Serum protein adsorption onto liposomes 
Quantification of proteins adsorbed onto the liposome surface was measured using the 
Bradford assay.31 Briefly, liposomes (20 µL) were mixed with 400 µL of a 10% (v/v in 10 mM 
PBS) FBS solution and incubated for 1 h at 37 °C with slight agitation. Afterwards, the 
liposomes were centrifuged (13,000 × g for 3 min) and washed twice with 10 mM PBS. The 
resulting lipid pellet was then dissolved in 100 µL of a 1:2 volumetric ratio of 10 mM PBS to 
ethanol. This dissolved pellet (30 µL) was added to a 96-well plate and mixed with 300 µL dye 
solution. After 10 min, the absorbance from the solution was measured at 595 nm. Bovine serum 
albumin standards (330 µL total volume) were used to generate linear calibration curves. 
3.2.8. Nitric oxide release from liposomes in blood and serum  
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Nitric oxide release from liposomes was measured in both animal blood and serum. 
Briefly, liposomes (30 µL) were mixed with 600 µL freshly-obtained citrated whole blood or 
serum (pre-incubated at 37 °C). The solution was stored in a 37 °C incubator for a pre-
determined period of time, after which an 80 µL aliquot was injected into a 2:1 volumetric ratio 
of ethanol to 0.183 M sulfuric acid (30 mL total volume) at 37 °C. The % NO remaining was 
determined by dividing the total NO released at each timepoint by the total NO released at the 
initial timepoint (~10 s after mixing liposomes with blood/serum) and multiplying by 100. 
3.3 Results and discussion 
3.3.1. Nitric oxide donor structure 
An important aspect in choosing an appropriate delivery system is the ability to easily 
modify drug-release kinetics. Altering the release rates of most liposome systems requires 
varying the lipid bilayer composition (e.g., cholesterol content, phospholipid property). Such an 
approach is not ideal since other aspects of the scaffold (i.e., hydrophobicity, aggregation, and 
the potential immune response) will be inevitably altered as well. One unique advantage of N-
diazeniumdiolate NO donors is the ability to independently manipulate liposomal NO-release 
kinetics at the molecular level using discrete NO donors. In this study, four different NO donors 
(Appendix B) were encapsulated within liposomes composed of DPPC. 
The size, polydispersity, and encapsulation efficiency (EE) of each NO donor-containing 
liposome was measured to determine how varying the NO donor affected the resulting liposome 
(Table 3.1). As expected, sizes of the liposomes remained consistent (~200 nm) regardless of the 
encapsulated NO donor, likely the result of the donors’ similar molecular weights. Low 
polydispersity index (PDI) values (~0.2) indicated that the liposomes were monodisperse and did 
not form aggregates. Both the size and monodispersity of the PAPA/NO liposomes were  
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Table 3.1. Physicochemical properties of DPPC liposomes encapsulating various NO donors. 
NO donor Size a (nm) 
Polydispersity 
index 
Encapsulation     
efficiency b (%) 
PROLI/NO 174 ± 18 0.166 ± 0.018 30.6 ± 1.9 
DEA/NO 234 ± 20 0.185 ± 0.024 33.7 ± 4.2 
PAPA/NO 203 ± 33 0.167 ± 0.070 33.4 ± 3.1 
SPER/NO 248 ± 54 0.251 ± 0.020 38.3 ± 3.9 
aZ-average size measured using DLS. bRatio of μmol of NO inside liposomes to μmol used for 
synthesis multiplied by 100.  
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Table 3.2. Nitric oxide-release properties of DPPC liposomes as a function of NO donor in PBS 
(pH 7.4) at 37 °C. 
NO donor t1/2a (h) tdb (h) [NO]totalc (μmol/mL) 
PROLI/NO 0.16 ± 0.05 2.8 ± 0.1  5.10 ± 0.51 
DEA/NO 0.31 ± 0.02 4.6 ± 2.3  9.16 ± 0.33 
PAPA/NO 2.60 ± 0.40  43.4 ± 3.9  8.83 ± 0.64 
SPER/NO 45.30 ± 4.60  168.2 ± 17.0 7.73 ± 0.71 
aHalf-life of NO release. bDuration of NO release until the measured NO reached 10 ppb per 300 
µL of liposomes (three-times the detection limit of the instrument). cTotal amount of NO released 
normalized to the injected volume from the liposome stock solution. Respective pH 7.4 half-lives 
of free (i.e., unencapsulated) PROLI/NO, DEA/NO, PAPA/NO, SPER/NO at 37 °C : 2 s, 2 min, 
15 min, and 37 min. 
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preserved even after a 3-month storage period at 4 °C  (193 nm and 0.211, respectively). The 
average EE was approximately 35%, regardless of the NO donor, a value similar to reported 
values for other solutes encapsulated by reverse-phase evaporation methods.24,28 The slightly 
lower EE observed for PROLI/NO liposomes (30%) is attributed to the unavoidable loss of NO 
during preparation. Indeed, this NO donor has a short NO-release half-life in its free form (t1/2= 2 
s). 
3.3.2. Nitric oxide-release measurements 
Nitric oxide release was measured in 10 mM PBS (pH 7.4, 37 °C) to evaluate the effect 
of NO donor identity on the liposomal NO-release rates under physiological conditions. Each of 
the encapsulated NO donors exhibited extended NO-release kinetics relative to the free NO 
donor (Table 3.2). For example, the half-life of SPER/NO increased from 37 min in its free form 
to ~2 d when encapsulated within the liposome. The prolonged NO release for all systems is 
attributed to the lipid bilayer providing a physical barrier against proton diffusion/exchange into 
or with the aqueous core.24 As the molar amount of the lipid was held constant for all liposomal 
preparations, the total NO payload was normalized to the volume of each liposome system 
injected during analysis. Relative to the average NO payloads reported previously for NO-
releasing liposomes (~6 μmol NO/mL liposomes or ~0.25 μmol NO/mg lipid),24 we measured 
payloads that were significantly larger (~8-9 μmol NO/mL) for DEA/NO, PAPA/NO, and 
SPER/NO containing liposomes. In contrast, the NO totals for the PROLI/NO liposomes were 
lower than other systems, which we again attributed to the rapid breakdown of the NO donor. 
Nitric oxide release from the liposomes was also evaluated in 10 mM MES buffer (pH 
5.4, 37 °C) to mimic NO release at more acidic disease sites (e.g., tumor microenvironments). A 
pH gradient is thus created across the lipid bilayer, causing a large influx of protons into the 
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liposomal core that reduced the internal pH.24 As expected, the lower intraliposomal pH resulted 
in rapid N-diazeniumdiolate decomposition, large levels of NO, and reduced NO-release half-
lives for the four liposome systems (Appendix B) relative to pH 7.4. The system with the most 
prolonged NO release (SPER/NO liposomes) exhibited a decrease in overall NO-release duration 
from >1 week (pH 7.4) to <48 h (pH 5.4). Dynamic light scattering measurements confirmed 
preservation of the liposome size (i.e., rupturing did not occur). Despite the significantly more 
rapid release, the NO-release kinetics were still tunable, even at low pH, with half-lives ranging 
from 4 min to 10 h depending on the N-diazeniumdiolate identity.  
3.3.3. Effects of lipid bilayer hydrophobicity and charge 
 The liposome structure and NO-release rates of PAPA/NO liposomes were studied as a 
function of the lipid bilayer composition and associated properties (lipid structures are provided 
in Appendix B). PAPA/NO was selected as the model NO donor for this work due to its 
moderate NO-release characteristics under the tested conditions. By preparing different 
liposomes using electrically neutral lipids of varying alkyl chain length (DMPC, C14, DPPC, C16, 
and DSPC, C18), liposome size and the NO-release characteristics could be studied as a function 
of bilayer hydrophobicity. In addition, parallel studies were performed using C16 cationic 
(DPTAP) and anionic (DPPG) lipids to investigate the effects of charge on these same 
properties. Charged lipids are typically used to encapsulate larger macromolecules (e.g., DNA) 
more effectively or to localize the vesicle at an area of interest due to coulombic attraction.32-33 
As the N-diazeniumdiolate NO donors are anionic, studying coulombic interactions using 
charged lipids, such as DPPG (negative) and DPTAP (positive), may elucidate unique effects on 
both EE and NO-release properties (i.e., NO payloads and release kinetics).  
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Table 3.3. Physicochemical properties of PAPA/NO liposomes as a function of bilayer 
composition. 
Lipid a Size b (nm) 
Polydispersity 
index 
Encapsulation 
efficiency c (%) 
DMPC (C14) 236 ± 44 0.215 ± 0.050 30.3 ± 1.5 
DPPC (C16) 203 ± 33 0.167 ± 0.070 33.4 ± 3.1 
DSPC (C18) 340 ± 77 0.328 ± 0.080 32.2 ± 2.7 
DPPG (- C16) 161 ± 11 0.203 ± 0.030 22.0 ± 3.2 
DPTAP (+ C16) 446 ± 63 0.497 ± 0.120 29.4 ± 0.6 
aCharge and alkyl chain length of the lipid is denoted in parentheses. bZ-average size measured 
using DLS. cRatio of the μmol of NO inside the liposomes to the μmol used for the synthesis, 
multiplied by 100.  
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Varying the phospholipid’s carbon chain length caused only slight deviations in the 
liposome size for the longest chain length (C18), as indicated by DLS (Table 3.3) and TEM 
analysis (Appendix B).  Liposomes made from DMPC (C14) and DPPC (C16) remained similar in 
size (~200 nm) with comparable PDI and EE values (~30%). In contrast, liposomes prepared 
using DSPC (C18) were significantly larger (340 nm) and more polydisperse, likely due to the 
longer alkyl chains disrupting bilayer formation.34 Anionic DPPG liposomes exhibited size and 
monodispersity similar to that of neutral DPPC liposomes (Table 3.3 and Appendix B), but 
demonstrated an 11% decrease in EE. We hypothesize that the repulsive interactions between the 
negatively charged phospholipid and anionic N-diazeniumdiolate prevented efficient 
encapsulation within the liposomal core. The effects of coulombic charge were probed further by 
comparing the EE values of DPPC and DPPG liposomes encapsulating either neutral (coumarin) 
or negatively charged (carboxyfluorescein) fluorophores. While similar coumarin EE values 
were observed for both liposome systems, neutral DPPC liposomes exhibited greater 
encapsulation of carboxyfluorescein relative to anionic DPPG (Appendix B). Therefore, charge 
interactions between the encapsulated molecule and the phospholipid may significantly affect the 
efficiency of drug encapsulation. 
Liposomes prepared using cationic DPTAP lipids had comparable EE values to the 
neutral liposomes. However, DLS measurements revealed substantially larger and more 
polydisperse sizes relative to liposomes prepared using the other lipids (Table 3.3). Large PDI 
values have been previously reported for liposomes synthesized utilizing TAP-based lipids in 
high ionic strength solutions as a result of aggregation.35-37 Indeed, we found that we were able to 
obtain better size (308 nm) and PDI values (0.316) after preparing DPTAP liposome solutions of 
a lower ionic strength (1 mM), corroborating the correlation between ionic strength and vesicle 
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aggregation. As an alternative to changing the ionic strength, DPPC was employed as a co-lipid 
for DPTAP liposome preparation. Positively charged liposomes with a 50:50 DPPC:DPTAP 
molar ratio were characterized as having similar size, PDI, and EE (227 nm, 0.168, and 31%, 
respectively) compared to pure DPPC liposomes. By utilizing this method, cationic liposomes 
with sizes and PDI values mirroring those of neutral and anionic liposomal systems were readily 
achieved. 
3.3.4. Bilayer properties and NO release 
Nitric oxide-release properties of the liposome systems were determined at pH 7.4 and 37 
°C (Table 3.4). With the exception of the liposomes composed of negatively charged DPPG 
lipids, each liposome system studied exhibited similar NO payloads (~8.5 µmol/mL). Although 
the repulsive ionic forces lowered the NO totals of the DPPG liposomes, the release kinetics 
remained similar to that from neutral liposomes, indicating that bilayer water permeability was 
not appreciably influenced by the bilayer’s negative charge. Conversely, aggregation of the 
positively charged DPTAP liposomes may likely have caused a greater proton influx to the 
liposome center with concomitantly more rapid NO release (i.e., shorter half-life) compared to 
the neutral liposome systems. To rule out the influence of electrostatically surface-bound NO 
donor on rapid NO release, DPTAP liposomes were incubated with an anion exchange resin. 
After filtering the liposomes from the resin, the measured NO-release kinetics were nearly 
identical to the liposomes prior to resin incubation, suggesting that DPTAP bilayer defects 
represent the only factor impacting the rapid NO release.  
We initially hypothesized that the liposome NO-release kinetics would be prolonged as 
the hydrophobicity (i.e., carbon chain length) of the phospholipid was increased. While the C18-
containing DSPC liposomes exhibited significantly longer NO-release kinetics, the DMPC and 
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Table 3.4. Nitric oxide-release properties of PAPA/NO liposomes as a function of bilayer 
hydrophobicity and charge in PBS (pH 7.4) at 37 °C. 
Lipid t1/2a (h) tdb (h) [NO]totalc (μmol/mL) 
DMPC (C14) 2.6 ± 0.5 42.9 ± 5.1 8.26 ± 0.29 
DPPC (C16) 2.6 ± 0.4  43.4 ± 3.9  8.83 ± 0.64 
DSPC (C18) 16.7 ± 1.2 85.6 ± 7.6 9.00 ± 0.74 
DPPG (- C16) 2.6 ± 1.0 38.1 ± 1.8 6.33 ± 1.17 
DPTAP (+ C16) 0.9 ± 0.4 18.4 ± 1.9 8.63 ± 0.43 
aHalf-life of NO release. bDuration of NO release until the measured NO reached 10 ppb per 300 
µL of liposomes (three-times the detection limit of the instrument). cTotal amount of NO released 
normalized to the injected volume from the liposome stock solution. 
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DPPC systems demonstrated similar NO-release half-lives. As such, it seemed unlikely that the 
extended NO-release kinetics observed for the DSPC liposomes was a result of greater alkyl 
character or hydrophobicity. Further, differential release kinetics due to varying transition phase 
temperatures between the phospholipids should not occur as cholesterol was included in all 
liposome formulations, which homogenizes the bilayer and attenuates the effects of temperature 
on ordering of the lipid phase.38  
 In lieu of hydrophobicity alone, the NO-release kinetics proved dependent on the 
compactness of the lipid chains upon liposome formation. Indeed, tighter packing of the lipid 
chains has been shown to occur as the headgroup surface area of the lipid decreases, resulting in 
reduced water permeability of the lipid bilayer.39 Given the area per lipid headgroup being nearly 
identical for DMPC and DPPC (~0.655 nm2) and distinct from DSPC (~0.430 nm2),40-41 the 
tighter lipid packing for the DSPC liposomes would slow the decrease in intraliposomal pH and 
N-diazeniumdiolate NO donor decomposition to NO. 
 Proton permeation into the liposome core was characterized by examining intraliposomal 
pH changes using a fluorescent dye. Pyranine (10 µM), a bilayer-impermeable pH-sensitive dye, 
was encapsulated within the liposomes to probe internal pH changes over time. Under basic 
conditions, pyranine produces a strong fluorescent signal (λ = 520 nm) that reduces in intensity 
upon becoming protonated (i.e., as pH decreases).42 After immersion into pH 7.4 buffer, the 
fluorescence from DMPC and DPPC liposomes would be expected to decrease at similar rates 
over time, whereas that from the DSPC liposomes would be more gradual due to the restricted 
water permeability. As shown in Figure 3.1, this behavior was followed exactly. Over 24 h, the 
fluorescence measured from DSPC liposomes approached that from the DMPC and DPPC 
vesicles. The smaller initial change in intraliposomal pH combined with the gradual fluorescence  
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Figure 3.1. Fluorescence emission at 520 nm from pyranine-encapsulated (■) DMPC, (●) 
DPPC, and (▲) DSPC liposomes diluted 100-fold in 10 mM PBS (pH 7.4, 37 °C) as a function 
of time. The spectra were collected using a 450 nm excitation wavelength. Inset depicts 
fluorescence from the first 5 min of data collection. 
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drop over time for DSPC liposomes clearly confirms the influence of headgroup-mediated 
water/proton permeation on NO release. Of note, DLS measurements confirmed typical size 
values, indicating that bursting of the liposomes did not occur during the experiment. 
As shown in Figure 3.2, lipids with similar packing (i.e., headgroup surface area) 
exhibited nearly identical water/proton permeation with similar NO-release kinetics regardless of 
charge or headgroup moiety.39 These results explain why the anionic (and lower EE) DPPG 
liposomes maintain identical NO-release properties as neutral DPPC liposomes. A range of NO-
release kinetics is therefore possible by varying the lipid bilayer composition (both partially or 
completely). For example, we used a 10:90 DPPE:DPPC molar mixture to produce PAPA/NO 
liposomes with intermediate NO-release half-lives (t1/2 = 3.7 h) relative to analogous single-lipid 
systems (DPPC t1/2 = 2.5 h; DPPE t1/2 = 6.6 h). Identical trends in NO release were observed at 
pH 5.4 (Appendix B), indicating that the bilayer composition-mediated control over NO release 
was maintained at lower pH as well. 
3.3.5. Nitric oxide-release kinetics in biological media 
 Bilayer composition has been shown to influence the in vivo fate of liposomes.46 For 
example, cationic liposomes are efficiently uptaken or internalized by cells, which is attributed to 
the electrostatic interactions with negatively charged cell membranes.47 Charged liposomes also 
promote protein binding and opsonization, facilitating rapid clearance from the bloodstream.48 
We thus investigated if the liposomal surface properties (e.g., charge and PEGylation) affected 
the NO-release kinetics in biological fluids where protein adsorption may occur. DPPC (neutral), 
DPPG (negative), 50:50 DPTAP:DPPC (positive), and 10:90 DPPE-PEG/DPPC (PEGylated) 
liposomes were selected due to their similar NO release (t1/2 ~2.5 h) and long-term structural 
stability (Appendix B).  
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Figure 3.2. Relationship between the liposomal NO-release half-life and phospholipid 
headgroup surface area using PAPA/NO-encapsulated liposomes. Each point represents a 
different phospholipid (see Materials section for list of lipids).40-41,43-45 
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NO-release kinetics were first measured in serum to determine if permanent or transient 
defects form in the liposome bilayer upon protein fouling, perhaps altering the NO release. 
Surprisingly, the NO release did not change appreciably (Figure 3.3a). Indeed, the liposomes 
exhibited similar half-lives (t1/2 ~2.5 h) to those measured in PBS, which agrees with the minimal 
protein adsorption that had occurred on the liposome surface in serum (Appendix B).49-52 
While measuring NO release in serum elucidated the effects of proteins on liposomal 
NO-release kinetics, serum lacks a number of complex cellular components and molecules (e.g., 
hemoglobin) that are capable of scavenging NO. Nevertheless, nearly analogous NO release was 
measured in whole blood between the different liposome compositions (Figure 3.3b). Even the 
PEG-stabilized liposomes exhibited only slight initial differences in NO-release rates. These 
results indicate that the surface properties of PAPA/NO-containing liposomes (e.g., charge) can 
be controlled independently of NO-release kinetics in blood, to achieve potential targeting and/or 
adjust bloodstream clearance.        
 A notable decrease in the NO-release half-life in blood was observed relative to PBS and 
serum. For example, neutral DPPC PAPA/NO liposomes having similar PBS and serum NO 
release (t1/2 = 2.6 ± 0.4 and 2.9 ± 1.0 h, respectively), exhibited 60% faster NO release (t1/2 = 1.0 
± 0.2 h) in whole blood (Figure 3.4). We hypothesize that these results are caused by the high 
concentration of NO scavengers in blood.53 At concentrations from 129−177 mg/mL (12.9−17.7 
g/dL) in humans, hemoglobin is among the most active NO scavengers in the bloodstream due to 
iron-NO radical complexation.53-58 As such, scavenging would lead to an increase in the 
measured real time NO-release kinetics due to the consumption of detectable NO. To explore 
this, NO release from neutral DPPC PAPA/NO liposomes was measured in 10 mM PBS (pH 7.4, 
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Figure 3.3. Nitric oxide release in (a) serum and (b) blood from (■) neutral DPPC, (▲) anionic 
DPPG, (●) cationic DPTAP, and (▼) PEGylated PAPA/NO liposomes. The amount of NO 
remaining within the liposomes was determined by injecting the liposomes into an acidic 
solution at discrete timepoints. 
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Figure 3.4. Neutral DPPC PAPA/NO liposome NO-release kinetics in (■) PBS, (●) serum, and 
(▲) blood. Statistical analysis yielded p < 0.02 between all PBS and blood values. The amount of 
NO remaining within the liposomes was determined by injecting the liposomes into an acidic 
solution at discrete timepoints. 
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37 °C) containing 157 mg/mL hemoglobin (Appendix B). The measured NO-release half-life 
indeed decreased (t1/2 = 0.5 h) relative to in pure PBS (t1/2 = 2.6 h), supporting blood hemoglobin 
being at least partially responsible for the observed differences in the NO-release kinetics for 
blood versus PBS/serum. The disparity between blood and PBS containing hemoglobin is likely 
due to compartmentalization of hemoglobin within erythrocytes (not free, as in the PBS 
solution), leading to less overall NO scavenging and longer measured NO-release durations.54 Of 
note, negligible hemolytic activity of the NO-releasing liposome systems (Appendix B) indicates 
that the liposomes do not enhance liberation of intracellular hemoglobin. 
3.4 Conclusions 
 Herein, the ability to precisley control NO-release half-lives was demonstrated by 
selection of an appropiate NO donor and varying the composition of the lipid bilayer. We found 
that the lipid headgroup surface area was the defining factor that controlled NO-release kinetics 
due to the dependence of bilayer proton permeability on lipid packing density. Liposomes 
prepared using different ionic charges and PEG-modified lipids exhibited low protein adsorption 
(≤5 g protein/mol lipid) and similar NO release in PBS and serum, regardless of the lipid 
identity. However, the overall NO-release flux in whole blood compared to PBS and serum was 
less, and thus the NO-release kinetics appeared shorter. These results were attributed to the large 
concentrations of hemoglobin in blood, a known NO scavenger. Our study may provide guidance 
for the development of other macromolecular scaffolds with respect to how charge may affect 
protein adsorption and the influence of complex cellular components of blood on in vivo NO-
release kinetics. 
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CHAPTER 4: ANTICANCER POTENCY OF NITRIC OXIDE-RELEASING 
LIPOSOMES3 
 
4.1 Introduction          
 Small molecule chemotherapeutics (e.g., doxorubicin and cisplatin) often exhibit off-
target cytotoxicity due to poor localization.1-5 The use of a large macromolecular (e.g., polymer, 
nanoparticle) carrier to deliver the therapeutic to the targeted site represents one method for 
mitigating the adverse side effects of small molecules. The leaky vasculature of tumors allows 
macromolecules to extravasate at the malignant site, with the delivery of the therapeutic payload 
via cellular uptake or triggered release (e.g., pH and temperature).6 Liposomes are among the 
most widely-investigated delivery systems available for drug delivery. Traditionally, liposomes 
are composed of an aqueous inner core separated from the external solution by a phospholipid 
bilayer. This unique architecture allows for the confinement of compounds with a wide range of 
molecular weights, hydrophobicities, and charges until delivery at a location of interest. The 
ability of liposomes to absorb and fuse with cell membranes enhances the intracellular uptake of 
the therapeutic payload, a process that is not typically observed for other macromolecular 
vehicles (e.g., nanoparticles). Liposomes have thus been developed for a number of therapeutic 
agents, such as gemcitabine and DNA.6-7 The exterior surface properties of the liposome (e.g., 
charge) may be tuned independently of the encapsulant, a critical feature for impacting targeting 
                                                
3 This chapter was adapted from an article that previously appeared in RSC Advances. The 
original citation is as follows: Suchyta, D.J.; Schoenfisch, M.H. “Anticancer potency of nitric 
oxide-releasing liposomes” RSC Advances 2017. 
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capabilities and/or reducing aggregation in the bloodstream. In this manner, liposomes have 
improved the anticancer delivery of many chemotherapeutics, including doxorubicin, arsenic 
trioxide, and daunorubicin.8-10 
Nitric oxide (NO), an endogenous diatomic free radical, is an important mediator of 
inflammation,11-13 vasodilation,14-15 biocidal action,16-18 cardio- and neuroprotection,19-20 and 
cancer cell proliferation/killing.21-23 Off-target toxicity of NO is mitigated by scavenging and/or 
reaction to nitrite/nitrate.14 Nitric oxide donors have been developed as a strategy for delivering 
NO to biological systems as dissolved NO rather than a gas. Examples of currently approved NO 
donors are sodium nitroprusside, isosorbide mononitrate, glyceryl trinitrate, and pentaerythrityl 
tetranitrate.24 N-diazeniumdiolates are a class of NO donors that spontaneously release NO under 
physiological conditions. The rate of NO release depends on the molecular structure of the amine 
precursor, facilitating diverse and tunable NO-release kinetics.25-26 With respect to 
chemotherapy, the pH-dependent release of N-diazeniumdiolates is advantageous because tumor 
microenvironments are generally more acidic (pH ~6) than healthy tissue (pH 7.4).27-28 The 
lower pH promotes accelerated NO release at the tumor. A vast literature has proven that small 
molecule N-diazeniumdiolates are capable of eliciting potent anticancer action.29-35 Clinical 
utility has not been achieved because of the excessive loss of NO, prematurely, prior to reaching 
the tumor site.  
In this study, two N-diazeniumdiolate-encapsulated liposome systems were prepared with 
distinct NO-release kinetics (fast and slow). The anticancer activity of these liposomes was 
evaluated against pancreatic, colorectal, and breast cancer cell lines. Confocal fluorescence and 
flow cytometry were used to measure both cellular uptake of the liposomes and intracellular NO 
delivery. The effect of the NO release on protein expression, specifically cleaved PARP, cyclin 
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B1, and cyclin D1, was also examined via Western blot analysis to assess apoptosis and cell 
cycle arrest/ejection. 
4.2 Experimental section 
4.2.1. Materials 
Dipalmitoylphosphatidylcholine (DPPC) and 1,2-dipalmitoyl-sn-glycero-3-
phosphoethanolamine-N-(lissamine rhoadmine B sulfonyl) ammonium salt (Rh-PE) were 
purchased from Avanti Polar Lipids (Alabaster, AL). Cholesterol (Chol), paraformaldehyde, fetal 
bovine serum (FBS), penicillin streptomycin, 1x Dulbecco’s modified Eagle’s medium 
(DMEM), McCoy’s 5A medium, RPMI 1640 medium, Dulbecco’s phosphate-buffered saline 
(DPBS) for cell culture, N-propyl-1,3-propanediamine (PAPA), and diethylenetriamine (DETA) 
were obtained from Sigma (St. Louis, MO). Prolong diamond antifade mountant, 4-amino-5-
methylamino-2’,7’-difluorofluorescein diacetate (DAF-FM), trypsin, Accutase, 1% (v/v) NP40 
lysis buffer, chloroform, phenazine methosulfate (PMS), anhydrous acetonitrile, anhydrous 
diethyl ether, dimethyl sulfoxide (DMSO), anhydrous ethanol (EtOH), sulfuric acid (H2SO4), 
protein stripping buffer, sodium hydroxide (NaOH), calcium chloride (CaCl2), PageRuler Plus 
prestained protein ladder, and secondary antibodies (both mouse and rabbit) for Western blotting 
were purchased from Fisher Scientific (Fair Lawn, NJ). Sephadex G-25 was obtained from GE 
Healthcare (Pittsburgh, PA). 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophen-yl)-2H-tetrazolium inner salt (MTS) was purchased from Promega (Madison, WI). 
Primary antibodies for total and cleaved PARP (rabbit), cyclin B1 (rabbit), cyclin D1 (rabbit), 
and vinculin (mouse) used in Western blotting were obtained from Cell Signaling (Danvers, 
MA). Western lightning ECL pro substrate for Western blot detection was from PerkinElmer 
(Waltham, MA). Phosphatase and protease inhibitors were purchased from Roche (Basel, 
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Switzerland). Criterion TGX Gel, tris/glycine transfer buffer with sodium dodecyl sulfate (SDS), 
tris-buffered saline with Tween 20 (TBST), and polyvinylidene fluoride (PVDF) transfer 
membrane were obtained from Bio-Rad (Hercules, CA). Nitric oxide (NO; 99.5%), nitrogen (N2; 
99.998%), argon (Ar; 99.995%), and NO calibration (26.80 ppm, balance N2) gases were 
obtained from Airgas National Welders (Durham, NC). A Millipore Milli-Q UV Gradient A10 
System (Bedford, MA) was used to purify distilled water to a resistivity of 18.2 MΩ·cm and a 
total organic content ≤6 ppb. MIA PaCa-2, AsPc1, and Pa14c pancreatic cancer cells were a gift 
from Dr. Channing Der of the Department of Pharmacology at the University of North Carolina 
(Chapel Hill, NC). MDA-MB-231, MCF-7, MDA-MB-468, HCT116, HT-29, and SW480 breast 
and colorectal cancer cells were a gift from Dr. Matthew Lockett of the Department of Chemistry 
at the University of North Carolina (Chapel Hill, NC). 
4.2.2. Synthesis of N-diazeniumdiolate NO donors 
A previously reported method was used to synthesize small molecule N-diazeniumdiolate 
NO donors.27 Briefly, DETA and PAPA were dissolved in anhydrous acetonitrile at a 
concentration of 33.3 mg/mL. The solution was then purged with Ar to 100 psi inside a stainless 
steel Parr bomb. Six consecutive purges with Ar (three quick purges of 10 s each, followed by 
three slow purges of 10 min each) were carried out to remove dissolved oxygen. The solution 
was subsequently pressurized to 145 psi with NO for 3 d, after which the solution was purged 
again with Ar (100 psi) at least six times to remove residual NO. The precipitated product was 
filtered over a Hirsch funnel, washed three times with diethyl ether, and dried under vacuum 
overnight. The final NO donor product was stored at -20 °C until use. 
4.2.3. Liposome synthesis 
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 The liposomes were prepared using a reverse phase evaporation method.37 A 1:1 molar 
ratio of lipid to Chol (49.5 µmol lipid:49.5 µmol Chol) was dissolved in a mixture of diethyl 
ether (5.0 mL) and chloroform (5.0 mL) in a round-bottom flask under N2 atmosphere. 
Fluorescent liposomes were prepared using the above protocol, but with 1 mol% lipid of Rh-PE. 
The N-diazeniumdiolate was dissolved in 10 mM NaOH to make a 14 mM stock NO donor 
solution. This solution was injected into the flask, and then sonicated for 4 min at 45 °C. The 
organic phase was removed by rotoevaporation to yield the aqueous liposome suspension. 
Liposomes were incubated at 45 °C for an additional 30 min, after which the unencapsulated 
material was removed using four Sephadex G-25 spin columns packed in 10-mL syringes. The 
liposomes collected from the column were stored at 4 °C. 
4.2.4. Characterization of liposomes 
Dynamic light scattering (DLS; Malvern Zetasizer Nano; UK) was used to determine 
liposome size distribution in water. Transmission electron microscopy (TEM) was used to 
confirm liposome formation. Liposome samples for TEM analysis were prepared by diluting the 
stock solution with Milli-Q water (1:1 volumetric ratio) and casting the suspension onto 
Formvar-coated, square mesh copper TEM grids (Electron Microscopy Sciences, Hatfield, PA). 
The solvent was allowed to evaporate for 45 min prior to applying a negative-stain using a 2% 
(w/v) uranyl acetate solution. A drop of the stain was left on the grid for 30 s and then removed 
using filter paper. The grid was dried for 5 min prior to imaging using a JEOL 100CX II 
transmission electron microscope (100 kV accelerating voltage). 
4.2.5. Nitric oxide release 
Nitric oxide storage and NO-release kinetics from the liposomes were measured using a 
Sievers Chemiluminescence Nitric Oxide Analyzer (NOA; Boulder, CO).38-39 Studies to evaluate 
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NO-release kinetics were performed in 10 mM PBS (pH 7.4) at 37 °C. The instrument was 
calibrated using air passed through a NO zero filter (0 ppm NO) and a 26.80 ppm NO standard 
(balance N2). Nitric oxide storage for encapsulation efficiency (i.e., the extent to which the NO 
donor is entrapped within the liposomal aqueous core) was performed in a 2:1 volumetric ratio of 
ethanol to 0.183 M sulfuric acid (30 mL total volume) at 37 °C. The encapsulation efficiency 
was calculated by comparing the liposome NO storage to the amount of NO in the free donor 
solution used during liposome preparation. All presented data is from n ≥ 3 separate liposome 
preparations. Nitric oxide release measurements were terminated when the NO concentration 
dropped below 10 ppb per 300 µL liposomes. 
4.2.6. Cytotoxicity assays 
Pa14c and MIA PaCa-2 cells were cultured in DMEM. HCT116 and HT-29 cells were 
cultured in McCoy’s 5A medium. MDA-MB-231, MCF-7, MDA-MB-468, SW480, and AsPc1 
cells were cultured in RPMI medium. All media were supplemented with 10 vol% FBS and 1 
wt% penicillin/streptomycin. Cells were maintained at 37 °C in a humidified incubator with 5 
vol% CO2. For cell viability evaluations, the MTS assay was used as previously described with 
cells plated in triplicate.40 Briefly, cells (2×103 cells/well) in DMEM were treated with various 
volumes of liposomes in a 96-well plate (100 µL total volume per well). Following a 72 h 
incubation period at 37 °C, the supernatant of each well was removed, rinsed with PBS (100 µL), 
and replaced with fresh DMEM (100 µL). The cells were further incubated with 20 µL of 
MTS/PMS reagent (20:1 v/v MTS to PMS) at 37 °C for ~90 min. The absorbances of the 
resulting solutions at 490 nm were measured using a Thermoscientific Multiskan EX plate reader 
(Waltham, MA). The ratio of absorbance values between the samples and the controls was 
represented as the percent cell viability. Dose response curves and LD50 values were plotted and 
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tabulated using GraphPad Prism 6 software (La Jolla, CA) and non-linear regression (three- 
parametric Hill function), respectively. All presented data are from n ≥ 3 separate experiments. 
4.2.7. Confocal fluorescence microscopy 
Cells were plated in 10×10 mm cloning cylinders (VWR, Atlanta, GA) secured to No 1.5 
glass cover slips (VWR, Atlanta, GA) using silicone grease. The slip was placed in a Petri dish 
prior to the addition of cell media. After 24 h, the medium within the cylinders was replaced with 
a 10 µM DAF-FM solution. An additional 30 min incubation period at 37 °C was then carried 
out before removing the DAF-FM solution. Fresh cell media was subsequently added and 
allowed to incubate for another 15 min at 37 °C to allow for saponification of the probe. 
Liposomes were added to the cells and incubated for 2 h, followed by rinsing twice with 100 µL 
DPBS. A 100-µL aliquot of 4 vol% paraformaldehyde solution (diluted with DPBS) was injected 
into the wells and incubated for 15 min at room temperature. The cover slips were then mounted 
on glass slides using a droplet of mounting media, sealed with nail polish (Electron Microscopy 
Sciences; Hatfield, PA), and imaged after 1 h using a Zeiss LSM 700 laser scanning confocal 
microscope. The excitation/emission wavelengths for DAF-FM and Rh-PE were 495/515 and 
560/583 nm, respectively. Fiji software was used for image processing and densitometry 
calculations. Autoquant X3 software (Media Cybernetics; Warrendale, PA) generated orthogonal 
views of the z-stacked images. All images were collected under constant exposure times. The 
images were also processed equivalently and normalized to a single brightness level. 
4.2.8. Flow cytometry  
Cells were plated (1×104 cells/well) in 96-well plates and allowed to adhere for 24 h in 
RPMI media (100 µL). The media was then removed and cells were incubated with fresh media 
containing 5 µM DAF-FM for 1 h. The media containing the DAF-FM was subsequently 
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removed and free or liposomal N-diazeniumdiolate NO donors were added to the wells 
(dissolved in fresh media) and allowed to incubate for specified times. Cells were then washed 
with DPBS and detached by exposure to Accutase (30 µL) for 5 min at room temperature. Media 
containing 5 mM CaCl2 was added (30 µL) to the wells while maintaining the plate at 0 °C for 
20 min. The plate was placed on a shaker for 30 s (2000 rpm) to resuspend cells prior to analysis 
with an iQue Screener Plus flow cytometer (IntelliCyt, Albuquerque, NM). A 33 s sampling (sip) 
time was used with a 0.5 s up time between wells. The plate was shaken (and the probe cleaned) 
for 20 s at 2000 rpm every 4 wells. Data acquisition and processing were carried out with 
ForeCyt software (IntelliCyt; Albuquerque, NM). Single color compensation controls were 
performed to minimize spectral overlap. Gates were placed around singlet cells to exclude data 
from aggregated cells. Fluorescence intensities were calculated and plotted versus number of 
events. 
4.2.9. Western blot analysis  
Cells were added to a 6-well plate (3×105 cells/well) and incubated for 24 h. Media was 
then removed and replaced with fresh media containing liposomes. At specified timepoints, the 
plates were placed on ice, washed once with cold DPBS, and incubated for 15 min with 1 vol% 
NP40 lysis buffer (50 µL) containing protease and phosphatase inhibitors. The wells were then 
scraped and the solution added to cold microcentrifuge tubes. Cellular debris was removed by 
centrifugation (4 °C, 5 min). Protein concentrations in samples were determined using the 
Bradford assay. Equal total protein amounts (~30 µg) were added to each lane of the gel (4–20% 
gradient). After electrophoresis, the proteins were transferred onto PVDF membranes, blocked 
with 5% (w/v) milk, and stained with primary antibody overnight. After incubation with the 
secondary antibody for 1 h, the membrane was incubated with the Western lightning ECL pro 
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substrate (10 min) and then imaged using a ChemiDoc chemiluminescence imaging system (Bio-
Rad; Hercules, CA). Western blot images were processed using Image Lab software (Bio-Rad; 
Hercules, CA). Fiji software was used for densitometry calculations. Loading controls were used 
as a normalization factor for densitometric calculations. 
4.3 Results and discussion 
The N-diazeniumdiolates used in this study (PAPA/NO and DETA/NO; Appendix C) 
were selected because of their dissimilar NO-release half-lives in PBS at pH 7.4 (0.25 h and 20 
h, respectively). On the basis of our previous work and others,28,41 we anticipated that the 
resulting NO-releasing liposomes would have different NO-release kinetics. Liposome formation 
was confirmed by dynamic light scattering (DLS) measurements. As shown in Figure 1, 
DETA/NO and PAPA/NO liposomes exhibited hydrodynamic sizes typical of liposomes 
synthesized via reverse-phase evaporation (Table 1).37 The slight difference in size between the 
systems should not appreciably affect their anticancer activity as liposomes with sizes of 
approximately 150 to 400 nm exhibit similar cellular uptake.42 Transmission electron microscopy 
(TEM) corroborated the DLS measurements and indicated negligible liposome-liposome fusion 
(Appendix C). Real-time NO release measurements demonstrated that the NO donor 
encapsulation efficiency was similar to efficiencies of other reverse-phase evaporated liposomes 
and consistent between the two liposome formulations (Table 1), likely the result of similar size 
of the NO donors.37 As expected, the liposomes released NO more slowly at physiological pH 
(7.4) than the corresponding small molecule NO donor alone (Figure 1). The PAPA/NO 
liposomes released ~50% of their total NO in 2.5 h, a ten-fold longer NO-release half-life than 
the free NO donor. As the rate of NO release impacts NO’s toxicity,29-35 the use of two distinct 
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N-diazeniumdiolates as encapsulants allows for the study of the anticancer therapeutic potential 
of the liposomes as a function of NO-release kinetics. 
4.3.1. Cytotoxicity of the liposomes  
The potential anticancer activity of the NO-releasing liposomes was initially tested 
against Pa14c pancreatic cancer cells, an aggressive pancreatic cancer cell line. The PAPA/NO 
and DETA/NO liposome systems showed a pronounced toxicity difference, attributable to the 
NO release (Figure 2A). At low NO payloads (~0.9 µg/mL), the viability was slightly enhanced 
for each liposomal system. Previous research has reported that low levels of NO induces EGF-
dependent cell proliferation.14,43 At NO payloads >1.5 µg/mL, the slower NO-release system 
(DETA/NO liposomes) was markedly more toxic towards the Pa14c cells. The less effective 
PAPA/NO liposomes required larger NO payloads to induce toxicity likely because of the faster 
release rate, resulting in the release of the majority of the NO payload before reaching the cell 
and/or cellular uptake. Significantly less toxicity (killing) was observed (Appendix C) when 
using a noncancerous epithelial cell line (HPNE), indicating that NO may elicit preferential 
cytotoxicity towards cancer cells due to its ability to further increase the oxidative/nitrosative 
stress that cancer cells are already under.44 
The cytotoxicity of the liposomes was next evaluated against a number of malignant lines 
from pancreatic, breast, and colorectal cancers to ascertain if the observed dependence on NO-
release kinetics applied to other cell lines. The slow NO-releasing liposomes (DETA/NO) 
consistently required lower NO payloads to elicit cytotoxic effects, regardless of cancer type or 
cell line (Figure 2B). In fact, the LD50 was <3 µg/mL NO for the DETA/NO liposomes against 
all cancer cell lines investigated, while the faster-releasing PAPA/NO liposomes required >6 
µg/mL NO to elicit cytotoxic action. These results agree with prior work that demonstrated that  
 101 
Table 4.1. Properties of NO-releasing liposomes. 
NO donor 
Hydrodynamic size a 
(nm) 
Encapsulation 
efficiency b (%) 
Total NO c (µg/mL) 
PAPA/NO 377 ± 52 19.0 ± 3.5 125.7 ± 41.1 
DETA/NO 246 ± 32 20.6 ± 3.2 133.2 ± 26.7 
aZ-average size measured using DLS. bRatio of µmol of NO inside liposomes to µmol used for 
synthesis, multiplied by 100. cTotal amount of NO release in acid normalized to the injected 
liposome volume.  
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Figure 4.1. Nitric oxide-release profiles from liposomal (●) DETA/NO and (▲) PAPA/NO in 10 
mM PBS (pH 7.4, 37 °C) over the first 72 h. 
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Figure 4.2. (A) Cytotoxicity of liposomal (●) DETA/NO and (▲) PAPA/NO as a function of NO 
payload against human Pa14c pancreatic cancer cells after 72 h of exposure. (B) Calculated LD50 
values for (grey bars) DETA/NO and (black bars) PAPA/NO liposomes against pancreatic, 
breast, and colorectal cancer cell lines. Of note, the LD50 of PAPA/NO liposomes against Pa14c 
cells was >16.2 µg/mL. NO payloads were calculated based on the total amount of NO released 
from the liposomes over 72 h in PBS. 
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free NO donors exhibiting slow NO-release kinetics required lower anticancer payloads relative 
to their fast-releasing counterparts.29,33,45 
A human breast cancer cell line (MCF-7) was chosen as a representative model for 
further evaluation of the NO-release kinetics and associated cytotoxicity because of the stark 
differences in the LD50 values for the PAPA/NO and DETA/NO liposomes. Our immediate goal 
was to determine if the PAPA/NO liposomes induced cytotoxicity earlier in the assay (i.e., 
before 72 h). Cells were exposed to the 72 h LD50 concentrations of the DETA/NO and 
PAPA/NO liposomes (0.75 µg/mL and 16.2 µg/mL after 72 h exposure, respectively) for 8, 24, 
48, and 72 h. As shown in Figure 3, neither the fast nor slow NO-releasing liposome system 
exhibited cytotoxic effects at early timepoints (8 h). Rather, mild cell proliferation was noted for 
both. After 24 h, cell viability diminished greatly (up to 60%) for cells exposed to the PAPA/NO 
system (16.2 µg/mL NO), with no further change through 72 h. PAPA/NO liposomes deliver 
~90% of the NO payload by 24 h (Figure 1), correlating with this observed cytotoxicity. The NO 
liberated from the DETA/NO liposomes (0.75 µg/mL) displayed a more consistent cell viability 
profile with a steady drop over the 72 h period. Cytotoxicity for PAPA/NO liposomes at 0.75 
µg/mL payloads was not induced at any time point (negligible toxicity relative to controls). 
Collectively, this data suggests that faster NO release (i.e., using shorter half-life NO donors) 
elicits cytotoxicity more rapidly than corresponding slower release, but necessitates larger NO 
payloads. The large levels of produced NO from the fast NO-releasing liposomes may be better 
at increasing the entropy of the cellular system through the denaturation of proteins than the slow 
NO-releasing liposomes. 
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Figure 4.3. Time-course cytotoxicity study of liposomal (●) DETA/NO and (▲) PAPA/NO at 
their respective LD50 values against human MCF-7 breast cancer cells. 
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4.3.2. Intracellular liposome uptake and NO delivery 
 The observed relationship between liposome NO-release kinetics and anticancer action 
was hypothesized to be the result of intracellular NO accumulation. Confocal fluorescence 
microscopy was employed to measure intracellular NO build-up over time for the two systems 
using DAF-FM, a molecular probe that selectively reacts with NO to form a fluorescent 
benotriazole compound.46 Additionally, cellular uptake of the liposomes was visualized by 
incorporating a fluorescent phospholipid (Rh-PE) into the lipid bilayer.47 A 2 h exposure period 
was initially selected for this study as cell have been shown to initiate liposomal uptake within 
this timeframe,48-49 allowing for visualization of delivered NO. The bright field and fluorescence 
images of MCF-7 cells after exposure to DETA/NO and PAPA/NO liposomes (at their LD50 
values) are provided in Figure 4A. Of note, the amount of NO released during the confocal 
experiment is significantly lower than the corresponding LD50 values due to the shorter exposure 
time (2 vs. 72 h). Liposome uptake was clearly observed after 2 h, with z-stack images revealing 
intracellular localization of the NO-releasing liposomes (Figure 5). The rapid uptake of the 
liposomes results from their ability to adsorb to and then fuse with the cell membrane, a 
phenomena that does not readily occur with other delivery vehicles (e.g., nanoparticles).6 
Relative to DETA/NO liposomes, cells exposed to PAPA/NO liposomes had substantially 
elevated levels of intracellular NO. Densitometry calculations were carried out to quantify 
intracellular NO levels for the two liposomes (Figure 4B). Treatment with PAPA/NO liposomes 
resulted in a 4-times larger fluorescence signal relative to DETA/NO after 2 h, supporting the 
results observed in the time-course study where the fast release system elicited more rapid 
cytotoxicity (at 24 h). The lack of cytotoxicity observed for the PAPA/NO liposomes at the same 
NO payloads as the DETA/NO liposomes (0.75 µg/mL) was supported by negligible intracellular  
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Figure 4.4. (A) Confocal fluorescence images of MCF-7 cells incubated with DAF-FM (green) 
and treated with NO-releasing liposomes (red) for 2 h. Scale bar represents 15 µm. Column 1 is 
controls. Column 2 and 3 are cells exposed to the LD50 values of DETA/NO and PAPA/NO 
liposomes, respectively. By 2 h, DETA/NO and PAPA/NO liposomes released ~1 and 30% of 
their NO payloads, respectively. (B) Densitometric analysis of intracellular DAF-FM levels 
relative to untreated controls. 
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Figure 4.5. Orthogonal view of MCF-7 cells after treatment with PAPA/NO liposomes. Scale 
bar represents 5 µm. 
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NO accumulation at 2 h (data not shown). Collectively, the greater NO accumulation and NO 
exposure observed for the PAPA/NO liposomes leads to more rapid anticancer action. 
4.3.3. Kinetics of intracellular NO accumulation 
The rapid NO delivery from the PAPA/NO liposomes was hypothesized to be key in 
eliciting cytotoxicity at short time periods (i.e., 24 h). The more gradual cell killing observed 
using the DETA/NO liposomes would be expected to parallel the build-up of intracellular NO 
over time. Flow cytometry was utilized to quantify NO accumulation within the MCF-7 cells 
over a 72 h period using the same DAF-FM probe (Figure 6). A large increase in intracellular 
fluorescence was observed by 24 h for cells treated with PAPA/NO liposomes (16.2 µg/mL NO). 
At 48 and 72 h, the fluorescence essentially remained at the same level, signaling that no more 
NO was delivered to the cell. In contrast, the fluorescence within cells treated with the slower 
NO-releasing DETA/NO liposomes (0.75 µg/mL NO) continued to increase steadily over the 
entire 72 h period. The therapeutic action of both slow and fast NO-releasing liposomes followed 
the same trend observed in the cytotoxicity time-course study, where cytotoxicity was elicited 
more rapidly with PAPA/NO liposomes and the DETA/NO liposomes required the full 72 h 
before eliciting toxicity. At equal NO payloads (0.75 µg/mL), minimal intracellular NO 
accumulation was observed for the PAPA/NO liposomes due to premature NO loss prior to 
cellular uptake (Appendix C), which is in agreement with cytotoxicity findings.  
A median fluorescence intensity comparison between free and liposomal NO donors was 
performed to highlight the benefits of using NO-releasing liposomes over the low molecular 
weight NO donors. Cells treated with NO-releasing liposomes exhibited greater intracellular NO 
accumulation (Figure 6), as a result of enhanced NO donor stability (within the liposomes) and 
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Figure 4.6. Change in median fluorescence intensity over time indicating intracellular NO 
accumulation, as determined by flow cytometry, after treating MCF-7 cells with 0.75 µg/mL NO 
from (●) liposomal and (▲) free DETA/NO, and 16.2 µg/mL NO from (■) liposomal and ( ) free 
PAPA/NO. 
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targeted cellular uptake. Similar behavior has been observed for other small molecule drugs (e.g., 
gemcitabine and doxorubicin) encapsulated within liposomes.8,50 
4.3.4. Effect of liposomes on intracellular signaling 
Western blot analysis was employed to evaluate if any differences existed in protein 
expression levels. Poly(ADP-ribose) polymerase (PARP) is a critical mediator of DNA repair 
and upon cleavage by caspase-3 initiates cellular breakdown and apoptosis.51 A measurement of 
increased PARP levels after treatment would indicate that cells underwent PARP-mediated 
apoptosis. Cyclin analysis would facilitate understanding the cell cycle and whether cells were 
arrested or ejected.52-53 The expressions of these regulator proteins in MCF-7 cells were 
measured after NO exposure at 24, 48, and 72 h (Figure 8A). Cleaved PARP levels were the 
greatest for cells treated with 16.2 µg/mL NO from PAPA/NO liposomes, indicating apoptosis, 
especially at early timepoints (i.e., 24 and 48 h). This data correlates well with the rapid 
cytotoxicity observed from the fast NO-release system (Figure 3).  Densitometric calculations 
were performed on the blots to more accurately compare protein levels between exposure 
conditions. Even though cells treated with DETA/NO liposomes exhibited reduced cyclin B1 
levels relative to controls by 24 h (Figure 8B), the levels were still greater than cells treated with 
PAPA/NO liposomes. At 72 h, the two systems, at their respective LD50 values, had similar 
expressions of cyclin D1 (Figure 8C), suggesting an equivalent capacity to either inactivate 
transcription factors that drive cell proliferation (i.e., prevent cell growth) or initiate cyclin D1 
destruction. Of note, minimal changes in protein expression were observed for cells exposed to 
PAPA/NO liposomes at NO payloads (0.75 µg/mL) equivalent to the DETA/NO liposomes, 
corroborating insufficient NO delivery and low toxicity. These results suggest that both types of  
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Figure 4.7. (A) Western blot of MCF-7 cells after no treatment (lane a), 0.75 µg/mL NO from 
DETA/NO liposomes (lane b), 0.75 µg/mL NO from PAPA/NO liposomes (lane c), and 16.2 
µg/mL NO from PAPA/NO liposomes (lane d). (B) Densitometric analysis of cyclin B1 levels 
after 24 h exposure. (C) Densitometric analysis of cyclin D1 levels after 72 h exposure. 
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NO-releasing liposomes trigger the same anticancer pathways, but to different degrees depending 
on the exposure time and NO concentration. Slower NO release elicits a more gradual increase in 
cleaved PARP levels (i.e., apoptosis) and arrested cells in the cell cycle, while faster NO release 
promotes rapid PARP cleavage and prevention of mitosis. 
4.4 Conclusions 
 The transition from low molecular weight NO donors to macromolecular NO-release 
systems for anticancer treatments may represent an important step in creating more effective 
chemotherapies. Two NO-releasing liposome systems with distinct NO-release kinetics were 
used to study cytotoxicity against pancreatic, colorectal, and breast cancer cell lines. Through the 
encapsulation of the low molecular weight NO donor within liposomes, greater intracellular NO 
accumulation was observed due to enhanced uptake. The preliminary cell studies herein suggest 
that NO-release kinetics play an important role in eliciting cell death, with a direct relationship to 
intracellular NO accumulation. Fast NO-releasing liposomes represent a less effective anticancer 
therapeutic as the NO is liberated too rapidly in advance of intracellular uptake. Further 
cytotoxicity studies using liposomes bearing cancer targeting ligands (e.g., folate) are the next 
steps in enhancing the selecitivty of the NO-releasing liposomes. This work points towards the 
promise of using NO-releasing liposomes as anticancer agents, and the importance of controlling 
NO-release rates for other macromolecular delivery scaffolds. The ability of NO to further 
increase the number of oxidative/nitrosative species that cancer cells are already exposed to is a 
unique mechanism to specifically target cancer cells over healthy cells. 
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CHAPTER 5: SUMMARY AND FUTURE DIRECTIONS 
 
5.1 Summary of dissertation research 
 The therapeutic potential of exogenous NO has been met with many obstacles that can be 
overcome using drug delivery vehicles. While macromolecular NO-release systems such as gold 
nanoparticles,1-2 silica nanoparticles,3-10 and dendrimers11-15 have been developed, they often fall 
short in terms of in vivo delivery due to limitations in NO donor stability. My dissertation 
research focused on the use of liposomes for N-diazeniumdiolate delivery vehicles with the 
intent to encapsulate and protect the NO donor. Chapter 2 detailed the synthesis and 
characterization of NO-releasing liposomes. As prepared using dipalmitoylphosphatidylcholine, 
liposomes were ~275 nm in size (diameter) and capable of releasing NO up to 7-times longer 
than the free NO donor alone. At 4 °C in a basic solution, the vesicles retained ~80% of their 
encapsulated NO at 3 months of storage. To ascertain utility of NO-releasing liposomes as 
anticancer agents, the cytotoxicity of the liposomes against pancreatic cancer cells was compared 
to the free NO donor. The free NO donor required much greater NO concentrations (2.4 mM) to 
elicit anticancer effects relative to the NO-releasing liposomes (0.183 mM). Thus, liposomes 
were shown to both enhance stability of the N-diazeniumdiolate and increase anticancer activity, 
attributed to a more localized NO delivery. 
 Chapter 3 described a systematic evaluation of the parameters influencing liposomal NO 
release. A change in liposomal NO-release kinetics was readily achieved by altering the structure 
of the encapsulated N-diazeniumdiolate and/or the composition of the lipid bilayer (i.e., 
phospholipid identity). As evidenced by the data, the lipid headgroup surface area was the key 
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factor in regulating NO-release kinetics. A notable increase in NO release was observed upon 
decreasing the headgroup surface area, which was attributed to the tighter headgroup packing 
impeding proton diffusion into the core. Nitric oxide release was also measured in blood and 
serum to understand the role of protein binding to the bilayer and potential bilayer disruption. 
The NO-release kinetics in serum were equivalent to those in buffer, while those measured in 
blood were ~60% faster. The faster release was attributed to the presence of cells (e.g., 
erythrocytes) and other potent NO scavengers such as hemoglobin, shifting the equilibrium of 
NO diffusion. However, lipid bilayer decomposition may also have contributed to the faster NO-
release kinetics. 
 The impact of NO-release kinetics on cancer cell killing was detailed in Chapter 4. 
Specifically, the effects of fast (t1/2 ~ 2.5 h) and slow (t1/2 > 72 h) NO release on cancer cell 
killing were evaluated using several cancer cell lines. Slow NO-releasing liposomes yielded 
consistently lower LD50 values (<230 µM NO) relative to the fast NO-releasing system (>230 
µM NO), regardless of the cancer cell (breast, colorectal, and pancreatic cancer). However, time 
course studies revealed that a more rapid decline in cell viability occurred for the fast NO-release 
system. Both confocal fluorescence microscopy and flow cytometry verified that the faster NO 
release led to an increased rate of intracellular NO accumulation. In contrast, slow NO release 
resulted in a more gradual intracellular NO build up. Western blotting analysis revealed that both 
the slow and fast NO-release systems induced apoptosis, albeit to different degrees. Overall, 
these studies suggest that faster NO-release kinetics elicit anticancer action at the expense of 
high NO donor concentrations, whereas lower concentrations of NO via slower NO-release 
kinetics necessitates longer exposures to elicit cell killing. The employment of slow NO-release 
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systems for anticancer action may therefore minimize adverse systemic effects due to the lower 
LD50 values. 
5.2 Future directions 
5.2.1 Conjugation of targeting ligands to liposome surface 
 In order to achieve active targeting in vivo, ligands should be appended to the liposome 
exterior that selectively bind to membrane moieties located on cancer cells. Conjugation may be 
performed using two different methods: bilayer insertion using long alkyl chains or covalent 
attachment to the lipid headgroup. Bilayer insertion of the targeting ligand is a more general 
approach that allows for a greater variety of ligands to be created at the expense of low bilayer 
incorporation efficiencies and risk of removal during transport.16-17 Long alkyl chains (e.g., 
dodecyl) are attached to the ligand that then insert themselves into the hydrophobic domain of 
the lipid bilayer. However, the single alkyl tail may disrupt the order of the bilayer, thus reducing 
the ligand’s stability and increasing the likelihood of its ejection in biological milieu. One 
advantage though is that many chemistries, including acid chloride and maleimide reactions, may 
be utilized to attach a large number of ligands (Table 5.1).17  
In contrast, covalent attachment relies on the reaction of an existing phospholipid 
comprising the bilayer with the targeting ligand. Distearoylphosphatidylethanolamine (DSPE) is 
widely used as a phospholipid for covalent attachment due to its reactive headgroup (i.e., a 
primary amine).18-19 For example, carboxylic acid moieties on folic acid have been reacted with 
DSPE’s primary amine to yield folate-modified phospholipids.20 By using covalent attachment, 
the targeting ligands are less prone to dislodge from the bilayer during blood exposure because 
their hydrophobic tails are identical to those comprising the existing bilayer.  
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Table 5.1. Ligands used for active targeting. a 
Targeting ligands and 
antibodies 
Alternative names  
(trade name) 
Target 
RGD peptide  Cellular adhesion molecules 
such as ανβ3- integrin 
NGR peptide  Aminopeptidase N (CD13) 
GM-CSF glycoprotein  GM-CSF receptor 
Folate  Folate receptor 
Transferrin  Transferrin receptor 
Galactosamine  Galactosamine receptors on 
hepatocytes 
Anti-VEGFR 2C3 Vasculature endothelial 
growth-factor receptor 
(FLK1) 
Anti-ERBB2 Trastuzumab (Herceptin) ERBB2 receptor 
Anti-CD20 Rituximab (Rituxan), 
ibritumomab tiuxetan 
(Zevalin) 
CD20, a B-cell surface 
antigen 
Anti-CD22 Epratuzumab, LL2, RFB4 CD22, a B-cell surface 
antigen 
Anti-CD19 B4, HD37 CD19, a pan-B cell surface 
epitope 
Anti-CD33 Gemtuzumab, ozogamicin 
(Mylotarg) 
CD33, a sialo-adhesion 
molecule, leukocyte 
differentiation antigen 
Anti-CD33 M195 CD33, a T-cell epitope 
Anti-CD25 Anti-Tac, LMB2 CD25, α-subunit of the 
interleukin-2 receptor on 
activated T cells 
Anti-CD25 Denileukin diftitox (Ontak) Interleukin-2 receptor 
Anti-HLA-DR10β Lym1 HLA-DR10β subunit 
Anti-tenascin 81C6 Extracellular-matrix protein 
overexpressed in many tumors 
Anti-CEA MN-14, F6, A5B7 CEA 
Anti-MUC1 HMFG1, BrE3 MUC1, an aberrantly 
glycosylated epithelial mucin 
Anti-TAG72 CC49, B72.3 TAG72, oncofetal antigen 
tumor-associated 
glycoprotein-72 
aAdapted with permission from Nature Reviews Cancer, 2002, 2, Allen, T.M. “Ligand-targeted 
therapeutics in anticancer therapy” pages 750–763, Copyright 2002 Nature Publishing Group. 
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Utilizing the above chemistries, many targeting ligands have been appended to the 
exterior of liposomes.18 Folic acid, a critical biomolecule required for DNA synthesis, has been 
conjugated to the surface of liposomes to enable binding to the overexpressed folate receptors on 
the surface of cancer cells.21-22 In order to compensate for the increased replication rates of 
cancer, folate receptors are more populated on their cell surface. Folate-appended arsenic 
trioxide liposomes were 9- and 28-times more toxic towards HeLa and KB cells, respectively, 
than the same liposomes without the folate groups. Transferrin, a beta globulin protein that 
functions to transport iron in biological fluids, represents another ligand that has been attached to 
liposomes. Like folate, the transferrin receptor is overexpressed on the surface of cancer cells.23-
24 As DNA polymerase requires iron for DNA replication, increased transferrin uptake helps 
maintain iron homeostasis.25 Liposomes bearing transferrin ligands have exhibited improved 
cellular uptake (~10-times greater) relative to controls as measured via confocal fluorescence 
microscopy.26  
The large nutrient requirement for tumors and cancer cells has lead to an emerging area 
of research whereby sugar units (e.g., glucose) are attached to the exterior of drugs, with the 
intent of facilitating more rapid uptake resulting from the high activity of the glucose transport 
receptors (e.g., GLUT-1) on cancer cells.27-28 Upon glucose conjugation to polymeric vesicles, 
for example, greater intracellular accumulation was observed as measured by transmission 
electron microscopy and flow cytometry.29 The attachment of similar ligands to the surface of 
NO-releasing liposomes may lead to greater accumulation at cancer sites. For any modification, 
it will be necessary to examine any influence on the NO release. Future work should include a 
multi-pronged study using cytotoxicity assays, confocal fluorescence microscopy, and flow 
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cytometry to elucidate if NO-releasing liposomes would benefit from the conjugation of 
targeting ligands. 
5.2.2 Dual-encapsulation to enhance anticancer action 
 While evidence of the chemotherapeutic effects of NO-releasing liposomes was provided 
in Chapter 4, reducing the cytotoxic concentrations into the nanomolar range would improve the 
therapeutic potential of our system. Our lab has previously reported on the synthesis of dual-
action scaffolds that are capable of inducing cell death via multiple mechanisms.30-33 Similarly, it 
is possible to encapsulate NO with other therapeutics within the liposomes to potentially improve 
anticancer activity. Molecules of varying charges, molecular weights, and solubilities, have all 
been encapsulated within liposomes. Indeed, the hydrophilic (i.e., aqueous core) and 
hydrophobic (i.e., lipid bilayer) domains located within liposomes facilitate encapsulation of 
molecules exhibiting differing properties (e.g., doxorubicin and DNA). 
The constricted vasculature of tumor sites inhibits extravasation of many drug delivery 
systems.34 Pretreatment with NO has been shown to increase the efficacy of current 
chemotherapeutics due to NO’s vasodilatory properties.35-36 The enlargement of tumor blood 
vasculature allows for improved delivery and accumulation of the drug delivery system at the 
malignant site. Unlike current methods, multi-drug encapsulation within liposomes would 
remove the need for pretreatment because the liposomes could be engineered to have NO 
released simultaneously with the drug of interest. 
 Future studies should focus on the combination of doxorubicin and N-diazeniumdiolates. 
Due to poor water solubility, doxorubicin is a difficult drug to deliver in the body. Barenholz 
described the benefit of encapsulating doxorubicin within liposomes.37 In this manner, large 
amounts of doxorubicin were loaded into liposomes using a unique transmembrane ammonium 
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sulfate gradient.38 Although showing some efficacy in vivo, rather large doses were required due 
in part to the constricted vasculature system. A number of adverse side effects were reported, 
including mouth sores and acral erythema (i.e., hand-foot syndrome). While Pedrini et al. 
combined liposomal doxorubicin with NO using nitrate-modified doxorubicin, this derivative, as 
with most organic nitrates, required enzymatic cleavage for the NO to be released.39 In contrast, 
encapsulated N-diazeniumdiolates would offer spontaneous release of NO under biological 
conditions. Incorporation of both N-diazeniumdiolates and doxorubicin into the liposome system 
may enable a practical chemosensitization scaffold with dual-action efficacy. 
 Gemcitabine represents an equally attractive co-encapsulant with NO donors. Known as 
the gold standard for treating pancreatic cancer, gemcitabine is utilized for its ability to replace 
essential building blocks in the synthesis of DNA.40 In contrast to NO, which would initiate cell 
membrane disruption, gemcitabine necessitates cellular uptake and replication in order to exert 
its therapeutic activity. Liposomes have long been investigated as delivery agents for 
gemcitabine due to the potential for enhanced cellular uptake relative to free molecules. In vivo 
studies demonstrated that liposomal gemcitabine showed greater reduction in tumor size at 3-
times lower concentrations (relative to free gemcitabine).40 Introducing NO into the liposomal 
system may increase accumulation of the vesicles at the cancer site and increase anticancer 
action to an even greater extent due to chemosensitization, as well as exerting 
nitrosative/oxidative stress from both inside and outside the cell. 
5.2.3 Antibacterial properties of NO-releasing liposomes 
 Liposomes have been utilized as antibacterial agents for the same reason they are 
attractive as chemotherapeutics. Efficient delivery and cellular uptake of small molecule 
antibiotics have been major obstacles for treating both chronic and acute infections. Through the 
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encapsulation of tobramycin and gentamicin, liposomes have shown to improve biocidal action 
against Pseudomonas aeruginosa relative to the free antibiotics.41 Depending on the bacterial 
strain, minimum inhibitory concentrations (MIC) were nearly 128-times lower when the 
antibiotic was encapsulated versus in free form, highlighting the potential of liposomes as 
vehicles for antibacterials.41Association with bacteria is often a decisive factor in determining the 
biocidal role of a therapeutic.7,9 As liposomes can be designed to have distinct exterior charge 
(i.e., electrostatic attraction to bacteria) and facilitate fusion into the bacteria, key targeting 
advantages over other drug delivery scaffolds (e.g., silica nanoparticles) become apparent.   
 Our lab has previously synthesized macromolecular NO-release scaffolds having strong 
biocidal action. To date, the two most potent include NO-releasing dendritic polymers and 
polysaccharides.11-15,42-45 The large NO payloads and bacteria-scaffold association of these 
delivery systems affords excellent bacteria eradication properties. While both scaffolds have 
demonstrated success, premature release of NO before localization at the bacterial membrane 
remains a potential concern. As demonstrated in Chapter 4, liposomes mitigate premature NO 
release via encapsulation of the NO donor. Encapsulation of macromolecular NO-release 
scaffolds thus might prove useful in further improving biocidal activity. 
 Khopade et al. have reported successful encapsulation of dendrimers within liposomes, 
resulting in final vesicle sizes ranging from 100 nm to 1 µm.46 Both dendrimer loading efficiency 
and release kinetics were tuned by varying the dendrimer structure or the lipid bilayer 
composition. Unfortunately, the use of dendrimers has been linked to liposome leakage and 
stability shortcomings due to the dendritic chains intercalating into the bilayer.47 It is therefore 
important to study the interaction of the dendrimer with the liposome membrane after 
encapsulation to ensure the formation of a structurally stable system. Dynamic light scattering, 
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fluorophore co-encapsulation, and nuclear magnetic resonance spectroscopy could each be 
utilized to examine liposome rupture and encapsulant retention. 
Likewise, polysaccharides could be encapsulated within liposomes. For example, Liu et 
al. coencapsulated a polysaccharide derived from the Ganoderma lucidum fungus (molecular 
weight=37 kDa) with ovalbumin (molecular weight=43 kDa) to create a potent vaccine.48 
Although polysaccharides are less likely to damage the liposome membrane due to their 
hydrophilic nature, lower encapsulation efficiencies may be observed as a result of their high 
molecular weight. Encapsulation studies should be performed as a function of the 
polysaccharides molecular weight to understand loading and the resulting antibacterial action. 
5.3 Conclusions 
 Current macromolecular NO-release scaffolds may have limited efficacy in delivering 
NO intravenously (i.e., bloodstream administration) to a target of interest due to premature NO 
release. Liposomes represent a unique alternative for in vivo NO delivery. The biodegradability 
and biocompatibility of liposomes mitigates potential immune response and cytotoxicity, while 
the lipid bilayer impedes proton diffusion into the aqueous core, thus protecting the NO donor 
from degradation and preserving its therapeutic payload. The studies provided in this dissertation 
support that liposomes can both encapsulate N-diazeniumdiolates and enhance their stability, and 
exhibit potent tumoricidal activity against representative aggressive cancer cells. In order to 
further increase the potential in vivo chemotherapeutic effects of the NO-releasing system, 
studies should be performed that evaluate the specificity of the liposomes for cancer cells. 
Additionally, a direct comparison to current chemotherapeutics (e.g., doxorubicin) in regards to 
anticancer action, specificity, and in vivo stability would highlight the benefits of NO-releasing 
liposomes as an alternative treatment strategy. Understanding the obstacles that limit the use of 
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NO as a systemic therapeutic is critical in order to design more effective in vivo delivery 
vehicles. 
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Appendix A: Supplemental Information of Chapter 2 
 
 
 
Figure A1. Nitric oxide release profile measured in real-time of free DPTA/NO versus liposomal 
DPTA/NO in 10 mM PBS (pH 7.4, 37 °C). 
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Figure A2. Transmission electron micrograph of DPTA/NO loaded liposomes after a 1:1 
dilution and negative-staining with 2% uranyl acetate. Any shape deformation is most likely 
attributed to the liposomes flattening on the grid’s surface. 
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Figure A3. Cytotoxicity on human PANC-1 cells after a 24 h incubation using varying 
concentrations of free DPTA/NO. Error bars indicated standard deviation from ≥3 separate 
experiments.  
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Appendix B: Supplemental Information of Chapter 3 
 
 
 
Figure B1. Proton-initiated decomposition mechanism of N-diazeniumdiolates to liberate NO. 
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Figure B2. UV-vis spectra of 0.020 mg/mL (a) PROLI/NO, (b) DEA/NO, (c) PAPA/NO, and (d) 
SPER/NO in 50 mM NaOH. Typical 252 nm absorbance peak associated with the 
diazeniumdiolate group is observed.1 
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Figure B3. FTIR spectra of (a) PROLI/NO, (b) DEA/NO, (c) PAPA/NO, and (d) SPER/NO. 
Precursor amine spectra are in black and NO donors are in red. N-O stretches (1236-1210 cm-1), 
in-plane N2 symmetric stretches (1200-1150 cm1 and 965-975 cm-1), and N-N stretches (1128-
1120 cm-1) can be observed due to the prescence of the diazeniumdiolate group.1-2 
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Figure B4. UV-vis spectra of 0.020 mg/mL (a) PROLI/NO, (b) DEA/NO, (c) PAPA/NO, and (d) 
SPER/NO in 10 mM PBS (pH 7.4) after incubation at 37 °C for 2 h. Absorbance peak at 210 nm 
is associated with nitrite/nitrate formation. 
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Figure B5. UV-vis spectra of 0.010 mg/mL (a) sodium nitrate and (b) sodium nitrite in 10 mM 
PBS (pH 7.4, 37 °C). Peak at ~350 nm is from sodium nitrite. 
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Figure B6. UV-vis spectra of 0.020 mg/mL (a) PROLI/NO, (b) DEA/NO, (c) PAPA/NO, and (d) 
SPER/NO in 10 mM MES buffer (pH 5.4) after incubation at 37 °C for 2 h. 
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Figure B7. N-diazeniumdiolate NO donors with their reported NO-release half-lives in 10 mM 
PBS (pH 7.4, 37 °C).3 
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Table B1. Nitric oxide-release properties of DPPC liposomes as a function of encapsulated N-
diazeniumdiolate NO donor in MES (pH = 5.4) at 37 °C. a 
NO donor t1/2b (h) tdc (h) [NO]totald (µmol/mL) 
PROLI/NO 0.06 ± 0.02 1.7 ± 0.9 4.71 ± 0.80 
DEA/NO 0.12 ± 0.04 5.5 ± 1.6 8.37 ± 0.62 
PAPA/NO 0.84 ± 0.24 20.7 ± 4.6 7.75 ± 1.09 
SPER/NO 10.4 ± 1.9 44 ± 9.0 6.81 ± 0.78 
aError indicates standard deviation from at least 3 separate liposome preparations. bHalf-life of 
NO release. cDuration of NO release until the measured NO reached 10 ppb per 300 µL of 
liposomes (three-times the detection limit of the instrument). dTotal amount of NO released 
normalized to the injected volume from the liposome stock solution. 
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Figure B8. Structures of lipids used to make the liposomes from Table 3. 
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Figure B9. Transmission electron micrographs of DMPC (C14), DPPC (C16), and DSPC (C18)-
based PAPA/NO liposomes. Scale bar represents 0.2 µm. 
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Table B2. Fluorophore encapsulation efficiency for DPPC and DPPG liposomes.a 
Molecule DPPC (C16) EE (%) DPPG (- C16) EE (%) 
Coumarinb  25.6 26.1 
5(6)-carboxyfluoresceinc 21.7 11.3 
aEncapsulation efficiency was calculated as the ratio of mol of fluorophore inside liposomes to mol 
used for synthesis multiplied by 100. A calibration curve was created using each fluorophore for 
quantification. bExcitation at 355 nm and emission measured at 510 nm. cExcitation at 495 nm 
and emission measured at 517 nm. 
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Figure B10. Transmission electron micrographs of DPPG (- C16) and DPTAP (+ C16) PAPA/NO 
liposomes. Scale bar represents 0.2 µm. 
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Table B3. Nitric oxide-release properties of PAPA/NO liposomes as a function of bilayer 
hydrophobicity and charge in MES (pH = 5.4) at 37 °C. 
Lipid t1/2a (h) tdb (h) [NO]totalc (µmol/mL) 
DMPC (C14) 1.6 ± 1.2 22.3 ± 2.6 7.90 ± 0.29 
DPPC (C16) 0.84 ± 0.24 20.7 ± 4.6 7.75 ± 1.09 
DSPC (C18) 12.3 ± 1.3 59.4 ± 7.7 8.91 ± 0.62 
DPPG (- C16) 1.2 ± 0.3 19.9 ± 6.5 6.13 ± 0.97 
DPTAP (+ C16) 0.09 ± 0.01 6.5 ± 2.1 7.94 ± 0.96 
aHalf-life of NO release. bDuration of NO release until the measured NO reached 10 ppb per 
300 µL of liposomes (three-times the detection limit of the instrument). cTotal amount of NO 
released normalized to the injected volume from the liposome stock solution. 
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Figure B11. (a) Z-average size and (b) polydispersity index values of PAPA/NO-encapsulated 
(▼) DPPC, (▲) DPPG, (■) 50:50 DPPC:DPTAP, and (●) 10:90 DPPE-PEG/DPPC liposomes 
over time as measured by dynamic light scattering. Liposomes were stored at 4 °C between 
measurements. 
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Figure B12. (a) Normalized absorbance measured at 450 nm for 5% (v/v) liposome solutions in 
serum. (b) Amount of protein adsorbed to the liposomes, normalized to moles of lipid, as 
measured by the Bradford assay. The DPTAP and PEG liposomes were composed of a 50:50 
DPTAP:DPPC and 10:90 DPPE-PEG:DPPC molar ratios, respectively. 
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Figure B13. Nitric oxide release from neutral DPPC PAPA/NO  
liposomes suspended in 10 mM PBS (pH 7.4, 37 °C) containing 157 
mg/mL hemoglobin. The amount of NO remaining within the 
liposomes was determined by injecting the liposomes into an acidic 
solution at discrete timepoints. 
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Figure B14. Hemolytic activity of various PAPA/NO-encapsulated liposome 
systems. The DPTAP liposomes are composed of a 50:50 DPTAP:DPPC molar 
ratio and PEG liposomes are composed of a 10:90 DPPE-PEG:DPPC molar ratio. 
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B.1 Experimental section 
B.1.1. Protocol for hemolysis assay 
 A standard hemolysis assay was employed for determining the hemolytic activity of the 
NO-releasing liposomes.4-6 Red blood cells (RBCs) are harvested from freshly-obtained citrated 
canine blood and resuspended in 0.9% isotonic saline to a 10% (v/v) concentration. The RBCs 
(300 µL) are mixed with the stock liposome solution (15 µL) and incubated at 37 °C for 30 min 
with slight agitation. Afterwards, the RBCs are separated from free hemoglobin by centrifugation 
at 1,000 × g for 10 min. The supernatant (80 µL) was added to a 96-well plate and the 
absorbance was measured at 405 nm using a Thermoscientific Multiskan EX plate reader 
(Waltham, MA). Absorbance values from negative controls (300 µL blood mixed with 15 µL 
0.9% saline) were subtracted from all absorbance values. The % hemolysis was determined by 
dividing the sample absorbance with that of RBCs incubated with 1% triton in saline. 
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Appendix C: Supplemental Information of Chapter 4 
 
 
 
 
Figure C1. Molecular structures of the N-diazeniumdiolate NO donors. 
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Figure C2. Transmission electron micrographs of (A) PAPA/NO and (B) DETA/NO liposomes. 
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Figure C3. Cytotoxicity plot of liposomal (▲) PAPA/NO and (●) DETA/NO as a function of 
NO concentration against human HPNE epithelial pancreatic cells. 
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Figure C4. Change in median fluorescence intensity over time, as determined by flow 
cytometry, after treating MCF-7 cells with free PAPA/NO at 16.2 µg NO/mL (green squares) 
and 0.75 µg NO/mL (black circles), and liposomal PAPA/NO at 16.2 µg NO /mL (red diamonds) 
and 0.75 µg NO/mL (blue triangles). 
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APPENDIX D: SELECTIVE MONOPHOSPHORYLATION OF CHITOSAN VIA 
PHOSPHORUS OXYCHLORIDE4 
 
D.1 Introduction 
 The medical field is increasingly turning to renewable biopolymers, such as cellulose,1-2 
collagen,3-4 alginate,5-7 and chitosan,8-10 for tissue engineering and drug delivery applications due 
to their favorable in vivo properties.11 For tissue reconstruction, such polymers tend to elicit a 
reduced immune response, lower implant rejection rates, and decreased toxicity as a result of 
biomimicry (i.e., the ability to mimic the natural tissue environment).12-14 The glycosidic 
linkages of biopolymers also promote facile biodegradation via enzymatic hydrolysis.13-15 
 Chitosan, a polysaccharide derived from crustacean shells, consists of repeating units of 
N-acetylglucosamine and D-glucosamine. The primary alcohols and amines of these units are 
readily accessible and enable a diverse range of chemical modifications.8 As such, researchers 
have engineered chitosan-based materials for wound dressing,16 metal and dye chelation,16 drug 
delivery,17 sensing,18 fuel cell,19 and antibacterial20-21 applications. For example, Ishiara22 
reported the modification of chitosan with azides to enhance the mechanical properties of the 
biopolymer for wound-healing applications. Sashiwa et al. added α-galactosyl pendants to 
chitosan to inhibit binding of human antibodies and evade the host immune response.23 The 
authors demonstrated the benefits of the α-galactosyl pendants in a pig liver xenotransplant 
model.  
 Chitosan’s poor solubility in physiological media represents a critical shortcoming that 
limits therapeutic utility. In general, chitosan of >20 kDa molecular weight is soluble only in 
                                                
4 This appendix was adapted from an article that previously appeared in Polymer Chemistry. The 
original citation is as follows: Suchyta, D.J.; Soto, R.J.; Schoenfisch, M.H. “Selective 
monophosphorylation of chitosan via phosphorus oxychloride” Polymer Chemistry 2017, 12, 
3569-3574. 
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acidic aqueous solutions.9 Though certain chemical modifications may alter functional aspects of 
chitosan for a given application, often the modification does not influence the solubility since 
many of these entities are electrically neutral (e.g., sugars) at pH 7.4. A satisfactory alternative to 
chemical modifications is to work with lower molecular weight oligosaccharides (~10 kDa) that 
are water-soluble.21 However, a large molecular weight scaffold is preferred for many 
biomedical applications (e.g., wound dressings and polymeric membranes). 
 Phosphorylation is a popular chemical modification strategy for improving the water 
solubility of chitosan and maintaining its molecular weight.22,24 At pH >6.5, phosphorylated 
chitosan (P-chitosan) consists of deprotonated phosphate groups that enables high water 
solubility for biological and industrial applications. For example, P-chitosan solutions have been 
used to enhance Ca2+ remineralization of dentine resulting from the high surface 
adsorption/interaction that P-chitosan promotes with enamel.25-27 Of note, the efficacy of P-
chitosan for dentine remineralization would be limited by poor water solubility and, likely, 
molecular weight. 
 Many researchers have phosphorylated chitosan predominantly by reaction with solutions 
of phosphoric acid, triethyl phosphate, and phosphorus pentoxide (P2O5).28-30 Unfortunately, 
chitosan is insoluble in many solvents, thus the ensuing heterogeneous reaction conditions result 
in poor phosphorylation and irreproducibility.29-30 To address this, Nishi et al. 28 reported an 
alternative phosphorylation reaction that employs methanesulfonic acid to solubilize the 
chitosan. Insoluble P2O5 was employed as the phosphorylating reagent, a chemical compound 
that results in the undesirable formation of polyphosphoric acids/ions.31 These polyphosphate 
byproducts are either free or bound to the chitosan through inter- and intramolecular bridging, 
making their removal difficult, and complicating adequate characterization of the resulting P-
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chitosan’s structure. In general, previous reports on chitosan phosphorylation have not 
adequately characterized the resulting product. Indeed, 31P NMR data is rarely provided resulting 
in questionable or even outright neglected phosphorylation conversion efficiencies. 
 The shortcomings of P2O5-based phosphorylation warrant further exploration into 
alternative phosphorylating reagents. Reactants that facilitate monophosphorylation (i.e., 
polyphosphate formation does not occur) are essential to both prevent intra- and intermolecular 
polyphosphate bridging and enable more accurate characterization. To this end, we explored the 
use of phosphorus oxychloride (POCl3) to generate P-chitosan. Phosphorus oxychloride is a 
liquid phosphorylating reagent utilized in the synthesis of phosphate esters and cross-linked 
starch and cellulose because of its high solubility in organic solvents.32-36 Furthermore, negligible 
self-reaction should prevent the formation of polyphosphates, making it a promising alternative 
to P2O5. Herein, we report the selective monophosphorylation of chitosan using POCl3 in 
methanesulfonic acid to produce a water-soluble product of high molecular weight. 
D.2 Experimental section 
D.2.1. Materials 
Low molecular weight chitosan (degree of acetylation: 27%), phosphorus pentoxide 
(P2O5), phosphorus oxychloride (POCl3), low viscosity alginic acid sodium salt, methanesulfonic 
acid (MSA), cellulose, deuterium oxide (D2O), D-glucosamine, D-glucosamine 1-phosphate, D-
glucosamine 6-phosphate, and N-acetylglucosamine were purchased from Sigma (St. Louis, 
MO). Tetrahydrofuran (THF), sodium hydroxide (NaOH), nitric acid (HNO3), orthophosphoric 
acid (H3PO4), diethyl ether, and calcium chloride (CaCl2) dihydrate were purchased from Fisher 
Scientific (Fair Lawn, NJ). Water was purified to a resistivity of 18.2 MΩ·cm and a total organic 
content ≤6 ppb using a Millipore Milli-Q UV Gradient A10 System (Bedford, MA). 
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D.2.2. Synthesis of phosphorylated chitosan 
Chitosan (200 mg) was added to a round-bottomed flask and dissolved in 10 mL 
methanesulfonic acid. After complete dissolution, 2.060 mL POCl3 were injected into this 
stirring solution. The reaction was allowed to proceed at room temperature for up to 72 h. To end 
the reaction, 1.40 mL of water were added to the flask and stirred for another 15 min. The 
solution was then transferred to centrifuge tubes, precipitated with diethyl ether, and centrifuged 
(4000 × g for 3 min) to pellet the P-chitosan. The P-chitosan was washed twice with THF, once 
with ethanol, dried under vacuum overnight, and stored at -20 °C until use. 
D.2.3. 1H and 31P nuclear magnetic resonance (NMR) spectroscopy 
All NMR spectra were collected at 23 °C in 5 mm NMR tubes using a Bruker AVIII 600 
MHz spectrometer equipped with a Quattro Nucleus Probe (QNP) C-P-N cryoprobe. Samples 
were prepared at ~2 mg/mL in D2O (1H NMR) or a 1:3 volumetric ratio of D2O to 50 mM NaOH 
(31P NMR). Proton spectra were acquired using a conventional 1-D pulse sequence with 16 
scans. Phosphorus spectra were collected using a standard proton decoupled pulse sequence with 
800 scans. Data was processed using Bruker’s TopSpin software. Relevant 1H NMR data of P-
chitosan (600 MHz, D2O, δ): 1.9 (C7: CHNHCOCH3), 2.67 (SO3CH3), 3.1 (C2: CHCHNH3+), 
3.4-3.9 (C3, C4, C5, C6: OHCH, OCHCH(OH)CH(NH2), OHCH2CH, OHCH2CH. 
D.2.4. X-ray photoelectron spectroscopy (XPS) 
 Samples for XPS analysis were prepared by casting 20 µL of 1 mg/mL P-chitosan in 
water onto gold-sputtered glass slides and evaporating the water under vacuum overnight. The 
sample-coated gold substrates were analyzed using a Kratos Axis Ultra DLD X-ray 
photoelectron spectrometer equipped with a monochromatic Al Kα X-ray excitation source (base 
pressure = 6 × 10-9 torr). Emitted photoelectrons were measured at a 90° take-off angle. A pass 
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energy of 20 eV was utilized for all high-resolution scans. A standard Shirley baseline correction 
algorithm was employed after data collection with relative sensitivity factors from the Kratos 
Vision software to calculate atomic concentrations.  
D.2.5. Molecular weight determination 
 The average molecular weight and polydispersity of the polymers were determined using 
gel permeation chromatography (GPC). Low molecular weight chitosan (1 mg/mL in 2 vol % 
acetic acid) and P-chitosan (1 mg/mL in water) solutions were passed through a 0.22 µm 
diameter syringe filter and injected (100 µL) onto a Waters 2695 GPC column (flow rate = 0.925 
mL/min) equipped with a Waters 2414 refractometric detector. Three Ultrahydrogel 1000, 
7.8x300 mm columns were connected in series with an Ultrahydrogel guard column. Molecular 
weight calibration curves were created using polyethylene oxide standards in a range from 
25−881 kDa. 
D.2.6. Calcium chelation 
 P-chitosan (10.0 mg) was dissolved in a 10 mM CaCl2 solution (2.5 mL) at 37 °C. The 
mixture was stirred in a 37 °C incubator for 2 min. The solution was then transferred to a 
centrifuge tube, diluted with 10.0 mL THF, and centrifuged at 4000 × g for 2 min. After 
decanting the liquid into a glass vial, the solvent was evaporated under vacuum. The remaining 
calcium chloride was digested in a known volume of 2 vol % HNO3 prior to calcium content 
analysis by inductively coupled plasma-optical emission spectrometry (ICP-OES). The ICP-OES 
was first calibrated using calcium standards (0.1−25 ppm) prepared in 2 vol % HNO3. The 
calcium emission intensity at 317.93 nm was used for quantification. 
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D.3 Results and discussion 
 The use of anhydrous liquid organic acids during the synthesis of P-chitosan is critical to 
prevent undesirable hydrolysis of the phosphorylating reagent. While other organic acids are 
available, methanesulfonic acid (MSA) is one of the few liquid organic acids that is sufficiently 
acidic enough to fully solubilize chitosan. Phosphorylating reagents such as P2O5 are insoluble in 
organic acids like MSA, but this issue can be resolved by employing POCl3. 
 Chitosan’s reactivity with POCl3 was initially examined using 1H NMR spectroscopy 
(Figure D.1). The protonation of chitosan’s primary amine was followed throughout the reaction 
and washing steps by monitoring the associated alpha-carbon (C2) proton peak. When 
protonated, the peak appears at 3.1 ppm. Washing P-chitosan with 50 mM NaOH, which 
deprotonates the amine, shifts the peak at 3.1 ppm upfield to 2.6 ppm. In addition to the 
protonation state of the amine, 1H NMR may be used to confirm the presence of ionically-bound 
MSA. Following extensive washing of P-chitosan to remove free acid, the peak near 2.7 ppm 
from the methyl hydrogens of MSA revealed that the methanesulfonate anion serves as a 
counterion to chitosan’s protonated amine. Subsequential washings with 2 M HCl replaces the  
methanesulfonate with a chloride counterion (Figure D.2). Unfortunately, actual phosphorylation 
is not directly observed using 1H NMR. 
 31P NMR spectroscopy may be employed to directly examine P-chitosan 
phosphorylation. Sample preparation under basic conditions was essential to differentiate 31P 
NMR phosphate peaks from one another. When samples are prepared solely in neutral D2O 
(Figure D.3a), a broad peak appears near 0.5 ppm, similar in location to that of phosphoric acid. 
Under basic conditions (13 mM NaOH in D2O) the appended phosphate groups are deprotonated, 
resulting in adequate  
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Figure D.1. 1H NMR spectrum of phosphorylated chitosan (molecular structure shown above). 
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Figure D.2. 1H NMR spectrum in D2O of P-chitosan after washing with 2 M HCl. 
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Figure D.3. 31P NMR spectra of phosphorylated chitosan (molecular structure shown above) 
prepared in (a) D2O and (b) 1:3 volumetric ratio of D2O to 50 mM NaOH. Numeric labels (1, 2, 
3) indicate the associated phosphate group.  
 
 
 
 
 
 
 
 
 
 
 
 169 
peak separation due to a downfield shift (Figure D.3b). The separated peaks at 4.30 and 3.65 
ppm are assignable to the phosphates attached to the primary and secondary alcohols of chitosan, 
respectively. Spectra acquired from solutions of D-glucosamine 1-phosphate and D-glucosamine 
6-phosphate corroborate these peak transitions and assignments (Figures D.4 and D.5). 
The 31P NMR peak near -2.5 ppm (Figure D.3) is assigned to the monophosphorylation of 
chitosan’s primary amine. While Wang et al. implied phosphorylation of the amine, clear 
evidence (31P NMR characterization) was not provided as to support primary amine 
phosphorylation.30 We sought to confirm amine phosphorylation by reacting other biopolymers 
(i.e., alginate, cellulose) lacking primary amines with POCl3 as well. 31P NMR analysis of both 
phosphorylated alginate and cellulose revealed no peaks near -2.5 ppm (Figures D.6 and D.7), 
confirming the identity of the -2.5 ppm peak as an amine-bound phosphate (both spectra 
contained peaks at ~4 ppm indicating phosphorylation of their alcohol groups). In contrast to 
prior work,30 we believe that only the primary amines and not the acetylated amines (i.e., 
amides) are participating in the reaction. The electron-withdrawing properties of the carbonyl 
group, in conjunction with resonance, likely reduce the nucleophilicity of the nitrogen atom, 
preventing the amide from attacking POCl3. To verify this hypothesis, we synthesized both 
phosphorylated D-glucosamine containing no amide groups and N-acetylglucosamine with amide 
groups under identical conditions that were used to prepare P-chitosan. As predicted, the 31P 
NMR spectrum of phosphorylated D-glucosamine revealed a peak at -2.5 ppm, while that of N-
acetylglucosamine lacked the -2.5 ppm peak (Figures D.8 and D.9). These results confirm that 
POCl3 phosphorylation only occurs at the alcohols and primary amines of chitosan. 
 The POCl3 reaction was also compared to the P2O5 reaction following a published 
protocol.28 While both phosphorylated amine and alcohol peaks were clearly apparent in the 31P 
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NMR spectra (Figure D.10) after chitosan phosphorylation with P2O5, several additional peaks 
appeared at more negative chemical shifts that were indicative of polyphosphate formation. In 
fact, the NMR data reveals the presence of both pyrophosphates37 (-6 to -11 ppm) and 
tripolyphosphates37 (-21 to -25 ppm). In contrast to the P2O5 reaction, the POCl3 reaction 
generates no polyphosphates, allowing for more reliable characterization and inherent P-chitosan 
homogeneity. 
D.3.1. Controlling phosphorylation efficiency 
 The extent of phosphorylation as a function of POCl3 and the chitosan concentration was 
characterized using X-ray photoelectron spectroscopy (XPS). The nitrogen atomic percent (N 1s 
peak) was used as a normalization factor across syntheses as changes in nitrogen content are 
unlikely to occur during phosphorylation. The molar ratio of POCl3 relative to chitosan alcohol 
groups was varied from 1 to 10, while the overall reaction time (48 h) and chitosan concentration 
(20 mg/mL) were kept constant. At molar ratios of POCl3 <10, phosphorylation was not 
observed at any appreciable level (i.e., below the XPS limit of detection). An increase in the P/N 
ratio to 0.232 was measured after reaction with a 10-molar excess of POCl3. The large excess of 
POCl3 required is attributed to the slower and less favorable reaction kinetics under strongly 
acidic conditions. 
Tuning the phosphorylation efficiency through simple changes in the reaction conditions 
(e.g., chitosan concentration) is highly desirable for chemical versatility. As shown in Table D.1, 
the P/N ratio correlated well with the concentration of chitosan from 5 to 80 mg/mL. We also 
monitored the Cl/N atomic ratio (zero for all concentrations) to ensure post-synthetic removal of 
unreacted POCl3 and appended chlorine groups. Likewise, the P/N ratio was measured as a 
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Figure D.4. 31P NMR spectrum of (top) D-glucosamine 6-phosphate and (bottom) D-glucosamine 
1-phosphate. Samples were prepared in 1:3 volumetric ratio of D2O to 50 mM NaOH. 
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Figure D.5. 31P NMR spectrum of D-glucosamine 6-phosphate prepared in (top) 1:3 volumetric 
ratio of D2O to 50 mM NaOH and (bottom) 1:3 volumetric ratio of D2O to 50 mM HCl. 
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Figure D.6. 31P NMR spectrum of phosphorylated alginate. Sample was prepared in 1:3 
volumetric ratio of D2O to 50 mM NaOH. 
 
 
 
 
 
 
 
 
 
 174 
 
Figure D.7. 31P NMR spectrum of phosphorylated cellulose. Sample was prepared in 1:3 
volumetric ratio of D2O to 50 mM NaOH. 
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Figure D.8. 31P NMR spectrum of phosphorylated D-glucosamine. Sample was prepared in 1:3 
volumetric ratio of D2O to 50 mM NaOH. 
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Figure D.9. 31P NMR spectrum of phosphorylated N-acetylglucosamine. Sample was prepared in 
1:3 volumetric ratio of D2O to 50 mM NaOH. 
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Figure D.10. 31P NMR spectra of phosphorylated chitosan synthesized by the (a) POCl3 method 
and (b) P2O5 method. Peaks located between -6 and -11 are assigned as pyrophosphates, while 
those located between -20 and -25 are tripolyphosphates. 
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Table D.1. Chitosan concentration effect on phosphorylation P/N atomic ratio.a 
Chitosan concentration (mg/mL) P/N atomic ratio 
5 n/a 
20 0.232 ± 0.029 
40 0.279 ± 0.038 
80 0.436 ± 0.066 
aError bars represent the standard deviation from n≥3 separate preparations using a 48 h 
reaction time. The chlorine-to-nitrogen atomic ratio was zero for all concentrations. 
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Figure D.11. Atomic P/N ratio as a function of reaction time for reactions with 20 mg/mL 
chitosan (10 molar ratio of POCl3). 
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function of reaction time for a 20 mg/mL chitosan solution and 10-molar excess of POCl3 
(Figure D.11). The phosphorus content increased steadily over the course of 3 d, allowing for 
precise tunability (up to 72 h) of the phosphate content. An ability to decrease the reaction time 
while maintaining high P/N ratios was also observed by heating the reaction. For example, 
increasing the temperature of the 3 h reaction to 37 °C resulted in atomic ratios (P/N = 0.162) 
near those obtained at 25 °C for 24 h (P/N = 0.142). 
D.3.2. Molecular weight 
Degradation of P-chitosan is a concern given that the phosphorylation reaction occurs in 
a strong organic acid. The O-glycosidic bonds that link monomers of chitosan together are prone 
to cleavage in acidic environments.38-39 The change in P-chitosan molecular weight versus 
reaction time was investigated using gel permeation chromatography (GPC).  Of note, the 
molecular weight of unmodified chitosan was ~85,000 g/mol (experimentally determined), a 
value within the range of typical chitosan materials (20,000−130,000 g/mol).40  As shown in 
Table D.2, only a slight reduction in molecular weight was observed over a 72 h reaction period. 
In the absence of phosphorylation (i.e., without the addition of POCl3), the molecular weight was 
~85,000 g/mol, indicating negligible acid degradation. The anhydrous nature of the reaction 
likely mitigates degradation due to minimal hydrolysis (the primary mechanism of breaking 
glycosidic bonds). The consistent molecular weight also suggests that the water solubility of P-
chitosan largely results from the addition of anionic phosphate groups. 
D.3.3. Calcium chelation efficiency 
A practical application for phosphorylated biopolymers is metal ion chelation. For 
example, phosphorylated chitosan effectively complexes Ca2+ to enhance tooth enamel 
remineralization and prevent future acid-catalyzed demineralization.26,41 We examined the Ca2+ 
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Table D.2. Molecular weight and dispersity (Đ) of P-chitosan as a function of POCl3 reaction 
time.a 
Reaction time (h) Molecular weight (Mn) Đ 
0 85,100 ± 200 1.72 ± 0.05 
24 78,700 ± 400 1.98 ± 0.05 
48 84,300 ± 350 1.60 ± 0.05 
72 83,800 ± 250 1.41 ± 0.09 
aError bars represent the standard deviation from n≥3 separate preparations. 
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chelation properties of P-chitosan by measuring total calcium chelation as a function of 
phosphorylation degree (Table D.3). P-chitosan chelation was compared to that observed from 
control chitosan (i.e., no phosphorylation). After brief exposure to a CaCl2 solution, and removal 
of the polymer, the supernatant was analyzed for Ca2+ as an indication of P-chitosan chelation 
efficiency. Chitosan lacking phosphorylation chelated approximately 24.9 µg Ca2+ per mg 
chitosan, an unsurprising result given previous research demonstrating chitosan’s native ability 
to bind divalent metal cations.42 The total amount of chelated calcium increased predictably with 
the P/N atomic ratio, with 46.2 µg Ca2+ per mg chitosan achieved at the greatest P/N atomic ratio 
(0.30). The data collected here supports the employment of P-chitosan into applications where 
calcium chelation is desired (e.g., oral care). 
D.4 Conclusions 
The reaction of chitosan with POCl3 is a simple and reliable strategy for achieving 
monophosphorylation of chitosan’s amine and alcohols. Precise tuning of the extent of 
phosphorylation is possible by adjusting specific reaction conditions (e.g., chitosan 
concentration, reaction time). Although alginate and cellulose were not extensively studied 
herein, similar monophosphorylation using POCl3 should be expected. Lastly, a range of P-
chitosan architectures (e.g., particles, hydrogels) could be expected given the preservation of 
high molecular weight throughout the reaction. 
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Table D.3. Calcium chelation amount of P-chitosan as a function of phosphorylation degree. 
P/N atomic ratio Chelated calcium (µg Ca2+/mg chitosan) 
0 24.9 ± 0.6a 
0.066 25.1 ± 1.8 
0.142 41.9 ± 0.8 
0.232 43.5 ± 1.0 
0.302 46.2 ± 0.7 
aDetermined using a water-soluble 5 kDa chitosan without any phosphorylation. 
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